[
  {
    "id": 1,
    "question": "以下關於頭頸癌根治性放射線化學治療,何者正確?",
    "options": [
      "針對 locally advanced HPV-positive oropharyngeal cancer,因其預後較佳,且對放射線治療效果良好,應優先考慮使用 cetuximab 合併放射治療。",
      "針對 locally advanced HPV-positive oropharyngeal cancer,使用 cetuximab 合併放射治療相較於 cisplatin 合併放射治療,overall survival 無顯著差異。",
      "針對 locally advanced head and neck squamous cell carcinoma, 使用 pembrolizumab 合併platinum-based CCRT 相較於僅接受platinum-based CCRT,無法顯示有較佳的 progression free survival。",
      "針對 locally advanced head and neck squamous cell carcinoma, 使用 avelumab 合併 platinum-based CCRT 相較於僅接受 platinum-based CCRT,有較佳的 progression free survival。",
      "以上皆非"
    ],
    "correctAnswer": 4,
    "explanation": "(A)(B) for HPV+ (p16+) oropharyngeal cancer, 是否可以downgrade tx to Cetuximab-RT\r\n\r\n\r\n根據三個臨床試驗: \r\n(Triweekly Cis vs Cetuximab)RTOG 1016, De-ESCALaTE\r\n(Weekly Cis vs Cetuximab)TROG 12.01\r\n結果均顯示 Cetuximab-RT OS較差, Locoregional failure rate較高\r\n\r\n(C) Keynote 412 => Pembrolizumab + CRT vs CRT, primary endpoint: EFS沒差 \r\n\r\n(D) JAVELINE head and neck 100 => Avelumab + CRT vs CRT, PFS沒差\r\n\r\n=> (A)(B)(D) 結論錯誤, (C)應是EFS不是PFS\r\n=> 答案為E\r\n\r\n[Ref.]\r\n*RTOG 1016: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32779-X/abstract\r\n*De-ESCALaTE\r\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32752-1/fulltext\r\n*TROG 12.01https://www.redjournal.org/article/S0360-3016(21)00376-X/abstract\r\n*Keynote 412\r\nhttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00100-1/abstract\r\n*Javeline head and neck 100\r\nhttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30737-3/abstract",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 2,
    "question": "一位 53 歲的男性病患罹患 hypopharyngeal squamous cell carcinoma,cT4aN0M0,經過手術之後之後再接受 adjuvant CCRT 獲得緩解。放射治療結束後約一年發生 multiple lung metastasis,以下治療中,何者證據最弱?",
    "options": [
      "Clinical trial",
      "EXTREME regimen",
      "Pembrolizumab alone",
      "Durvalumab plus Tremelimumab",
      "Pembrolizumab plus platinum/5-FU"
    ],
    "correctAnswer": 3,
    "explanation": "這題考了幾個臨床試驗\r\n(B) EXTREME (收no prior tx for 6 months)\r\n(C) (E) Keynote 048 (收no prior tx for 6 months)\r\n(D) KESTREL =>Durvalumab + Tremelimumab not superior to the EXTREME regimen characterized by high PD-L1 expression (TC ≥50% or IC ≥25%)\r\n\r\nPS: 其實不知道(A)來幹嘛的...不過(D)確定是失敗的臨床試驗，故選(D)\r\n\r\n[Ref.]\r\n*KESTREL study\r\nhttps://www.annalsofoncology.org/article/S0923-7534(22)04778-0/fulltext",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 3,
    "question": "關於 nasopharyngeal carcinoma ,下列敘述何者正確?",
    "options": [
      "WHO type I NPC 的病理檢體, EBER 檢驗多為陽性。",
      "WHO type III NPC 為 non-keratinizing differentiated type。",
      "Locally advanced NPC (Stage III-IVA) 約佔整體 NPC 的 30-40%。",
      "De novo metastatic NPC (Stage IVB) 約佔整體 NPC 的 10-20%。",
      "鼻咽癌好發的年齡族群較其他頭頸癌大。"
    ],
    "correctAnswer": 3,
    "explanation": "(A) 錯誤, 應是WHO type 3\r\n(B) 錯誤, WHO type 3 應是 non-keratinizing “undifferentiated” type\r\n(C) 錯誤, LA-NPC 比例 文獻上提到 ~70%\r\n(https://www.sciencedirect.com/science/article/pii/S0305737224001683)\r\n(D) 正確, prospective PET screening for NPC, de novo metastatic NPC  14.8%\r\n(https://ascopubs.org/doi/10.1200/JCO.2012.46.0816?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed)\r\n(E) 錯誤, 鼻咽癌好發年齡族群較其他頭頸癌小 (111年癌登年報)\r\n*頭頸癌(Figure 1)\r\n*鼻咽癌(Figure 2)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/003/explain_figures/Figure 1.jpg",
      "/qabank/003/explain_figures/Figure 2.jpg"
    ]
  },
  {
    "id": 4,
    "question": "關於 nasopharyngeal carcinoma 的 induction chemotherapy ,下列敘述何者正確?",
    "options": [
      "3 cycles of gemcitabine/cisplatin following by standard chemoradiotherapy 與 standard chemoradiotherapy 相較,可明顯改善 locally advanced NPC 的 overall survival, distant recurrence-free survival,但對於 locoregional recurrence-free survival 沒有幫助。",
      "Gemcitabine/ cisplatin 作為 NPC induction chemotherapy or adjuvant chemotherapy 皆有良好的效果。",
      "作為 Induction chemotherapy,gemcitabine/cisplatin 與 cisplatin/5-FU 效果相當。",
      "作為 Induction chemotherapy,gemcitabine/cisplatin 顯著優於 cisplatin/5-FU。",
      "作為 Induction chemotherapy,docetaxel/cisplatin/5-FU 顯著優於 docetaxel/cisplatin。"
    ],
    "correctAnswer": 0,
    "explanation": "(A) 正確\r\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa1905287\r\n\r\n(B) 錯誤, adjuvant GP no RFS benefit\r\nhttps://ascopubs.org/doi/10.1200/JCO.2018.77.7847?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed\r\n\r\n(C) (D) 錯誤 目前應沒有induction GP vs PF的臨床試驗\r\n(E) 錯誤  目前沒有induction TPF vs TP的臨床試驗\r\n\r\n**附上IC for NPC study連結\r\n> Induction PF: Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial\r\nhttps://pubmed.ncbi.nlm.nih.gov/31425966/\r\n\r\n> Induction TPF: Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial\r\nhttps://pubmed.ncbi.nlm.nih.gov/27686945/\r\n\r\n> Induction TP: Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma\r\nhttps://pubmed.ncbi.nlm.nih.gov/19064973/\r\n\r\n**PS: 這題(A)明顯正確\r\n(C)(D)(E)滿怪的...如果cross-trial comparison, (D)可能勉強也對..\r\n附上所有induction therapy 3-y OS比較圖",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/004/explain_figures/Figure 1.jpg"
    ]
  },
  {
    "id": 5,
    "question": "關於 recurrent or metastatic nasopharyngeal carcinoma 治療，下列敘述何者正確?",
    "options": [
      "Locally recurrent nasopharyngeal carcinoma 在手術可行的情形下，可以考慮直接以手術切除。",
      "作為第一線治療，gemcitabine/cisplatin versus cisplatin/5-FU 並未顯現出較好的治療成效。",
      "Gemcitabine/ cisplatin 和 cisplatin/5-FU 相比，造成較少的 hematologic adverse events。",
      "作為第一線治療，toripalimab plus chemotherapy versus chemotherapy alone 無法顯著改善 progression free survival。",
      "作為第一線治療，pembrolizumab plus chemotherapy versus chemotherapy alone 可以顯著改善overall survival。"
    ],
    "correctAnswer": 0,
    "explanation": "(B)(C)根據GEM20110714，GC有顯著較長的PFS和OS，但有較多的grade 3 and 4 hematologic adverse events\n(D)根據JUPITER-02，toripalimab+GP vs GP有PFS好處(Final OS也有好處: not reached vs 33.7m, HR 0.63)\n(E)Pembro在recurrent/metastatic NPC只有KN-122（cisplatin pretreated recurrent NPC）研究Pembro mono therapy vs physician choice chemotherapy, 即便在trial收錄病人PD-L1 CPS>1佔7成的情況下OS也沒有benefit (ORR也沒有)。目前也無第一線治療比較Pembro + Chemo vs Chemo alone in NPC。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 6,
    "question": "依據現有之證據，以下頭頸腫瘤中使用 next-generation sequencing，何者發現 druggable mutation 的機會最低?",
    "options": [
      "Adenoid cystic carcinoma of salivary gland",
      "Salivary duct carcinoma of salivary gland",
      "Myoepithelial carcinoma of salivary gland",
      "Follicular thyroid cancer",
      "Papillary thyroid cancer"
    ],
    "correctAnswer": 0,
    "explanation": "(A)Adenoid cystic carcinoma: MYB-NFIB gene fusion(還未有針對該gene fusion的藥物)，NOTCH1，low TMB\n(B)Salivary duct carcinoma: PIK3CA(50%), HER2 amplification(15-40%)\n(C)Myoepithelial carcinoma: BRAF(5%), PIK3CA\n(D)Follicular thyroid cancer: PI3K/Akt\n(E)Papillary thyroid cancer: RET gene rearrangements(10-20%), BRAF V600E(60%)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 7,
    "question": "關於唾液腺腫瘤，下列何者為真?",
    "options": [
      "Histology prevalence 最高的是 salivary duct carcinoma",
      "對於 adenoid cystic carcinoma，cisplatin/doxorubicin/cyclophosphamide 可以提供約 50-60%的\nresponse rate",
      "對於 adenoid cystic carcinoma，應常規使用 next-generation sequencing screening for druggable\nmutation",
      "對於 adenoid cystic carcinoma，lenvatinib 是一個可以考慮的治療方式",
      "對於 salivary duct carcinoma 以及 mucoepidermoid carcinoma，platinum-based chemotherapy\n為治療首選"
    ],
    "correctAnswer": 3,
    "explanation": "(A)最常見的惡性salivary gland tumor是mucoepidermoid carcinoma(30-35%)，salivary duct carcinoma占1-3%\n(B)ACC對化療的反應差，就不同化療處方response rate為10-30% (常見chemotherapy為CAP in combination or 單用anthracycline, vinorebline; Paclitaxel可用在非ACC之外的其他salivary cancer而不用在ACC因為效果太差)\n(C)ACC較常見MYB-NFIB gene fusion，NOTCH1，low TMB，沒有明確druggable target，NGS非常規建議\n(D)在R/M ACC的phase II trial中DCR 88% (PR 15.6%, SD 75%)(J Clin Oncol 2019;37:1529-1537)\n(E)應先檢驗HER2是否陽性(30% mucoepidermoid carcinoma, 40% salivary duct carcinoma), 若有HER2陽性應先使用HER2 directed therapy",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 8,
    "question": "以下有關藥物及其主要或特有副作用的配對中，何者不正確?",
    "options": [
      "CDK4/6 inhibitor: neutropenic fever",
      "PI3K inhibitor: hyperglycemia",
      "Trastuzumab deruxtecan (TDXd): interstitial pneumonitis",
      "PARP inhibitor: anemia",
      "Aromatase inhibitor: joint pain"
    ],
    "correctAnswer": 0,
    "explanation": "使用CDK4/6 inhibitors容易造成neutropenia，臨床試驗中ribociclib or palbociclib產生grade 3 neutropenia的比例大於50%，abemaciclib約20%，然而統計發生neutropenic fever的風險相對低(約1-2%)。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 9,
    "question": "46 歲 de novo stage IV 乳癌，cT2N3M1，ER+ PR+ HER2-，肺部有兩個 1-2 cm nodules，肝臟也有一個 3 cm 轉移病灶，無其他臟器轉移症狀，七個月前還有月經來。以下有關第一線治療的敘述中，何者錯誤？",
    "options": [
      "可檢測 FSH/LH/estrodiol 決定是否要 加上 GnRHa 治療",
      "腫瘤檢測如果有 PIK3CA 突變，應該第一線使用 CDK4/6 inhibitor+PI3K inhibitor 治療",
      "可考慮卵巢切除，加上 aromatase inhibitor+CDK4/6 inhibitor",
      "不想切除卵巢，可以用 GnRHa+tamoxifen/AI+CDK4/6 inhibitor",
      "除非有臟器危象(visceral crisis)，否則化學治療應該在第二或三線再考量"
    ],
    "correctAnswer": 1,
    "explanation": "此題考轉移性荷爾蒙受體陽性乳癌的治療架構\nACDE選項考Ovary function suppression, ET及CDK4/6i的應用\nB選項考二線後的治療選項\n\n附上2024 ASCO education book 架構圖(https://ascopubs.org/doi/10.1200/EDBK_432442), 需注意圖中4L+未包含Dato-Dxd (TROPION Breast 01, PFS benefit+, OS benefit-, 於2025/01 FDA approved, 可能為今年考點)\n\n目前荷爾蒙受體陽性轉移性乳癌第一線治療\nEndocrine therapy（SERM or Aromatase inhibitor） + CDK4/6i\nCDK4/6i選擇可以是\n- Palbociclib（PALOMA-2)\n- Ribociclib（MONALEESA-2）\n- Abemaciclib（MONARCH-3）\nPALOMA-2, MONALEESA-2, MONARCH-3皆收錄停經後乳癌患者，而由MONALESSA-7（Ribociclib使用於Pre- or Peri-menopause）將CDK4/6i使用範圍拓展到停經前患者也可使用。\n\n依照題幹\nA: Postmenopause需要連續無月經達12個月，7個月前仍有月經來上尚無法判定已屬於Postmenopause，可檢測FSH/Estradiol判斷卵巢功能是否尚未符合停經後標準評估需不需要進行Ovary function suppression（OFS）。\nB: 錯誤, 二線標準治療為SERD為主幹(如Fulvestrant), 再依照PI3k-Akt pathway alteration有無選用PI3K inhibitor（如alpelisib in SOLAR-1 study and BYlieve study）或AKT inhibitor（capivasertib in capitello-291）, 目前PI3k-Akt pathway alteration相關的抑制劑皆是在二線（含）以後。\nC, D: 如果不驗FSH/E2, 只以連續無月經月份判斷病患仍不算進入Postmenopause故需要OFS，方式可以採手術（卵巢切除）或是藥物（GnRHa）。進行OFS後治療就同Postmenopausal，使用Endocrine therapy + CDK4/6i。\nE: 沒有Visceral crisis優先用ET+CDK4/6i，只是因為之前的研究沒有收Visceral crisis病患。有Visceral crisis也並非就需把化療拉到第一線, 此觀念已在RIGHTCHOICE study後被推翻（ET+Ribociclib vs Chemotherapy, ORR皆約6成, 且PFS與Adverse event表現都是CDK4/6i組更好, 故不管有無Visceral crisis, ET+CDK4/6i都可以作為第一線選項)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/009/explain_figures/Treatment of HR+ Breast cancer algorithm.png"
    ]
  },
  {
    "id": 10,
    "question": "對於早期乳癌的治療，gene expression profile 可以用來評估復發機率，以及是否使用adjuvant chemotherapy 來預防復發。下列哪一種檢查不應該應用於早期乳癌病患 adjuvant treatment 的決定？",
    "options": [
      "21-Gene Recurrence Score (Oncotype DX)",
      "70-Gene Assay (Mammaprint)",
      "Tumor tissue NGS (Next generation gene sequencing)",
      "Prediction Analysis of Microarray-50 (PAM50, PAM50 Risk of Recurrence Score, or Prosigna)",
      "12-Gene Risk Score (Endopredict)"
    ],
    "correctAnswer": 2,
    "explanation": "除NGS外四個選項皆可，HR+ HER2-早期乳癌, 可以下列四種基因檢測綜合判斷是否需要加上化療。\n\n檢測平台         LN          檢測參數及判定\nOncoType DX ->   -    | 21 gene及含量判定recurrence score\nMammaPrint  -> - or + | 70 gene 判斷風險(需合併clinical risk評估臨床風險)\nPAM50       ->   -    | 50 gene 判斷屬於哪種subtype(Luminal A, B, HER2, basal-like)及風險\nEndopredict -> - or + | 12 gene 判斷EPclin Score",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 11,
    "question": "Which of the following description regarding uveal melanoma is wrong?",
    "options": [
      "Uveal melanomas can arise anywhere in the uveal tract, with less than 75% arising in the choroid, and the remainder arising in the iris or ciliary body",
      "Molecular markers common in uveal melanomas include chromosomal abnormalities (particularly chromosomes 3 and 8), and mutations in GNAQ or GNA11 (>80% of uveal cases), BAP1, SF3B1, and EIFAX",
      "Treatment efficacy of immune checkpoint inhibitors in uveal melanoma is similar to cutaneous\nmelanoma",
      "Uveal melanoma most often metastasizes to the liver (90% of the time). Other common sites\nof metastasis, listed in order of decreasing prevalence, are lung, bone, skin/soft tissue, and\nlymph nodes",
      "Tebentafusp, a TCR/Anti-CD3 bispecific fusion protein targeting gp100, may provide benefit\nto patients with metastatic uveal melanoma"
    ],
    "correctAnswer": 0,
    "explanation": "A可能有爭議但C明顯錯誤，故應選C\n\nA：大多數統計資料Uveal melanoma中Choroid佔85-90%，剩餘是iris及ciliary body合計佔剩餘10%。無法確定考題用的是哪份資料。需要知道最多的是Choroid即可。\n\nB: uveal melanoma\n腫瘤發展早期的突變跟G-protein α subunits相關, 佔85% (GNAQ and GNA11, mutually exclusive), 會活化下游MAPK pathway。\n腫瘤發展晚期的突變為BAP1, SF3B1 (splicing factor 3B subunit 1), EIF1AX (eukaryotic translation initiation factor 1A X-linked)。有SF3B1, EIF1AX突變預後比較好。BAP1可以是germline (亦容易造成mesothelioma)。\nRef: Devita 12th p. 1605\n\nC錯誤：Immunotherapy在Cutaneous melanoma的成功沒有辦法複製在Uveal melanoma, 舉例以CheckMate-067為例（Ref C2），ORR分別為Ipi 19%, Nivo 44.9%, Ipi+Nivo 58.3%。而Uveal melanoma即便用Ipi+Nivo combined IO therapy ORR也只有13.7%（Meta-analysis, Ref C2）, 其於大多資料Nivo單用約5%, Ipi單用為0%。Devita亦有提出可能原因為Uveal melanoma TMB明顯不如Cutaneous melanoma。\n\nRef C1: https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.9506\nRef C2: https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.9534\n\nD: 最常見metastasis分為liver (>90%), Lung (24%), Bone (16%), 最少的是LN & Brain (<6%)\n\nE: Metastatic uveal melanoma的ICI治療效果明顯不如cutaneous melanoma, 應依照IMCgp100-202 trial結果優先考慮於HLA-A*02:01 positive病人使用Tebentafusp (BiTE targeting gp100 & CD3), 於trial中使用Tebentafusp對比於physician choice therapy (Pembro, Ipi or DTIC)有OS benefit, 此藥物另一個特色是即使用Tebentafusp後best reponse是PD的病人存活也比使用physician choice therapy後best response是PD的病人來得長（表示此藥物的機轉特別, response即便連SD都無法達到也能延長存活）。\n\n若病患為HLA-A*02:01 negative則才考慮IO, 若病患為liver dominant disease則應該積極考慮local therapy。附上uptodate流程圖更利於理解。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/011/explain_figures/Metastatic uveal melanoma treatment.png"
    ]
  },
  {
    "id": 12,
    "question": "According to NCCN guidelines, which of the following therapies can be considered for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) that is borderline resectable or unresectable, or for whom surgery may carry high morbidity?",
    "options": [
      "Curative radiation therapy",
      "Neoadjuvant cemiplimab",
      "Neoadjuvant cisplatin",
      "Neoadjuvant pembrolizumab",
      "Neoadjuvant nivolumab"
    ],
    "correctAnswer": 0,
    "explanation": "針對不適合手術或無法手術病患, curative RT為最建議方式。化療可考慮與RT並用作爲CCRT (with cisplatin, PF, TP, cetuximab等radiosensitizer)。僅在不適合手術或RT的病患使用immunotherapy (如Cemiplimab, Pembrolizumab)作為systemic treatment。\n\n附2025 Ver2 NCCN guideline for Squamous Cell Skin Cancer供參考",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/012/explain_figures/Agents combined with RT.png",
      "/qabank/012/explain_figures/NCCN guideline.png"
    ]
  },
  {
    "id": 13,
    "question": "Which of the following statements about Merkel cell carcinoma (MCC) are INCORRECT?",
    "options": [
      "Sun exposure is believed to be a major risk factor for MCC.",
      "MCC is rarely clinically suspected at presentation because the primary tumor lacks distinguishing features and is often asymptomatic. In a study of 195 patients with pathologically confirmed MCC, 88% of MCC tumors were asymptomatic and correct clinical diagnosis was rare (only 1%).",
      "Merkel cell polyomavirus (MCPyV) is detected in 43% to 100% of tumors, and a much higher mutational burden is found in MCPyV-positive tumors.",
      "Cytokeratin 20 (CK20) and TTF-1 are two useful markers in differential diagnosis between MCC and small cell lung cancer (SCLC) since CK20 is positive in 75% to 100% of MCC and rarely positive in SCLC. TTF-1 is never positive in MCC, but is often positive in SCLC (>80%).",
      "Avelumab, nivolumab, and pembrolizumab are included as recommended systemic therapy options for treatment of disseminated disease."
    ],
    "correctAnswer": 2,
    "explanation": "此題完全出自NCCN guideline的discussion\r\n\r\n(A) 正確。UV-mediated somatic mutation, oncogenic viral infection (Merkel cell polyomavirus (MCPyV)), immunosuppression為oncogenesis三大機轉。腫瘤較常發生在sun exposure area，白人、老年人風險較高。\r\n\r\n(B) 正確。這段後的內文為: 根據臨床診斷56% of MCC剛開始都被認為是benign cysts/lesions，其他文獻證實MCC常被誤診成benign lesions或non-melanoma skin cancers (NMSCs)、other rare malignant skin tumors。\r\n\r\n(C) 錯誤。MCPyV is detected in 43% to 100% of tumor是正確的，但MCPyV-negative tumor的mutational burden才是較高的，推測是跟UV damage有關。\r\n\r\n(D) 正確。MCC是neuroendocrine cell origin (正常皮膚組織內Merkel cell功能是slowly adapting type I mechanoreceptor)，癌化後組織學下跟其他small round cell tumors相似。其中最難分辨的是病灶是primary MCC或metastatic SCLC，可藉由CK20與TTF-1鑑別。\r\n\r\n(E) 正確。NCCN對於disseminated disease首選為clinical trials及IO (見figure 1)\r\n📍JAVELIN Merkel 200 (phase 2): 收錄fresh M1，avelumab，ORR 39.7%, PFS 4.1 mo, OS 20.3 mo。\r\n📍KN-017 (phase 2): 收錄fresh advanced，pembrolizumab，ORR 58%, PFS 16.8 mo, OS (3y) not reached。\r\n📍CM-358 (phase 1/2): 收錄”resectable”，neoadjuvant nivolumab，pCR 47.2%, ORR 54.5%。雖是做在neoadjuvant但其效果於其他IO相似，因此也列在NCCN的建議上。\r\n📍POD1UM-201 (phase 2): 收錄fresh advanced，retifanlimab (anti-PD1)，ORR 52%\r\n\r\nReferences: Devita (12th Ed.) Section 9 Cancer of Skin - Merkel cell carcinoma、NCCN guideline - Merkel cell carcinoma",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/013/explain_figures/Figure 1.jpg"
    ]
  },
  {
    "id": 14,
    "question": "下列關於NivoCUP的臨床試驗敘述，何者錯誤？",
    "options": [
      "A phase 2, single-arm, multicenter study in Japan",
      "受試者包含previously untreated及treated的原發部位不明轉移癌病患",
      "整體反應率為22.2%，其中PD-L1 TPS ≥1%的反應率為41%，明顯比PD-L1 TPS <1%的反應率高",
      "TMB在本試驗的中位數為7.75 mut/Mb，其中TMB ≥7.75 mut/Mb的反應率為28%，明顯比TMB <7.75 mut/Mb的反應率高",
      "目前NCCN guideline 建議可使用nivolumab在PD-L1 TPS ≥1%的原發部位不明轉移癌的病患"
    ],
    "correctAnswer": 4,
    "explanation": "NivoCUP是在日本進行的phase 2 study\r\n📌 收錄CUP (排除favorable prognosis及組織學是melanoma, sarcoma, lymphoma)，其中adenocarcinoma約占64%, SqCC約10%, undifferentiated (一組11.1%, 一組0%)\r\n📌 接受nivolumab 240 mg q2w\r\n📌 Primary endpoint: ORR in previously treated group\r\n📌 Results\r\n📍 In previous treated group (N=45): ORR 22.2%, DCR 53.3%, PFS 4 mo, OS 15.9 mo\r\n📍 In previous untreated group (N=10): ORR 18.2%, DCR 54.5%, PFS 2.8 mo, OS NR\r\n\r\n(A) 正確。\r\n\r\n(B) 正確。previously untreated 10位、treated 45位\r\n\r\n(C) 正確。如Figure 1, Figure 2\r\n\r\n(D) 正確。以median TMB 7.75 mut/Mb為切點\r\nHigh (≥7.75 mut/Mb) vs Low (< 7.75 mut/Mb) : ORR 28 vs 12%, DCR 60 vs 36%, PFS 5.1 vs 19% (HR 0.34), OS 20.4 vs 8.4 (HR 0.57)\r\n\r\n(E) 錯誤。目前NCCN (2025 Ver.2)對於IO在CUP，只建議tumor-agnostic therapy的pembrolizumab in dMMR/MSI-H, TMB-H (KN-158) (NCCN放在adenocarcinoma, SqCC)及dostarlimab in dMMR (GARNET trial) (NCCN只放在adenocarcinoma, SqCC無)\r\n\r\nReferences: Ann Oncol. 2022 Feb;33(2):216-226.、NCCN guideline - Occult Primary",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/014/explain_figures/Figure 1.jpg",
      "/qabank/014/explain_figures/Figure 2.jpg",
      "/qabank/014/explain_figures/Figure 3.jpg",
      "/qabank/014/explain_figures/Figure 4.jpg"
    ]
  },
  {
    "id": 15,
    "question": "下列有關Von Hippel Lindau (VHL) disease 的敘述，何者有誤？",
    "options": [
      "VHL disease 是autosomal dominant syndrome。",
      "發生率為1/36000，好發年齡為60歲左右。",
      "VHL 相關疾病為hemangioblastoma, neuroendocrine tumor, pheochromocytoma/paraganglioma 及renal cell carcinoma。",
      "VHL gene 在chromosome 3，屬於tumor suppressor gene。",
      "Belzutifan 可用來治療VHL 相關的pancreas neuroendocrine tumor 及renal cell carcinoma，其機轉為抑制VHL gene。"
    ],
    "correctAnswer": 1,
    "explanation": "📍Pathophysiology\r\n如Figure 1，一般生理狀況下，VHL protein以oxygen-dependent方式水解HIF-α (hypoxia-inducible factor)，缺氧時VHL protein無法水解HIF-α造成其累積，導致HIF-mediated gene expression的target (VEGF, GLUT1, PDGF)增加來因應缺氧時的環境 (vascularization, enhancing glucose utilization, increasing red-cell production through transcriptional signals)。\r\nVHL disease突變的VHL protein無法接上HIF-α(oxygen-independent)，造成HIF-α stabilization大量累積，導致tumor growth, neovascularization。\r\n\r\n(A) 正確。\r\n\r\n(B) 錯誤。發生率為1/36000是對的，但好發在20-40歲。\r\n\r\n(C) 正確。VHL disease相關疾病為clear cell renal tumors, retinal angiomas, central nervous system, hemangioblastomas, tumors of the adrenal gland (pheochromocytoma), endolymphatic sac and pancreatic islet cell, cysts in the pancreas and kidney。\r\n\r\n(D) 正確。位在chromosome 3p25-26，是典型的”two-hit”tumor suppressor gene，兩個allele都inactivated才會致癌。\r\n\r\n(E) 這選項略有爭議。Belzutifan是HIF 2-α inhibitor，FDA根據LITESPARK-004 (phase 2)核准使用在VHL associated RCC, CNS hemangioblastoma, pNET not requiring immediate surgery。機轉是結合在HIF 2-α上，使其無法活化造成上述相關VEGF等產出，並不與VHL gene直接相關。然而相較之下(B)為明顯的錯誤，故仍選(B)較恰當。\r\n\r\nReferences: Devita (12th Ed.) p.733-735, Lancet Oncol. 2024 Oct;25(10):1325-1336.",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/015/explain_figures/Figure 1.jpg"
    ]
  },
  {
    "id": 16,
    "question": "下列有關Multiple Endocrine Neoplasia (MEN) 的敘述，何者有誤？",
    "options": [
      "MEN1 大多是 autosomal dominant syndrome。",
      "MEN1 是因為 MEN1 gene 突變導致。",
      "MEN2 主要突變在 RET oncogene 的 exon 10 和 11，MEN3 主要在 RET M918T 的點突變。",
      "MEN3 的發生率比 MEN2 高且預後比較好。",
      "MEN4 突變在 CDKN1B gene，是 MEN1 的亞型。"
    ],
    "correctAnswer": 3,
    "explanation": "📍整理表格請見Table 1\r\n\r\n(A), (B), (C) 正確\r\n\r\n(D) 錯誤。MEN2B (MEN3)非常少見，且因RET M918T mutation會造成aggressive, early-onset medullary thyroid carcinoma (MTC)，所以預後較差。\r\n\r\n(E) MEN4與MEN1臨床表現相似，但致病基因不同，在Harrison及相關paper大多是獨立出來，不過(D)選項明顯錯誤，故選(D)較適當。\r\n\r\nReferences: NCCN guideline - Neuroendocrine and Adrenal Tumors、Harrison Ch. 388 Multiple Endocrine Neoplasia Syndromes、Intern Med J. 2019 Aug;49(8):954-961.、Ann Transl Med. 2021 Jun;9(11):944",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/016/explain_figures/Table 1.jpg"
    ]
  },
  {
    "id": 17,
    "question": "One 55 year-old male patient got metastatic urothelial carcinoma. He received gemzar-carboplatin treatment. Initially, the response was stable disease; however, disease progression developed 1 month later. After disease progression, his kidney function was still cisplatin-ineligible. The\nECOG status was 1. The PD-L1 was less than 10 % in the CPS score. The next-generation sequencing data from the cancer tissue showed FGFR3–TACC3_V1 fusion. In the current situation, what is the best-recommended treatment for his disease, and what is its evidence?",
    "options": [
      "Enfortumab vedotin (EV-301)",
      "Avelumab (JAVELIN Bladder 100)",
      "Erdafitinib (THOR)",
      "Pembrolizumab (KEYNOTE-052)",
      "re-challenge with gemcitabine"
    ],
    "correctAnswer": 2,
    "explanation": "(C)為正解。 根據 THOR study (2023 NEJM), ≥2 lines setting, 在有FGFR3/2 alteration 的unresectable/metastatic UC病人，Erdafitinib勝過ChT (cohort 1), 然而在cohort 2中Erdafitinib vs pembrolzumab並無達到統計差異。回顧題幹，此病人有FGFR3–TACC3_V1 fusion，為THOR study include的FGFR alteration之一（FGFR3 S249C mutations (47 percent), FGFR3 Y373C mutation (17 percent), FGFR3TACC3_V1 fusion (10 percent)），故二線d可使用Erdafitinib做為治療，惟病人尚未接受過免疫治療，若可。此病人使用pembrolizumab亦無不可，但引用的evidence是KN-045而非KN-052。[KN-052為 1st-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic UC]\n若病人無FGFR alterations, 依照guideline可以為病人選擇pembrolizumab (KN-045) 非選項(D)Pembrolizumab (KEYNOTE-052) 。\n(A) Enfortumab vedotin (EV-301)則適用於PD after anti-PD-(L)1的情況。\n(B) Avelumab (JAVELIN Bladder 100)適用時機則應是病人CR/PR/SD after GP or GC，接上maintenance avelumab。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/017/explain_figures/ESMO_UC.jpg",
      "/qabank/017/explain_figures/THOR_trial.jpg",
      "/qabank/017/explain_figures/THOR_trial_2.jpg"
    ]
  },
  {
    "id": 18,
    "question": "Recently, the combination of new hormonal agents (NHA) with PARP inhibitors can be used to treat metastatic prostate cancer (PC). The following statements are incorrect:",
    "options": [
      "The target population is metastatic castration-resistant prostate cancer.",
      "There are several studies that demonstrated positive results, such as talazoparib+enzalutamide  and olaparib+abiraterone.",
      "EMA agrees that olaparib can be in combination with abiraterone as 1st-line treatment in  all comer setting.",
      "EMA agrees that combination of talazoparib and enzalutamide for the treatment of patients   with metastatic prostate cancer.",
      "Denosumab can not reduce the risk of bone side effects."
    ],
    "correctAnswer": 4,
    "explanation": "這題主要是要考PROpel study (olaparib+abiraterone+prednisone /prednisolone)及TALAPRO-2 study (talazoparib + enzalutamide)，兩者皆是mCRPC 1st line的study。\n(E)選項錯誤。整體而言FDA比EMA嚴格，FDA approve olaparib用於BRCA mutation病人，而talazoparib通過的是HRR mutation；EMA則都是all comer。 啊不過這兩個trial其實在all comers population皆為positive trials.\n((考得也太細惹拔QQ\n(A)正確，target population為mCRPC。\n(B)正確，PROpel study (olaparib+abiraterone+prednisone /prednisolone)及TALAPRO-2 study (talazoparib + enzalutamide)皆為positive trial。\n(C)正確，根據上表EMA適應症有通過 olaparib in combination with abiraterone as 1st-line treatment in all comer setting.\n(D)正確，根據TALAPRO-2 study，EMA通過talazoparib+enzalutamide in mCRPC 1st line treatment. 此外，今年ASCO GU發表了OS的data，\n“Among the 805 unselected patients followed for a median of approximately 53 months, median OS reached 45.8 months with talazoparib plus enzalutamide versus 37.0 months with placebo plus enzalutamide—about a 9-month survival advantage (HR 0.796, 95% CI [0.661, 0.958]; 2-sided P = .0155)—which met the threshold for statistical significance (P ≤ .022)”",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/018/explain_figures/EMA_PARP.jpg",
      "/qabank/018/explain_figures/PROpel.jpg",
      "/qabank/018/explain_figures/PROpel_rPFS.jpg",
      "/qabank/018/explain_figures/TALAPRO2_OS.jpg",
      "/qabank/018/explain_figures/TARLAPRO_2.jpg"
    ]
  },
  {
    "id": 19,
    "question": "One 29 year-old male patient got testicular seminoma. Initial tumor marker was within normal limit. After staging work-up, he received orchiectomy. The pathological stage is stage I seminoma. Which of the following statements regarding the treatment is correct ?",
    "options": [
      "Active surveillance",
      "Adjuvant treatment with radiotherapy to para-aortic lymph nodes",
      "Adjuvant 20 Gy administered in 10 daily 2.0 fractions to para-aortic and/or ipsilateral iliac  lymph nodes",
      "Adjuvant 1-2 cycles of chemotherapy with carboplatin, dosed at the area under the curve  (AUC) of 7",
      "All of above"
    ],
    "correctAnswer": 4,
    "explanation": "根據NCCN guideline, stage I testicular seminoma可以採取(A)Active surveillance (B)(C) Adjuvant RT (D) Adjuvant 2 cycles of chemotherapy with carboplatin (AUC=7); 因此答案為以上皆是(E)。\n(B)正確，如附圖，seminoma最容易擴散的LN為para-aortic nodes, 因此RT建議縮小範圍包含圖示中的區域以減少併發症。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/019/explain_figures/NCCN_seminoma.jpg",
      "/qabank/019/explain_figures/NCCN_seminoma_RT.jpg",
      "/qabank/019/explain_figures/para_aorticRT.jpg"
    ]
  },
  {
    "id": 20,
    "question": "About bone targeting agents in the treatment of metastatic prostate cancer, which of the following statements is correct ?",
    "options": [
      "Use of Radium-223 in mCRPC with bone metastasis by Phase III ALSYMPCA Trial via   beta particle effect.",
      "The addition of radium-223 to abiraterone or enzalutamide may improve symptomatic skeletal  event-free survival in patients with castration-resistant prostate cancer and bone metastases.",
      "Lutetium-177 (177Lu)–PSMA-617 is a radioligand therapy that delivers alpha-particle   radiation to kill cancer cells.",
      "177Lu-PSMA-617 can be used to treat PSMA PET-positive bone metastasis of CRPC by VISION trial.",
      "錯誤。Denosumab 可以 reduce the risk of bone side effects。"
    ],
    "correctAnswer": 3,
    "explanation": "正確答案為D。\n(D)正確。描述雖然正確，但應注意VISION trial中Lutetium-177 (177Lu)–PSMA-617對於mCRPC病人，可治療全身PSMA-positive lesions，而不僅是bone metastasis。(177Lu)–PSMA-617 + SOC vs SOC可以延長PSMA-positive mCRPC病人的rPFS及OS。\n\n(A)錯誤。Radium-223為alpha emitter。ALSYMPCA證實Radium-223能延長mCRPC with bone metastases病人的overall survival以及延緩time to first skeletal-related event (SRE)。\n(B)錯誤。PEACE-3 trial (Ra-223+enzalutamide) 證實比起對照組enzalutamide alone能延長mCRPC with bone metastases病人的rPFS and OS。然而ERA-223 trial (Ra-223+abiraterone)在mCRPC with bone metastases病人，則無法延長OS or symptomatic skeletal event-free survival，甚至有更高的incidence of bone fractures。\n(C)錯誤。Lutetium-177 (177Lu)–PSMA-617為beta emitter而不是deliver alpha-particle radiation。\n(E)錯誤。Denosumab 可以 reduce the risk of bone side effects。例如2011年發表於Lancet的這篇RCT證實denosumab相較於zolendronic acid可顯著降低SRE(skeletal-related events)。[Lancet. 2011 Mar 5;377(9768):813-22]",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/020/explain_figures/ALSYMPCA.jpg",
      "/qabank/020/explain_figures/Lu_177_PSMA_therapy.jpg",
      "/qabank/020/explain_figures/Ra223decay.png",
      "/qabank/020/explain_figures/VISION_tiral.jpg"
    ]
  },
  {
    "id": 21,
    "question": "晚期子宮內膜癌的免疫治療，下列何者是錯誤的？",
    "options": [
      "根據 KEYNOTE-028、KEYNOTE-158，pembrolizumab 單獨使用在 deficient MMR /   microsatellite instability-high（MSI-H）腫瘤比較有效果，proficient MMR / microsatellite  stable（MSS）腫比較沒有效果。",
      "根據 GARNET，dostarlimab 單獨使用在 deficient MMR / microsatellite instability-high（MSI-H）  腫瘤有效果，在 proficient MMR / microsatellite stable（MSS）腫瘤沒有效果。",
      "根據 KEYNOTE-146，pembrolizumab 加上 lenvatinib 合併使用在 deficient MMR / microsatellite   instability-high（MSI-H）腫瘤客觀反應率是 63.6%，在 proficient MMR / microsatellite stable  （MSS）腫瘤客觀反應率是 36.2%。",
      "根據 KEYNOTE-775，pembrolizumab 加上 lenvatinib 合併使用相較於 doxorubicin 或 paclitaxel  在 proficient MMR / microsatellite stable（MSS）腫瘤的第二線治療有較長的中位數無惡化存  活期（6.6 個月 vs. 3.8 個月，危險比：0.60）及中位數總存活期（17.4 個月 vs. 12.0 個月，  危險比：0.68）。",
      "以上只有 3 個是正確的。"
    ],
    "correctAnswer": 1,
    "explanation": "(A)KN028收入24位PD-L1 positive(CPS>=1)的endometrial cancer病人，其中19位有分析MSI status: 1位MSI-H, 18位non-MSI high, ORR為13%；KN158則收入68位MSI-H的endometrial cancer病人，ORR為48.5%。雖然為cross trial comparison, 不過依據這兩個試驗結果做出選項的推論應算合理。\r\n\r\n(B)選項錯誤。GARNET trial中，dMMR/MSI-H組別ORR為43.5%；pMMR/MSS組ORR為14.1%，有3個病人達到CR及19個PR。選項” proficient MMR / microsatellite stable（MSS）腫瘤沒有效果。”錯誤。\r\n\r\n(C)(D)選項正確。\r\n因此答案為B",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 22,
    "question": "晚期子宮內膜癌的第一線免疫治療，下列何者是錯誤的？",
    "options": [
      "根據 RUBY，dostarlimab 加上 paclitaxel / carboplatin 合併使用相較於 paclitaxel / carbiplatin  使用有較長的 5 年無惡化存活率（36.1% vs. 18.1%，危險比：0.64）及 5 年總存活率（71.3%   vs. 56.0%，危險比：0.64）。",
      "根據 NRG_GY018，pembrolizumab 加上 paclitaxel / carboplatin 合併使用相較於 paclitaxel /   carbiplatin 使用在 mismatch repair-proficient (pMMR)的病患族群，有較長的中位數無惡化存  活期（13.1 個月 vs. 8.7 個月，危險比：0.54）。",
      "根據 AtTEnd，atezolizumab 加上 paclitaxel / carboplatin 合併使用相較於 paclitaxel / carbiplatin  使用，有較長的中位數無惡化存活期（10.1 個月 vs. 8.9 個月，危險比：0.74）。",
      "根據 DUO-E，durvalumab 加上 paclitaxel / carboplatin 合併使用相較於 paclitaxel / carbiplatin  使用，有較長的中位數無惡化存活期（危險比：0.71）。",
      "以上只有 3 個是正確的。"
    ],
    "correctAnswer": 0,
    "explanation": "(A)RUBY trial part 1尚未report 5年follow-up data; 選項引用的是2023年3月發表的第一次interim analysis結果：2年PFS HR=0.64, 2年OS HR=0.64，而非5年。2024年8月發表的second interim analysis, 2年 PFS為36.1%(dostarlimab), 18.1% (paclitaxel / carbiplatin), HR 0.64；2年OS則為70.1%(dostarlimab), 54.3% (paclitaxel / carbiplatin), HR 0.69。因此A選項錯誤。\r\n(B)(C)(D)選項正確。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 23,
    "question": "關於子宮頸癌，下列何者是錯誤的？",
    "options": [
      "局部晚期子宮頸癌的患者的 5 年總存活率約 60%，子宮頸癌合併遠端轉移的患者的 5 年總存活率約 19%。",
      "根據 CALLA，durvalumab 加上同步化學放射治療相較於 placebo 加上同步化學放射治療  使用在局部晚期子宮頸癌有較長的無惡化存活率（危險比：0.84）。",
      "根據 ENGOT-cx11 / GOG-3047 / KEYNOTE-A18，pembrolizumab 加上同步化學放射治療  相較於 placebo 加上同步化學放射治療使用，在局部晚期子宮頸癌有較長的無惡化存活 率（危險比：0.70）。",
      "根據 KEYNOTE-158，pembrolizumab 使用在持續、復發、轉移的子宮頸癌的客觀反應率是 14.3%，pembrolizumab 使用在持續、復發、轉移 PD-L1 陽性的子宮頸癌的客觀反應率是 17%。",
      "根據 KEYNOTE-826，pembrolizumab 加上含鉑類化學治療（± bevacizumab）合併使用相較  於 placebo 加上含鉑類化學治療（± bevacizumab）使用在持續、復發、轉移的子宮頸癌，  有較長的 24 個月總存活率：所有受試者（50.4% vs. 40.4%）、PD-L1 CPS >或= 1（53.0%  vs. 41.7%）、PD-L1 CPS >或= 10（54.4% vs. 44.6%）。"
    ],
    "correctAnswer": 1,
    "explanation": "(A) Locally advanced cervical cancer包含FIGO IB3~IVA:\r\n- Confined to the cervix with a clinically visible tumor >4 cm in greatest dimension (stage IB3)\r\n- Invades beyond the uterus but not to the pelvic wall or to the lower third of vagina (stage II)\r\n- Extends to the pelvic sidewall, and/or involves the lower third of vagina, and/or causes hydronephrosis or a nonfunctioning kidney, and/or involves pelvic and/or para-aortic lymph nodes (stage III)\r\n- Invades the mucosa of the bladder or rectum, or extends beyond the true pelvis (stage IVA)\r\n根據Uptodate提供的資料Survival by FIGO stage for patients with cervical cancer: 2018 FIGO statistics，FIGO IB3~IVA的患者5年存活率約為55%，IVB(有遠端轉移)的5年存活率約14.7%，與選項描述尚在相近範圍。\r\n\r\n(B)選項描述的數值正確，不過CALLA為一失敗的臨床試驗：PFS hazard ratio 0.84 (95% CI, 0.65-1.08; P = .17)，p值並未達標。因此無法宣稱durvalumab+CCRT使用在局部晚期子宮頸癌有較長的無惡化存活率。\r\n\r\n(C)(D)(E)選項正確。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/023/explain_figures/5yearOS.jpg"
    ]
  },
  {
    "id": 24,
    "question": "關於表皮卵巢癌的標靶治療，下列何者是錯誤的？",
    "options": [
      "約 30%的 high-grade 表皮卵巢癌有 BRCA1/2 基因突變。",
      "BRACA1/2 基因突變的表皮卵巢癌使用 PARP 抑制劑做為第一線治療的維持治療，可顯著  延長無惡化存活期（中位數增加 2 年以上，危險比介於 0.30 和 0.40 之間）、總存活期（中位數增加 1.5 年以上，危險比介於 0.55 和 0.62 之間）。",
      "BRCA1/2 基因突變的的表皮卵巢癌經過完善減積手術和含鉑化學治療，超過 5 年仍 disease-free 約有 15-20%。BRCA1/2 基因突變的的表皮卵巢癌，若經完善減積手術和含鉑化學治  療後，再使用 PARP 抑制劑做為第一線治療的維持治療，超過 5 年仍然 disease-free 約 50%。",
      "約 60%的表皮卵巢癌是 BRCA1/2 基因野生型、genomic instability scores（GIS）high。",
      "BRACA1/2 基因野生型、genomic instability scores（GIS）high 的表皮卵巢癌使用 PARP  抑制劑做為第一線治療的維持治療，可顯著延長無惡化存活期（危險比 0.50）、 總存活期  （危險比 0.70）。"
    ],
    "correctAnswer": 3,
    "explanation": "(A)正確，2019年一篇流行病學研究統計74位High grade ovarian cancer病患中有25.7%有BRCA mutation。\r\nGynecol Oncol Rep. 2019 Aug 13;29:102-105.\r\n\r\n(B)3個PARPi用於1L maintenance therapy的試驗:\r\n🚩SOLO1: Olaparib vs. placebo as 1L maintenance therapy \r\nmPFS: 56.0 months (Olaparib) vs. 13.8 months (placebo) HR: 0.33\r\nmOS: NR vs 75.2 months, HR: 0.55\r\n🚩PAOLA-1: Olaparib+Bevacizumab vs. Bevacizumab alone as 1L maintenance therapy\r\nBRCAm: mPFS: 60.7 months vs. 21.7 months (placebo) HR: 0.45\r\nmOS: 73.2 months vs. 53.8 months HR: 0.60\r\n🚩PRIMA: Niraparib vs. placebo as 1L maintenance therapy\r\nHRD+: mPFS: 21.9months vs. 10.4 months (placebo) HR: 0.43\r\nmOS 71.9 months vs. 69.8 months HR:0.95\r\n其實PRIMA並未符合題幹敘述。\r\n\r\n(C)正確。SOLO1(Olaparib)和PAOLA-1(Olaparib)的五年PFS，治療組約在50%，對照組約在20%左右。但PRIMA(Niraparib)則是35% vs. 16%，其實並未符合選項敘述。\r\n\r\n(D)錯誤，EOC約50%病人為HRD+，其中一半和BRCA mutation/pathogenic variants相關，另一半為GIS high。GIS high佔全部ovarian cancer病人的25%。\r\n\r\n(E)正確，此群病人即為HRD+ excluding tBRCAm。選項描述為PAOLA-1 trial試驗的結果：PFS HR=0.47, OS HR=0.71",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/024/explain_figures/figure1.jpg",
      "/qabank/024/explain_figures/figure2.jpg"
    ]
  },
  {
    "id": 25,
    "question": "關於非小細胞肺癌的建議，下列哪個敘述是錯誤的？ [ 註明：(C)(D)(E)中提及之期刊，均根據AJCC TNM stage system(8th ed)]",
    "options": [
      "根據 KEYNOTE-671 trial，手術前 neoadjuvant therapy 使用 pembrolizumab plus platinum-doublet   chemotherapy x 4 cycles followed by surgery then adjuvant pembrolizumab 相較於直接 surgery   then adjuvant pembrolizumab ，可顯著延長 event-free survival(EFS)",
      "根據CheckMate 816 trial，手術前neoadjuvant therapy使用nivolumab 加上 platinum-doublet   chemotherapy x 3 cycles相較於neoadjuvant chemotherapy，可顯著延長event-free survival(EFS)。",
      "根據ADAURA trial，對於completely resected stage IB–IIIA or stage IIIB (T3, N2) NSCLC   and positive for EGFR (exon 19 deletion, exon 21 L858R) mutations，術後可考慮使用adjuvant   osimertinib for 3 years。",
      "根據KEYNOTE-091 trial，對於completely resected stage IIB–IIIA, stage IIIB (T3, N2), or   high-risk stage IIA NSCLC and negative for EGFR exon 19 deletion or exon 21 L858R   mutations or ALK rearrangements，不管PD-L1表現如何，術後可考慮使用adjuvant   pembrolizumab for up to 1 year。",
      "根據IMpower010 trial，對於completely resected stage IIB–IIIA, stage IIIB (T3, N2), or  high-risk stage IIA NSCLC with PD-L1 ≥1% and negative for EGFR exon 19 deletion or   exon 21 L858R mutations or ALK rearrangements，術後可考慮使用adjuvant atezolizumab  for up to 1 year。"
    ],
    "correctAnswer": 0,
    "explanation": "(A) 錯誤, KEYNOTE-671 trial 研究比較 neoadjuvant pembrolizumab + platinum-doublet chemotherapy (4 cycles) followed by surgery and adjuvant pembrolizumab vs. surgery followed by adjuvant pembrolizumab。\r\n實際的比較組別應該是：\r\n評估 neoadjuvant pembrolizumab + chemotherapy vs. chemotherapy alone  → surgery → adjuvant pembrolizumab\r\n主要結果：\r\nNeoadjuvant pembrolizumab + chemotherapy 組相較於純化療組顯著延長 EFS。\r\n但試驗對照組並非「直接手術後 adjuvant pembrolizumab」，所以該敘述錯誤。\r\n(B) 正確\r\nCheckMate 816 trial 證實 neoadjuvant nivolumab + platinum-doublet chemotherapy (3 cycles) 相較於單純 neoadjuvant chemotherapy 顯著延長 EFS。\r\n(C) 正確\r\nADAURA trial 研究顯示 對於完全切除 (completely resected) 的 IB-IIIA 或 stage IIIB (T3, N2) EGFR 突變 (exon 19 deletion, exon 21 L858R) 陽性 NSCLC，術後使用 adjuvant osimertinib 3 年可顯著改善無病存活期 (DFS)。\r\n(D) 正確\r\nKEYNOTE-091 trial 研究顯示 完全切除的 IIB-IIIA、IIIB (T3, N2) 或 high-risk IIA 期 NSCLC，EGFR 和 ALK 陰性，不論 PD-L1 表現如何，術後使用 adjuvant pembrolizumab 可長達 1 年。\r\n(E) 正確\r\nIMpower010 trial 研究顯示 PD-L1 ≥1% 且 EGFR/ALK 陰性的 NSCLC (stage IIB–IIIA, stage IIIB T3N2, or high-risk IIA)，術後使用 adjuvant atezolizumab 可長達 1 年。\r\n\r\n1. KEYNOTE-671 Trial: (Perioperative Pembrolizumab in Resectable NSCLC)\r\n目的：評估 perioperative pembrolizumab + Ch/T vs. neoadjuvant Ch/T 在resectable NSCLC (stage II, IIIA, IIIB T3N2) 中的療效。\r\n對象：可手術切除的 II, IIIA, IIIB (T3N2) NSCLC\r\n治療組別：\r\n試驗組：\r\nNeoadjuvant：pembrolizumab (200 mg) + platinum-doublet chemotherapy (Q3W x 4 cycles) > Surgery > Adjuvant pembrolizumab (200 mg Q3W x 13 cycles)\r\n對照組：\r\nNeoadjuvant：placebo + platinum-doublet chemotherapy (Q3Wx 4 cycles) > Surgery > Adjuvant placebo \r\nPrimary endpoint：\r\nEvent-Free Survival (EFS)\r\nOverall Survival (OS)\r\n主要結果\r\nEFS：顯著延長 EFS (HR = 0.58, 95% CI: 0.46–0.72, p<0.001)。\r\nOS： 顯著延長 OS (HR = 0.72, 95% CI: 0.56–0.93, p = 0.004)。\r\npCR: 顯著提高 (18.1% vs. 4.0%)。\r\nMPR (major pathologic response): 顯著提高 (30.2% vs. 11.0%)。\r\n\r\n2. CheckMate 816 Trial (Neoadjuvant Nivolumab in Resectable NSCLC)\r\n目的：評估 neoadjuvant nivolumab + 化療 vs. neoadjuvant 化療 在 resectable stage IB-IIIA NSCLC。\r\n對象：可手術切除的 stage IB (≥4 cm), II, IIIA NSCLC\r\n治療組別：\r\n試驗組：\r\nNeoadjuvant：nivolumab (360 mg) + platinum-doublet chemotherapy (Q3W，共 3 cycles)\r\nSurgery\r\n對照組：\r\nNeoadjuvant：platinum-doublet chemotherapy (Q3W，共 3 cycles)\r\nSurgery\r\nPrimary endpoint：\r\nEvent-Free Survival (EFS)\r\nPathologic Complete Response (pCR)\r\n主要結果\r\nEFS： EFS 顯著提高 (HR = 0.63, p = 0.005)。\r\npCR： pCR 顯著提高 (24.0% vs. 2.2%)。\r\nR0 resection ：顯著提高 (83.2% vs. 75.4%)。\r\nOS (早期分析)：有延長趨勢 (HR = 0.57, 95% CI: 0.38–0.87)。\r\n臨床意義\r\n確立 neoadjuvant nivolumab + 化療作為可切除 NSCLC 的治療選項。\r\n顯著改善 pCR 和 EFS，提高 R0 切除率。\r\n\r\n3. ADAURA Trial (Adjuvant Osimertinib in EGFR+ NSCLC)\r\n目的：評估 adjuvant osimertinib 在 EGFR 突變陽性 (exon 19 deletion, exon 21 L858R) NSCLC 中的療效。\r\n對象：completely resected stage IB-IIIA or stage IIIB (T3N2) EGFR+ NSCLC\r\n治療組別：\r\n試驗組：\r\nAdjuvant：osimertinib (80 mg/day, 持續 3 年)\r\n對照組：\r\nPlacebo\r\nPrimary endpoint：\r\nDisease-Free Survival (DFS)\r\nOverall Survival (OS) (次要終點)\r\n主要結果\r\nDFS (II-IIIA)：osimertinib 顯著延長 DFS (HR = 0.17, 95% CI: 0.12–0.23, p<0.001)。\r\nDFS (全體 IB-IIIA)：HR = 0.20, 95% CI: 0.15–0.27, p<0.001。\r\nOS：更新分析 osimertinib 顯著延長 OS (HR = 0.49, p<0.001)。\r\n臨床意義\r\n確立 adjuvant osimertinib 為 EGFR+ NSCLC 的標準術後治療。\r\n\r\n4.KEYNOTE-091 Trial (Adjuvant Pembrolizumab in Resectable NSCLC)\r\n研究設計\r\n目的：評估 adjuvant pembrolizumab 在 EGFR/ALK 陰性 NSCLC 的療效。\r\n對象：completely resected stage IIB-IIIA or IIIB (T3N2) or high-risk stage IIA NSCLC\r\n治療組別：\r\n試驗組：\r\nAdjuvant：pembrolizumab (200 mg Q3W，最多 1 年)\r\n對照組：\r\nPlacebo\r\nPrimary endpoint：\r\nDFS\r\n主要結果\r\nDFS：pembrolizumab 顯著延長 DFS (HR = 0.76, p = 0.0014)。\r\n臨床意義\r\n確立 adjuvant pembrolizumab 為 EGFR/ALK 陰性 NSCLC 的標準術後治療。\r\n\r\n5.IMpower010 Trial (Adjuvant Atezolizumab in Resectable NSCLC)\r\n研究設計\r\n目的：評估 adjuvant atezolizumab 在 PD-L1 ≥1% 且 EGFR/ALK 陰性 NSCLC 的療效。\r\n主要結果：\r\nDFS (PD-L1 ≥1%)：HR = 0.66, 95% CI: 0.50–0.88, p = 0.0039。\r\nDFS (全體 stage II-IIIA)：HR = 0.79, 95% CI: 0.64–0.96, p = 0.020。\r\n臨床意義\r\n確立 adjuvant atezolizumab 作為 PD-L1 ≥1% NSCLC 的標準術後治療。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 26,
    "question": "關於 ERBB2 (HER2) Mutations 非小細胞肺癌的建議，下列哪個敘述是錯誤的？",
    "options": [
      "ERBB2 (HER2) Mutations發生在大約 3% of patients with advanced nonsquamous非小細胞  肺癌，非小細胞肺癌大部分的ERBB2 (HER2) Mutations可以像乳癌一樣使用  immunohistochemistry評估，較不需要用到NGS。",
      "非小細胞肺癌的ERBB2 (HER2) Mutations較常發生在女性及不吸菸者。",
      "非小細胞肺癌的 ERBB2 (HER2) Mutations 較常發生的是 insertion/duplication events in   exon 20。",
      "資料顯示 ERBB2 mutations 的非小細胞肺癌病人可能 respond to first-line immunotherapy   regimens。",
      "根據 DESTINY-Lung01 trial，metastaticHER2-mutant 非小細胞肺癌病患 refractory to standard treatment 後，使用 trastuzumab deruxtecan 仍有 55% objective response rate 及 92% disease   control rate，median progression-free survival 8.2 months。"
    ],
    "correctAnswer": 0,
    "explanation": "(A) 錯誤，ERBB2 (HER2) mutations 在 非小細胞肺癌 (NSCLC) 中發生於 3% 的 NSCLC 病患。\r\n但與乳癌不同，HER2 mutations 主要透過 NGS (Next-Generation Sequencing) 檢測，而非 IHC (Immunohistochemistry) 評估。\r\n因為在 NSCLC 中，HER2 mutations 與 HER2 overexpression 不一定一致，NGS 檢測更為準確，主因是IHC或FISH僅在 HER2 amplification 時可能有用，但對於肺癌常見的是HER2 mutations，IHC 並非主要檢測方法。以DESTINY-Lung01 Trial的Biomarker analysis 中收錄的病人是以 NGS 檢驗到HER2 mutation/amplification 的病患，其中HER2 mutation exon 20 insertions 就占了86%\r\n(B) 正確，HER2 mutations 在非小細胞肺癌中較常見於女性及不吸菸者，與 EGFR 突變 的族群相似。\r\n(C) 正確，HER2 mutations 在 NSCLC 最常見於 exon 20 insertion/duplication events，約佔 90% 的 HER2 mutations (DESTINY-Lung01 Trial 是86%)\r\n(D) 正確，雖然HER2 mutations 的 NSCLC 病人對免疫治療反應有限，特別是單獨使用因HER2 mutant NSCLC 多數 PD-L1 表達不高，TMB 也較低，但根據meta-analysis，HER2 mutations 對化療 + 免疫治療合併仍有有一定反應 Zhang J, Han W, Guo J, Zhang C, Cao L, Peng L, Han X, Wang Z. Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis. J Cancer Res Clin Oncol. 2024 Jan 27;150(2):42. doi: 10.1007/s00432-023-05509-0\r\n(E) DESTINY-Lung01 Trial：研究 HER2-mutant NSCLC 病人，在標準治療失敗後，使用 trastuzumab deruxtecan。\r\nORR (Objective Response Rate)：55%\r\nDCR (Disease Control Rate)：92%\r\nmPFS (Median Progression-Free Survival)：8.2 個月\r\nmOS (Median Overall Survival)：17.8 個月\r\n證實 T-DXd 對 HER2-mutant NSCLC 有高反應率",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 27,
    "question": "關於治療 EGFR-mutated 的肺癌患者，下列敘述何者錯誤？",
    "options": [
      "Exon 19 del 相較於 Exon 21 L858R mutation 的病患，在接受 EGFR tyrosine kinase inhibitor  (TKI)後有更長的 Progression free survival (PFS)及 Overall survival (OS)。",
      "根據 FLAURA2 trial， 對於 EGFR-mutated advanced NSCLC，Osimertinib plus chemotherapy  相較於 Osimertinib monotherapy，progression-free survival 有顯著延長。",
      "根據 FLAURA trial，第一線使用 Osimertinib 相較於 1st generation TKI 不僅 PFS 有顯著差異，在 updated analysis 中 OS 也有顯著的延長。",
      "對於使用 EGFR target therapy 中 progression 的病人，MET amplification & ERBB2 amplification  是其中有可能的機轉，若能 test 則較佳",
      "對於使用 EGFR target therapy 中 progression 的病人，可做 liquid biopsy for NGS testing 取代  對 progressing lesion 做 tissue biopsy，因 histology transformation such as small cell transformation   幾乎不會發生。"
    ],
    "correctAnswer": 4,
    "explanation": "(A) 正確，Exon 19 deletion (del19) 相較於 Exon 21 L858R mutation，使用 EGFR TKI 後的 PFS 和 OS 較長。\r\nFLAURA trial 的亞組分析顯示，del19 患者的 PFS 和 OS 優於 L858R 突變患者。\r\n(B) 正確，FLAURA2 trial 研究比較了 osimertinib  vs. osimertinib + 化療 (pemetrexed + platinum) 在 EGFR 突變晚期 NSCLC 患者中的效果。\r\n主要結果：\r\nPFS 顯著延長（HR = 0.62, 95% CI: 0.49–0.79, p<0.001）。\r\nORR (Objective Response Rate) 也較高。\r\n(C) 正確，FLAURA trial 研究 osimertinib vs. 第一代 EGFR TKI (gefitinib, erlotinib) 作為 EGFR 突變 NSCLC 的一線治療。\r\n主要結果：\r\nPFS：osimertinib 顯著優於 第一代 TKI (18.9 vs. 10.2 個月)。\r\nOS (updated analysis)：osimertinib 顯著延長 OS (38.6 vs. 31.8 個月, HR = 0.80, p=0.046)。\r\n(D) 正確，EGFR target therapy 進展後，MET amplification 及 ERBB2 amplification 是常見的抗藥性機轉。\r\nReference: Coleman N, Hong L, Zhang J, Heymach J, Hong D, Le X. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. ESMO Open. 2021 Dec;6(6):100319. doi: 10.1016/j.esmoop.2021.100319. Epub 2021 Nov 24. \r\n其他抗藥性機轉包括：\r\nEGFR C797S 突變 (Osimertinib 抗藥性)\r\nHistologic transformation (如小細胞轉化)\r\n其他 bypass pathway activation (如 RAS/PI3K pathway activation)。\r\n\r\n(E) 錯誤\r\nliquid biopsy可用於偵測抗藥性突變 (如 EGFR T790M, MET amplification)，但不能完全取代組織切片 (tissue biopsy)，因為：\r\nHistologic transformation (如小細胞轉化, squamous transformation) 可能發生，liquid biopsy無法檢測這些變化。\r\n在部分 EGFR TKI 進展患者 (~5-10%)，會發生small cell transformation，這需要透過組織切片才能來確診。\r\n如果僅依賴 liquid biopsy，可能會錯失 histologic transformation 導致的治療策略改變",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 28,
    "question": "一位 64 歲男性經由電腦斷層導引切片診斷為肺鱗狀上皮癌(lung squamous cell carcinoma)，  全身性檢查發現有多處雙側肺對肺、肝臟轉移，基因檢測 Roche cobas EGFR mutation test   v2 kit: mutation not detected，ALK immunohistochemistry: negative，PD-L1: 80%，下列治療  何者並非 NCCN guideline 建議?",
    "options": [
      "Carboplatin + paclitaxel + atezolizumab",
      "Pembrolizumab alone",
      "Atezolizumab alone",
      "Carboplatin + paclitaxel + pembrolizumab",
      "Nivolumab + ipilimumab + paclitaxel + carboplatin"
    ],
    "correctAnswer": 2,
    "explanation": "(A) Carboplatin + paclitaxel + atezolizumab ✅ (可行，但非首選)\r\n\r\nIMpower131 trial 顯示，對於 PD-L1 高表現 (≥50%) 的 肺鱗狀細胞癌患者，使用 Carboplatin + nab-paclitaxel + atezolizumab 可延長 PFS，但OS沒有顯著。\r\n因此NCCN guidelines 建議 Atezolizumab 合併化療作為可選方案但 非主要首選方案。\r\n(B) Pembrolizumab alone ✅ (可行)\r\n\r\nKEYNOTE-024 & KEYNOTE-042 trials 顯示：\r\nPD-L1 ≥50% 可單獨使用 pembrolizumab，且相較於化療，能顯著改善 PFS 和 OS。\r\n\r\n(C) Atezolizumab alone ❌ (非 NCCN 指南建議)\r\nIMpower110 trial 顯示 Atezolizumab Alone 雖在 PD-L1 ≥50% NSCLC有顯著療效，但基於IMpower110 trial在OS subgroup analysis並沒有達到顯著，且PD-L1 高表達 (≥50%) 的鱗狀 NSCLC subgroup數據未單獨報告 OS，另外IMpower131化療加上免疫的效果都差強人意，單獨只用Atezolizumab令人不太放心，最終NCCN建議單獨免疫治療僅推薦Pembrolizumab\r\n\r\n(D) Carboplatin + paclitaxel + pembrolizumab ✅ (標準治療)\r\n\r\nKEYNOTE-407 trial 確立了 Carboplatin + paclitaxel + pembrolizumab 為 PD-L1 高表達 (≥50%) 鱗狀肺癌的標準一線治療。\r\n(E) Nivolumab + ipilimumab + paclitaxel + carboplatin ✅ (可行)\r\nCheckMate 9LA trial 顯示，nivolumab + ipilimumab  + 2 cycles 化療 可顯著改善 OS。\r\n\r\n1. IMpower131 Trial (Carboplatin + nab-Paclitaxel + Atezolizumab in Squamous NSCLC)\r\n研究設計\r\n目的：評估 Carboplatin + nab-Paclitaxel + Atezolizumab 相較於 Carboplatin + nab-Paclitaxel (化療對照組) 在 轉移性鱗狀非小細胞肺癌 (LUSC, stage IV) 的療效。\r\n對象：未接受過系統性治療的轉移性鱗狀 NSCLC (Stage IV LUSC)\r\n治療組別：\r\n試驗組：\r\nAtezolizumab + Carboplatin + nab-Paclitaxel\r\n對照組：\r\nCarboplatin + nab-Paclitaxel (化療)\r\n主要終點：\r\nProgression-Free Survival (PFS)\r\nOverall Survival (OS)\r\n主要結果\r\nPFS (PD-L1 ≥50%)：\r\nAtezolizumab + 化療顯著延長 PFS (6.3 vs. 5.6 個月, HR = 0.71, p = 0.0001)。\r\nOS (全體受試者)：\r\n未達統計顯著差異 (HR = 0.88, p = 0.14)。\r\n臨床意義\r\nIMpower131 顯示 Atezolizumab + 化療可改善 PFS，但對 OS 的影響有限。\r\n\r\n2. KEYNOTE-024 & KEYNOTE-042 Trials (Pembrolizumab  Monotherapy  in  High PD-L1 NSCLC)\r\n研究設計\r\n目的：評估 Pembrolizumab  alone  vs. 標準化療 在 PD-L1 高表達 (≥50%) 的 NSCLC 之間的療效比較。\r\n對象：PD-L1 TPS ≥50% (KEYNOTE-024) 或 PD-L1 TPS ≥1% (KEYNOTE-042) 的轉移性 NSCLC\r\n治療組別：\r\n試驗組：\r\nPembrolizumab 單藥\r\n對照組：\r\n鉑類化療 (Carboplatin 或 Cisplatin + Pemetrexed 或 Paclitaxel)\r\n主要終點：\r\nOverall Survival (OS)\r\nProgression-Free Survival (PFS)\r\n主要結果\r\nKEYNOTE-024 (PD-L1 ≥50%)：\r\nOS：Pembrolizumab 顯著延長 OS (26.3 vs. 14.2 個月, HR = 0.62, p < 0.0001)。\r\nPFS：Pembrolizumab 顯著優於化療 (10.3 vs. 6.0 個月, HR = 0.50, p < 0.001)。\r\nKEYNOTE-042 (PD-L1 ≥1%)：\r\nOS (PD-L1 ≥50%)：HR = 0.69, p < 0.0001。\r\n但 PD-L1 1-49% 患者的 OS 改善不如高表達組。\r\n臨床意義\r\nPembrolizumab alone治療可作為 PD-L1 ≥50% 轉移性 NSCLC 的一線標準治療。\r\n\r\n3. IMpower110 Trial (Atezolizumab  Monotherapy in  High  PD-L1 NSCLC)\r\n研究設計\r\n目的：評估 Atezolizumab 單藥 vs. 化療 在 PD-L1 高表達 NSCLC 的療效。\r\n對象：PD-L1 TPS ≥50% 的轉移性非小細胞肺癌 (NSCLC)\r\n治療組別：\r\n試驗組：\r\nAtezolizumab  alone\r\n對照組：\r\n鉑類化療\r\n主要終點：\r\nOverall Survival (OS)\r\n主要結果\r\nOS (PD-L1 ≥50%)：\r\nAtezolizumab 顯著延長 OS (20.2 vs. 13.1 個月, HR = 0.59, p = 0.0106)。\r\n臨床意義\r\nIMpower110 支持 Atezolizumab 單藥作為 PD-L1 ≥50% 非鱗狀 NSCLC (Adenocarcinoma) 的一線選擇。\r\n\r\n\r\n4. KEYNOTE-407 Trial (Carboplatin + Paclitaxel + Pembrolizumab in  Squamous NSCLC)\r\n研究設計\r\n目的：評估 Carboplatin + Paclitaxel + Pembrolizumab vs. 化療 在 轉移性肺鱗狀細胞癌 (LUSC, stage IV) 的療效。\r\n對象：轉移性 LUSC\r\n治療組別：\r\n試驗組：\r\nCarboplatin + Paclitaxel + Pembrolizumab\r\n對照組：\r\nCarboplatin + Paclitaxel (化療)\r\n主要終點：\r\nOverall Survival (OS)\r\nProgression-Free Survival (PFS)\r\n主要結果\r\nOS：\r\nPembrolizumab + 化療組 OS 顯著延長 (15.9 vs. 11.3 個月, HR = 0.64, p < 0.0001)。\r\nPFS：\r\nPembrolizumab + 化療組 PFS 亦顯著延長 (6.4 vs. 4.8 個月, HR = 0.56, p < 0.0001)。\r\n臨床意義\r\nKEYNOTE-407 確立了 Pembrolizumab + 化療為 PD-L1 高表達 LUSC 的標準治療。\r\n\r\n5.CheckMate 9LA Trial (Nivolumab + Ipilimumab + Chemotherapy in NSCLC)\r\n目的：評估 Nivolumab + Ipilimumab + 短程化療 vs. 標準化療 在 晚期 NSCLC (包括 LUSC) 的療效。\r\n研究類型：Phase 3, Randomized, Open-label\r\n主要結果：\r\nOS：Nivolumab + Ipilimumab + 化療 顯著延長 OS (15.6 vs. 10.9 個月, HR = 0.66, p < 0.0001)。\r\n臨床意義\r\nCheckMate 9LA 支持 Nivolumab + Ipilimumab + 化療作為 NSCLC 的一線治療。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 29,
    "question": "關於肺癌標靶藥物及基因突變配對，下列敘述何者錯誤？",
    "options": [
      "MET exon 14 skipping – selpercatinib, pralsetinib",
      "ROS1 rearrangement – crizotinib, entrectinib",
      "EGFR exon 20 insertion mutation - amivantamab",
      "NTRK1/2/3 gene Fusion – larotrectinib, entrectinib",
      "KRAS G12C mutation –sotorasib, adagrasib"
    ],
    "correctAnswer": 0,
    "explanation": "根據NCCN Non-small Cell Lung Cancer, Version 3.2025 — January 14, 2025\r\n其中A選項中selpercatinib, pralsetinib為口服給予的highly selective RET inhibitors。Pivotal trial  LIBRETTO-001 (Selpercatinib) 以及 ARROW trial (pralsetinib)。因此，此兩者藥物不用於MET exon 14 skipping的mutation",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/029/explain_figures/Fig 1.jpg"
    ]
  },
  {
    "id": 30,
    "question": "一位 62 歲男性,健康檢查意外發現胸部腫塊,而經電腦斷層及支氣管鏡診斷為右側肺部肺腺癌,有惡性肋膜積水,基因檢測 Roche cobas EGFR mutation test v2 kit: mutation not detected,ALK immunohistochemistry: negative,PD-L1: 10%,ECOG PS 為 1。針對上述病患,下列敘述何者錯誤?",
    "options": [
      "可接受 atezolizumab + bevacizumab + carboplatin + paclitaxel 做為第一線治療。",
      "此病患可選擇 pembrolizumab + cisplatin + pemetrexed 做為第一線治療。",
      "若病患第一線已接受過 platinum-doublet chemotherapy 疾病仍進展,可考慮使用pembrolizumab 或 nivolumab 或 atezolizumab 或 durvalumab 做為二線治療。",
      "若病患第一線已接受過 pembrolizumab + cisplatin + pembrolizumab 疾病仍進展,可考慮使用 ramucirumab/docetaxel 做為二線治療。",
      "若病患在接受過 4-6 個療程的化學治療加上免疫治療,且疾病整體無惡化的情形下,可考慮單獨使用免疫治療做為 maintenance therapy。"
    ],
    "correctAnswer": 2,
    "explanation": "根據NCCN Non-small Cell Lung Cancer, Version 3.2025 — January 14, 2025\r\n\r\n首先：題幹關鍵詞「 右側肺部肺腺癌,有惡性肋膜積水」 因此至少M1a起跳, 根據AJCC 8版staging為Stage IVA\r\n\r\n再者：基因檢測結果沒有EGFR mutation/ ALK rearrangement，僅有PD-L1: 10%\r\n\r\n治療  可以使用免疫加上化療\r\n\r\n(A) 正確。根據IMpower150 (N Engl J Med 2018;378:2288-2301)   atezolizumab + bevacizumab + carboplatin + paclitaxel (ABCP) 是轉移性EGFR/ALK 陰性的晚期非鱗狀 NSCLC 一線治療選擇。 與 BCP（bevacizumab + carboplatin + paclitaxel）相比，ABCP 組的 PFS/OS皆有顯著提升。\r\n\r\n(B) 正確。依據 KEYNOTE-189 (N Engl J Med 2018;378:2078-2092) pembrolizumab + platinum-based chemotherapy（cisplatin/ carboplatin + pemetrexed）為轉移性 EGFR/ALK 陰性、PD-L1 any expression nonsquamous NSCLC 之一線治療；相較於單純化療，Pembrolizumab+C/T 顯著提升 OS/ PFS，且 PD-L1 ≥1% 皆有療效，PD-L1 ≥50% 效果更明顯。\r\n\r\n(C) 錯誤。Durvalumab 不適用於二線治療\r\n*Nivolumab（CheckMate 017/057; J Clin Oncol. 2021 Mar 1;39(7):723-733.）\r\n*Atezolizumab（OAK；Lancet. 2017 Jan 21;389(10066):255-265.）\r\n*Pembrolizumab（KEYNOTE-010；Lancet. 2016 Apr 9;387(10027):1540-1550.）\r\n\r\n(D) 正確。根據 REVEL trial（Lancet. 2014 Aug 23;384(9944):665-73.），ramucirumab + docetaxel 在接受過 platinum-based chemotherapy 失敗的轉移性NSCLC 可提升 OS/ PFS，為二線標準治療選擇之一\r\n\r\n(E) 根據臨床試驗設計KEYNOTE-189(Pembrolizumab), IMpower150(Atezolizumab),CheckMate 9LA (Nivolumab/ipilimumab) 可考慮單獨使用免疫治療做為 maintenance therapy",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 31,
    "question": "罹患惡性腫瘤的病患因為 cerebral metastases with/without intracranial hemorrhage、leptomeningeal metastases、dural sinus thrombosis due to cancer-associated hypercoagulability 或 CNS infection in immunocompromised hosts 等原因,可能引發「increased intracranial pressure (IICP)」的急症。以下為有關 IICP 藥物治療及處置的敘述,正確的是:",
    "options": [
      "Intracranial hemorrhage 所引起的腦水腫應投予大劑量 systemic corticosteroids(相當於 100 mg/day dexamethasone)。",
      "Mannitol 為 hyperosmolar agent,可降低 ICP,常用的劑量為 7.5~ 10g/kg、每 4-6 小時投予一次。",
      "氣管插管施以 mechanical hyperventilation 可有效地降低 ICP,該處置應將病患的 PaCO2下降至 12~15mmHg,才能獲致最佳的治療效果。",
      "Obstructive hydrocephalus 應考慮神經外科手術處置(如 external ventriculostomy 或ventriculoperitoneal shunting);但,normal pressure hydrocephalus (NPH)不應該考慮外科治療。",
      "若病患懷疑罹患 CNS lymphoma、且尚未獲得組織學診斷時,應避免使用 systemic corticosteroids。"
    ],
    "correctAnswer": 4,
    "explanation": "(A) 錯誤。類固醇主要對 vasogenic edema（如腫瘤引起的腦水腫） 有效，但對出血性腦水腫無效，甚至可能增加感染、胃潰瘍及高血糖風險。\r\n\r\n(B) 錯誤。NCCN Guidelines 及神經重症學指南：建議使用較低劑量（0.25-1 g/kg），並監測 血漿滲透壓（維持 ≤320 mOsm/L），避免過度使用導致反彈性顱內壓升高。\r\n\r\n(C) 錯誤。急性 IICP 危急處理時，可短暫降低 PaCO₂ 至 30-35 mmHg（但避免長期維持）；過度換氣（PaCO₂ <25 mmHg）會造成腦血流灌注不足，導致缺血性腦損傷。\r\n\r\n(D) 錯誤。VP shunting（腦室腹腔分流術）是 NPH 的標準治療選擇之一，可改善典型症狀（步態不穩、尿失禁、認知功能下降）。\r\n\r\n(E) 正確。在 CNS lymphoma 診斷未確立前，避免使用corticosteroids，因為 類固醇會造成腫瘤細胞退縮，可能影響 病理組織學診斷，導致無法獲得確切的組織學證據 (NCCN Guidelines 及多篇研究，類固醇可能使腫瘤縮小甚至暫時消失，影響腫瘤的組織切片診斷)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 32,
    "question": "下列關於 chronic myeloid leukemia (CML)的敘述何者錯誤?",
    "options": [
      "Ponatinib 可用於治療具有 T315I mutation 之 CML",
      "於 chronic phase 時第一線治療,dasatinib 與 imatinib 治療效果 OS (overall survival) 並無明顯差別。",
      "於 chronic phase 時第一線治療,imatinib 比起 nilotinib 雖治療效果 OS (overall survival)並無明顯差別,但 imatinib 有較快的 treatment response。",
      "Asciminib 結合於 the myristoyl site of the BCR-ABL protein,可用於之前已接受過兩種或以上之 tyrosine kinase inhibitors (TKIs)治療的 CML 病患。",
      "使用 dasatinib 於第一線治療 chronic phase CML (typical e13a2 or e14a2 BCR-ABL1transcripts),效果達到 deep molecular response大於 3 年且使用時間大於 5 年,可以考慮停藥觀察 BCR-ABL 表現量。"
    ],
    "correctAnswer": 2,
    "explanation": "(A) 正確。根據PACE trial (Blood. 2018 Jul 26;132(4):393-404.)。其中T315I mutation 對 imatinib、dasatinib、nilotinib、bosutinib 等 第一、二代 TKIs 具有抗藥性，但 Ponatinib 可克服 T315I 突變。 \r\n\r\n(B) 正確。根據 DASISION trial（N Engl J Med 2010;362:2260-2270）。Dasatinib 相較於 Imatinib達到 MMR 及 CCyR 的速率較快；長期 OS 並未顯示顯著差異。\r\n\r\n(C) 錯誤。根據ENESTnd trial（N Engl J Med 2010;362:2251-2259）。試驗顯示Nilotinib 300 mg BID 在 12 個月時達到 MMR（Major Molecular Response）/ DMR（Deep Molecular Response）的比率高於 Imatinib 400 mg QD; CCyR（Complete Cytogenetic Response） 也比 imatinib 來得快; 長期 OS 並未顯示出顯著差異。\r\n\r\n(D) 正確。根據ASCEMBL trial （Blood (2021) 138 (21): 2031–2041.）\r\n\r\n(E) 正確。根據 EURO-SKI  trial（J Clin Oncol. 2024 Jun 1;42(16):1875-1880.）及DADI  trial（Lancet Haematol. 2020 Mar;7(3):e218-e225.） \r\n Dasatinib 可作為 TKI 停藥（treatment-free remission, TFR）策略的一部分。\r\n*Treatment-free remission (TFR )的條件：\r\n- 持續 DMR（MR4.0 或 MR4.5）≥ 3 年\r\n- TKI 治療時間 ≥ 5 年\r\n\r\n*另個研究DASFREE trial（Br J Haematol. 2023 Sep;202(5):942-952.）也支持 dasatinib 停藥可行，但須密切監測 BCR-ABL1 表現量。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/032/explain_figures/Fig 1.jpg"
    ]
  },
  {
    "id": 33,
    "question": "下列關於 Hodgkin lymphoma 的敘述何者錯誤?",
    "options": [
      "Early-stage Hodgkin lymphoma 的風險因子包含: bulky disease、ESR 及侵犯的淋巴區域。",
      "Interim PET/CT scan 的評估結果可用以決定後續治療。",
      "高復發風險的 Hodgkin lymphoma，於自體幹細胞移植後，接受 anti-CD30 antibody-drug   conjugate (ADC)–brentuximab vedotin 的鞏固治療可改善 PFS。",
      "根據 ECHELON-1 的結果: 在 stage III/IV Hodgkin lymphoma 的第一線治療中，brentuximab   vedotin 合併化療相較於傳統的化療 ABVD，有較長的 PFS 及 OS，且較少的 febrile   neutropenia。",
      "relapse/refractory Hodgkin lymphoma 接受 PD-1 inhibitor，若接受異體幹細胞移植，可能有較高風險產生 graft versus host disease (GVHD)。"
    ],
    "correctAnswer": 3,
    "explanation": "錯誤的選項是 (D)，因為 ECHELON-1 研究顯示 brentuximab vedotin + AVD 確實有較長的 PFS，但沒有顯著改善 OS，且 febrile neutropenia 反而較高。\r\n(A)Early-stage Hodgkin lymphoma (HL) 的風險因子包括 bulky disease（通常指縱膈腫塊直徑 ≥10 cm）、ESR（erythrocyte sedimentation rate，紅血球沉降速率）升高，以及受侵犯的淋巴區域數目（通常 >3 個淋巴結區域代表較高風險）。\r\n(B)Interim PET/CT scan（通常在 2-3 個療程後進行）可用於評估治療反應，根據 Deauville score 來決定是否需要調整後續治療。例如，若 PET/CT 顯示良好反應（Deauville 1-3），可能可減少治療強度；若反應不佳（Deauville 4-5），可能需要升級治療策略。\r\n(C)高復發風險的 Hodgkin lymphoma（例如初始疾病廣泛、初治後快速復發或對治療反應不佳），在接受**自體幹細胞移植（ASCT）**後，若再接受 anti-CD30 antibody-drug conjugate (ADC) - brentuximab vedotin 作為鞏固治療，可顯著改善 無進展生存期（PFS）。這點已經在 AETHERA trial 中得到證實。\r\n(E)在 relapse/refractory Hodgkin lymphoma（復發/難治性 HL）中，PD-1 inhibitors（如 nivolumab、pembrolizumab） 是有效的治療選擇。然而，若患者後續接受 異體幹細胞移植（allo-HSCT），則可能增加移植物抗宿主病（GVHD）的風險，因為 PD-1 抑制可能增強 T 細胞活性，進而誘發更嚴重的免疫反應。這一點在臨床上已被觀察到，因此選項是正確的。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 34,
    "question": "台灣已通過 Chimeric antigen receptor T cell (CAR-T)的健保適應症，下列關於 CAR-T 應用於diffuse large B-cell lymphoma (DLBCL)的敘述，何者錯誤?",
    "options": [
      "Tisagenlecleucel (tisa-cel) 是一種 針對 CD19 的 CAR-T。",
      "曾接受 bendamustine 治療 CAR-T 細胞治療效果和存活較差。",
      "Cytokine release syndrome (CRS)為 CAR-T 常見的副作用，所有發生 CRS 的病人都必須進行血液培養、尿液培養、胸部 X 光等檢查，用以排除感染的可能性。",
      "當出現 grade 2以上CRS時應給予tocilizumab 治療。",
      "當病人接受 CAR-T 後出現意識混亂、癲癇發作或語言障礙等神經學表現，應評估是否為immune effector cell-associated neurotoxicity syndrome (ICANS)，並應先給予 tocilizumab 治療。"
    ],
    "correctAnswer": 4,
    "explanation": "錯誤的選項是 (E)，因為 ICANS 的首選治療是類固醇（如 dexamethasone），而非 tocilizumab。\r\n(A)主要適用於 復發/難治性（R/R）大B細胞淋巴瘤（DLBCL）。CD19 是 B 細胞表面的標誌，許多 CAR-T 細胞治療（如 tisa-cel、axi-cel、liso-cel）都是針對 CD19 設計的，以選擇性攻擊 B 細胞惡性腫瘤\r\n(B)Bendamustine 是一種烷化劑類的化療藥物，會抑制 T 細胞的功能與數量，影響 CAR-T 細胞的擴增與持久性，進而降低治療效果。接受 bendamustine 作為bridging therapy 的患者，其 CAR-T 細胞增殖較差，治療反應較低，PFS 和 OS 皆較短。\r\n(C)細胞激素釋放症候群（CRS, Cytokine Release Syndrome） 是 CAR-T 療法的最常見副作用，通常發生在治療後幾天內，嚴重時可導致高燒、低血壓、低氧、器官衰竭。由於 CRS 與感染症狀類似，所有發生 CRS 的患者應進行感染評估，包括 血液培養、尿液培養、胸部 X 光 等，以排除感染導致的敗血症或肺炎。\r\n(D)Tocilizumab 是一種 IL-6 receptor antagonist，可減輕 CAR-T 細胞引起的過度免疫反應，特別適用於 中重度 CRS（Grade 2–4）。若患者合併低血壓、低氧，應及早給予 tocilizumab。若症狀更嚴重（如 Grade 3-4），可能需要合併類固醇治療。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 35,
    "question": "下列關於 multiple myeloma (MM)治療的敘述，何者錯誤?",
    "options": [
      "接受自體幹細胞移植後，銜接 lenalidomide 維持治療可延長 PFS。",
      "Carfilzomib 為第二代的 proteasome inhibitor，可用以治療 relapse/refractory MM，相較於  第一代 的 bortezomib 較少出現心衰竭或心律不整等副作用。",
      "Daratumumab 為 anti-CD38 單株抗體，使用前應建立病人完整的血型報告。",
      "Elotuzumab 為 anti- SLAMF7 單株抗體，可與 pomalidomide 及 dexamethasone 合併使用於  治療 lenalidomide-refractory MM。",
      "Ide-cel 為針對 BCMA 的 CAR-T，於 relapse/refractory MM 相較於傳統治療有較長的 PFS。"
    ],
    "correctAnswer": 1,
    "explanation": "錯誤的選項是 (B)，因為 Carfilzomib 的心血管副作用（如心衰竭、心律不整）比 bortezomib 更常見，而不是較少。\r\n其餘選項均符合臨床研究結果與現行治療指引。Carfilzomib 是第二代 proteasome inhibitor（PI），可用於治療復發/難治性多發性骨髓瘤（R/R MM）。與第一代 bortezomib 相比，carfilzomib 確實有較低的周邊神經病變（peripheral neuropathy）風險，這是 bortezomib 常見的副作用。但 carfilzomib 反而較容易導致心血管副作用，如高血壓、心律不整及心衰竭。研究顯示，carfilzomib 相關的 高血壓（~12-15%）、心衰竭（~4-7%）與心律不整（~3-5%）的風險較 bortezomib 更高。因此，說「carfilzomib 心臟副作用較少」是錯誤的。\r\n(A)Lenalidomide 維持治療可延長 PFS。自體幹細胞移植（ASCT） 是年輕且體能狀況良好的多發性骨髓瘤（MM）患者的標準治療方式之一。研究（如 CALGB 100104 和 IFM 2005-02）顯示，移植後使用 lenalidomide 作為維持治療，可顯著延長無進展生存期(PFS），甚至改善整體存活（OS）。\r\n然而，lenalidomide 維持治療可能增加次發性惡性腫瘤（secondary malignancy）的風險，因此需權衡風險與效益。\r\n(C)Daratumumab 為抗 CD38 單株抗體，使用前應建立病人的完整血型報告。Daratumumab 是一種 anti-CD38 單株抗體，作用於 MM 細胞上的 CD38 分子，能透過抗體依賴性細胞毒性（ADCC）和補體依賴性細胞毒性（CDC）來破壞腫瘤細胞。由於 Daratumumab 會與紅血球上的 CD38 交叉反應，可能干擾血型檢測（如 Indirect Coombs test），影響輸血匹配，使用前需建立完整的血型檔案。此外，Daratumumab 可能引起輸液相關反應（infusion-related reactions, IRR），因此需預防性給藥（如類固醇、抗組織胺、乙醯半胱氨酸等）。\r\n(D)Elotuzumab 為 anti-SLAMF7 單株抗體，可與 pomalidomide 及 dexamethasone 合併用於 lenalidomide-refractory MM。 Elotuzumab 針對 SLAMF7（Signaling Lymphocytic Activation Molecule Family member 7），可增強 NK 細胞對 MM 細胞的毒殺作用。在 lenalidomide-refractory MM 中，elotuzumab 可與 pomalidomide（第二代 IMiD）及 dexamethasone 併用，此組合已獲批用於治療 R/R MM（ELOQUENT-3 研究）。\r\n(E)Ide-cel 為針對 BCMA 的 CAR-T，於 relapse/refractory MM 相較於傳統治療有較長的 PFS。BCMA（B-cell maturation antigen） 是 MM 細胞特異性標記，CAR-T 細胞療法如 idecabtagene vicleucel（Ide-cel, Abecma） 可針對 BCMA 來清除 MM 細胞。KarMMa 研究顯示，對於多線治療失敗的 R/R MM，ide-cel 可顯著延長 PFS，相較於標準治療有更高的緩解率。另一款針對 BCMA 的 CAR-T 療法 cilta-cel（ciltacabtagene autoleucel, Carvykti） 亦顯示類似效果，甚至 PFS 更長。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 36,
    "question": "以下關於 Diffuse large B-cell lymphoma (DLBCL)關於 germinal center B-cell (GCB) and activated B-cell (ABC) type 之敘述，何者錯誤 ?",
    "options": [
      "CD10 and BCL6 比較容易在GCB type表現。",
      "interferon response factor 4/MUM1 比較容易在 ABC type 表現。",
      "GCB type 比例較高。",
      "DLBCL 表現為 CD10-, BCL6+, MUM1+依據 Hans algorithm 為 GCB type。",
      "DLBCL with double expression 大多為 ABC type。"
    ],
    "correctAnswer": 3,
    "explanation": "錯誤的選項是 (D)，因為 CD10-, BCL6+, MUM1+ 依據 Hans algorithm 應歸類為 ABC type，而非 GCB type。\r\nHans algorithm 是最常用的 DLBCL 亞型分類方法，主要依據 CD10、BCL6 和 MUM1（IRF4）表現來區分 GCB 或 ABC type：\r\nCD10+ → GCB type\r\nCD10-，BCL6+，MUM1- → GCB type\r\nCD10-，BCL6+，MUM1+ → ABC type（錯誤選項的條件）\r\nCD10-，BCL6-，MUM1+ → ABC type\r\n因此，CD10-, BCL6+, MUM1+ 為 ABC type，而非 GCB type，這是此選項錯誤之處。\r\n(A)CD10 和 BCL6 比較容易在 GCB type 表現。Diffuse large B-cell lymphoma (DLBCL) 根據基因表現可分為 germinal center B-cell-like (GCB) 型 和 activated B-cell-like (ABC) 型。CD10 和 BCL6 是 生發中心（germinal center, GC）相關標誌，因此 GCB type 常表現 CD10 和 BCL6。\r\n(B)Interferon response factor 4 (IRF4)/MUM1 比較容易在 ABC type 表現。MUM1（IRF4）是 plasma cell differentiation marker，與活化 B 細胞相關，主要表現在 ABC type DLBCL。GCB type 一般不會表現 MUM1，或者表現量較低。\r\n(C)GCB type 比例較高。DLBCL 約 50–60% 屬於 GCB type，而 ABC type 約佔 30–40%。GCB type 預後較佳，而 ABC type 預後較差，對標準 R-CHOP 治療反應較差。\r\n(E)DLBCL with double expression（即 Myc 和 BCL2 高表現的 \"double expressor lymphoma\"）大多為 ABC type。\"Double expressor\" lymphoma 指的是 Myc+ 和 BCL2+（IHC 檢測），這類 DLBCL 通常預後較差。研究顯示 \"double expressor\" lymphoma 主要屬於 ABC type，因為 ABC type DLBCL 更常伴隨 BCL2 過度表現，而 GCB type 則較少見。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 37,
    "question": "關於 primary central nervous system lymphoma (PCNSL)的描述，以下何者錯誤？",
    "options": [
      "PCNSL 被歸類在 non-Hodgkin lympoma 內，發生率約佔 NHL 1%,好發年齡中位數約 65 歲。",
      "PCNSL 約 90%為 diffuse large B cell lymphomas, 其餘包含 T-cell, Burkitt, lymphoblastic  及 poor characterized low-grade lymphomas。",
      "針對 PCNSL，HD-MTX based chemotherapy +/- whole brain radiotherapy(WBRT)是證實有效  的治療方式。",
      "大部分的病患接受 HD-MTX based therapy 後，復發機會極低。",
      "PCNSL 最常見的長期併發症為延遲性神經毒性，其中年紀>60 歲或接受過 WBRT 的  病患發生機率較高。"
    ],
    "correctAnswer": 3,
    "explanation": "Despite recent therapeutic progress and improved survival for many patients with primary central nervous system lymphoma (PCNSL), up to 50% of patients will experience refractory or relapsed disease following first-line treatment with high dose methotrexate (HD-MTX) based regimens. The majority of such events occur within 2 years.\r\n\r\nref: Ambady P, Doolittle ND, Fox CP. Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice. Ann Lymphoma. 2021;5:23. doi:10.21037/aol-21-20",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 38,
    "question": "55 歲女性初診斷胃腺癌第四期，合併肝及腹腔轉移，ECOG PS 0，病理組織免疫染色檢查  結果為 HER2: 3+、PD-L1 CPS=1、pMMR，下列何種配方為此病患之第一線治療首選?",
    "options": [
      "Fluoropyrimidine, cisplatin and trastuzumab",
      "Fluoropyrimidine, oxaliplatin and trastuzumab",
      "Fluoropyrimidine, oxaliplatin, trastuzumab, and nivolumab",
      "Nivolumab and ipilimumab",
      "Fluoropyrimidine, oxaliplatin, trastuzumab, and pembrolizumab"
    ],
    "correctAnswer": 4,
    "explanation": "KEYNOTE-811 試驗顯示，在 HER2 陽性晚期胃癌患者中，pembrolizumab + trastuzumab + 化療（如 5-FU + oxaliplatin） 能顯著提高ORR，增加PFS，因此成為 FDA 批准的標準一線治療方案。(小補充：CheckMate-649雖然顯示 nivolumab + 化療可以提高胃癌患者的存活率但是選擇的是HER2 陰性患者，因此nivolumab + trastuzumab 的組合仍缺乏明確的大型 III 期臨床試驗支持。)因此，根據目前的臨床試驗數據，KEYNOTE-811 試驗提供了最強的證據支持 pembrolizumab + trastuzumab 作為 HER2 陽性胃癌一線治療的一部分，這使得選項 (E) 更符合目前的標準治療建議。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 39,
    "question": "下列有關 Peptide Receptor Radionucide Therapy (PRRT) 的敘述, 何者有誤?",
    "options": [
      "評估病人是否適合接受 PRRT, 最重要是要看腫瘤 SSTR 的表現。",
      "SSTR 的表現主要是由 SSTR-PET/CT or SSTR-PET/MRI 來評估, Krenning score ≥1 即可考慮  接受 PRRT。",
      "PRRT 的長期副作用要小心血液疾病,如骨髓增生不良性疾病或白血病。",
      "NETTER1 結果顯示 PRRT 在 SSTR 陽性的 midgut NET, 比高劑量 octreotide 更能增加 ORR  及延長 PFS。",
      "NETTER2 結果顯示 PRRT 在 SSTR 陽性的 G2 or G3 GEP NET, 比高劑量 octreotide 更能增加  ORR 及延長 PFS。"
    ],
    "correctAnswer": 1,
    "explanation": "Krenning 評分用於評估神經內分泌腫瘤對生長抑素受體的攝取程度。 通常，當 Krenning 評分大於 2 時，表示腫瘤有明顯的 SSTR 表現，能有效吸收放射性同位素，才考慮進行 PRRT 治療。 因此，選項 (B) 中提到的 Krenning 評分 ≥1 即可考慮接受 PRRT 是不正確的。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 40,
    "question": "關於局部晚期食道癌的 chemoradiotherapy (CRT)治療，下列描述何者不正確?",
    "options": [
      "使用配方應優先考慮carboplatin plus paclitaxel regimen (CROSS trial) 或是 fluorouracil plus  cisplatin (CALGB 9781 trial)。",
      "CROSS and CALGB 9781 trial 兩組的對照組都是手術切除，因此目前仍無 carboplatin plus  paclitaxel vs fluoruracil plus cisplatin 兩種 regimens 的 head to head 直接比較。",
      "CROSS trial 因收案量不足而提早結束，因療效不成熟，台灣健保局不願給付 carboplatin plus paclitaxel 在食道癌患者使用。",
      "CRT後接受手術切除，若病理報告呈現 residual tumor，可以考慮使用 nivolumab  一年來增加 disease-free survival。",
      "CRT後接受手術切除，若病理報告呈現 complete pathology response，後續不用接受  adjuvant treatment。"
    ],
    "correctAnswer": 2,
    "explanation": "CROSS 試驗是一項大型隨機對照試驗，評估了 carboplatin 加 paclitaxel 的新輔助化療聯合放療在食道癌治療中的效果。 該試驗結果顯示，該治療方案可提高患者的總生存率。 因此，選項 (C) 中關於 CROSS 試驗因收案量不足而提早結束，且療效不成熟的描述是不正確的。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 41,
    "question": "70歲女性病患，罹患胃癌四期合併肝轉移，MSS、HER2 3+、CPS 1，第一線接受herceptin + pembrozilumab + capecitabine + oxalipatin 治療3個月後，腫瘤反應PR，但3個月後再度評估顯示progressive disease with enlarged liver metastases，下列何者治療方式較不考慮?",
    "options": [
      "考慮重新切片重新檢測HER2，若HER2 持續overexpression，考慮 Fam-trastuzumab deruxtecan作為二線治療",
      "可以考慮使用 ramucirumab plus paclitaxel",
      "可以考慮單獨使用 docetaxel",
      "可以考慮單獨使用 ramucirumab",
      "可以考慮單獨使用 trifluridine-tipiracil"
    ],
    "correctAnswer": 4,
    "explanation": "(A) 正確。根據DESTINY-Gastric02 ，在接受過trastuzumab-containing regimen後progression的HER2+ advanced gastric or GEJ cancer，若重新切片仍是HER2+，用TDXd治療有顯著療效，ORR 38%，PFS 5.5 months\r\n(B) 正確。 根據RAINBOW，胃癌二線治療ramucirumab + paclitaxel vs. placebo + paclitaxel，OS 9.6 vs. 7.4 months (HR=0.807, p=0.0169)，ramucirumab + paclitaxel 是二線治療的標準選擇\r\n(C) 正確。根據COUGAR-02，docetaxel monotherapy可作為二線治療選項，尤其是Ramu不適合的病人(ESMO guideline, gastric cancer) \r\n(D) 正確。 根據REGARD，ramucirumab monotherapy可作為二線治療選項，尤其是不適合化療的病人\r\n(E) 錯誤。根據TAGS，trifluridine-tipiracil是三線或後續治療的選項\r\n=> Ans. (E)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/041/explain_figures/Figure_41.jpg"
    ]
  },
  {
    "id": 42,
    "question": "Which one is not the recommendation for molecular therapeutic targets testing in unresectable or metastatic biliary tract cancers?",
    "options": [
      "NTRK gene fusion",
      "BRAF V600E mutation",
      "IDH1 mutation",
      "KRAS G12D mutation",
      "FGFR2 fusion or rearrangement"
    ],
    "correctAnswer": 3,
    "explanation": "(A) 可用NTRK inhibitor (e.g. repotrectinib [TRIDENT-1], larotrectinib [HONG et al], entrectinib [DOEBELE et al])\r\n(B) 可用dabrafenib + trametinib [ROAR trial]\r\n(C)可用ivosidenib [ClarIDHy]\r\n(D) 錯誤。KRAS inhibitor not in current guideline\r\n(E) 可用FGFR inhibitor (pemigatinib [FIGHT-202], futibatinib [FOENIX])\r\n=> Ans. (D)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/042/explain_figures/Figure_42.jpg"
    ]
  },
  {
    "id": 43,
    "question": "Which description about the treatment for advanced hepatocellular carcinoma is wrong?",
    "options": [
      "According to IMbrave150 trial results, patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival than sorafenib.",
      "According to HIMALAYA study results, the median overall survival was 16.43 months with STRIDE regimen (tremelimumab 300 mg one dose plus durvalumab), 16.56 month with durvalumab, and 13.77 months with sorafenib. The overall survival hazard ratio for STRIDE versus sorafenib was 0.78. Overall survival with durvalumab monotherapy was non inferior to sorafenib (hazard ratio, 0.86).",
      "According to 9DW trial results, nivolumab plus ipilimumab demonstrated statistically significant OS benefit vs lenvatinib or sorafenib in patient with previously untreated unresectable hepatocellular carcinoma, as well as higher ORR and durable responses.",
      "According to LEAP-002 study results, the addition of pembrolizumab to lenvatinib as first-line therapy for advanced hepatocellular carcinoma has shown statistically significant OS benefit.",
      "In the phase III IMbrave 050 trial, patients with HCC at high risk of recurrence after resection or local ablation who received adjuvant atezolizumab plus bevacizumab had significantly improved recurrence-free survival compared with those who had active surveillance."
    ],
    "correctAnswer": 3,
    "explanation": "(A) 正確。根據IMbrave150，在unresectable HCC一線治療，atezolizumab + bevacizumab vs. sorafenib，ORR 30% vs. 11%，PFS 6.8 vs. 4.3 months，OS 19.2 vs. 13.4 months\r\n(B) 正確。根據HIMALAYA，此選項敘述內容正確\r\n(C) 正確。根據CheckMate 9DW， 在unresectable HCC一線治療，Nivo + Ipi vs. Lenvatinib/Sorafenib，OS 23.7 vs. 20.6 months (HR 0.79, p=0.0180)，ORR 36% vs. 13% (p<0.0001)，DOR 30.4 vs. 12.9 months\r\n(D) 錯誤。根據LEAP-002，在unresectable HCC一線治療，lenvatinib + pembrolizumab vs. lenvatinib + placebo，OS 21.2 vs. 19 months (HR 0.84, p = 0.0227)，OS未達到統計上的顯著差異\r\n(E) 正確。根據IMbrave050，HCC post resection/ablation的高復發風險病人，adjuvant atezolizumab + bevacizumab vs. active surveillance，在interim analysis (Oct 21, 2022)，RFS (recurrence-free survival)的HR 0.72 (p=0·012) [附註: 後來2024年年中ESMO Congress 2024 update [A. Yopp, LBA39]結果顯示initial RFS benefit was not sustained，因此目前最新數據是不支持給adjuvant Atezo/Bev (ESMO guideline: hepatocellular carcinoma 2025)\r\n=> Ans. (D)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 44,
    "question": "Which of the following statements about the advanced pancreatic cancer treatment is wrong?",
    "options": [
      "Patients who have response or stable disease after 4–6 months of chemotherapy may undergo maintenance therapy with olaparib for germline BRCA1/2 mutations.",
      "For metastatic pancreatic adenocarcinoma patients after prior gemcitabine-based therapy failure, the sequent treatment could be 5-FU + leucovorin + liposomal irinotecan.",
      "Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS G12V mutation.",
      "According to the NAPOLI 3 study in first line treatment of metastatic pancreatic cancer, the median overall survival was 11.1 months with NALIRIFOX versus 9.2 months with nab-paclitaxel–gemcitabine (hazard ratio 0.83)",
      "Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects."
    ],
    "correctAnswer": 2,
    "explanation": "(A) 正確。​根據POLO study，對於有germline BRCA1/2 mutation且在接受1-line platinum-based therapy後疾病沒有progression的轉移性胰臟癌病人，Olaparib (PARP inhibitor) maintenance vs. placebo，PFS 7.4 vs. 3.8 months (HR 0.53, p=0.004)，即Olaparib maintenance可延長PFS\r\n(B) 正確。​根據NAPOLI-1，對於接受gemcitabine-based therapy治療失敗後的轉移性胰臟癌病人，可用5-FU + Leucovorin + liposomal irinotecan作為二線治療，可延長survival (OS 6.1 vs 4.2 months [HR=0.67, p=0.012])\r\n(C) 錯誤。​Sotorasib是針對KRAS G12C mutation，但KRAS G12V mutation對Sotorasib並不敏感\r\n(D) 正確。​根據NAPOLI-3，在轉移性胰臟癌的一線治療中，NALIRIFOX (liposomal irinotecan + oxaliplatin + leucovorin + fluorouracil)的median OS 11.1 months，而Nab-Paclitaxel + Gemcitabine的median OS 9.2 months，hazard ratio為0.83 (p=0.036)\r\n(E) 正確。​在PRODIGE 24/CCTG PA.6試驗中，在resected pancreatic ductal adenocarcinoma (R0 or R1)病人，adjuvant mFOLFIRINOX vs. adjuvant Gemcitabine，DFS (disease-free survival) 21.6 vs. 12.8m (HR 0.58, p<0.001)，OS 54.4 vs. 35.0 months (HR 0.64, p=0.003)，Grade 3-4 adverese events: 75.9% vs. 52.9%，即mFOLFIRINOX的survival比較好但毒性較高\r\n=> Ans. C",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 45,
    "question": "關於 mismatch repair-deficient (dMMR/MSI-H)大腸癌的敘述，下列何者錯誤？",
    "options": [
      "BRAF-mutation 的大腸癌病患相較於 BRAF-wild type 的大腸癌病患更容易檢驗出 MMR deficiency。",
      "dMMR/MSI-H 常見於右側大腸癌，在早期大腸癌若有 dMMR/MSI-H 為良好的預後因子。",
      "約 15%大腸癌病患為 dMMR/MSI-H，其中 sporadic dMMR 多為 MLH1 promoter methylation， 而 germline dMMR 多為 MLH1, MSH2 mutation。",
      "根據 KEYNOTE-177，pembrolizumab 相較於 chemotherapy，可顯著延長 PFS 至 16 個月。",
      "在 dMMR/MSI-H 的大腸癌病患接受免疫治療時，PD-L1 高表現的病患，其治療反應率及存活率相較於 PD-L1 低表現的病患有明顯的差異。"
    ],
    "correctAnswer": 4,
    "explanation": "(A) 對。 The presence of BRAF V600E mutation or MLH1 promoter methylation is consistent with sporadic cancer. Number of sporadic cancer >>> Lynch syndrome (ref. Colon Cancer NCCN V1 2025, COL-B)\r\n\r\n\r\n(B) 對。Features associated with MMR-defective tumors… 87% were located within the proximal colon, 61% showed an expanding growth pattern, 54% were poorly differentiated, 85% had any degree of mucinous differentiation, and 89% lacked dirty necrosis。所以”dMMR/MSI-H 常見於右側大腸癌，其病理特徵為 poor differentiation” 這句話是對的 (ref. Am J Clin Pathol 2008;129:238-244)\n\nThe favorable impact of dMMR on outcomes seems to be more limited in stage III colon cancer and may vary with primary tumor location. 所以dMMR/MSI-H狀態對於早期大腸癌 (Stage II) 來說是較好的預後因子。(ref. Colon Cancer NCCN V1 2025, MS-20)\r\n\r\n\r\n(C) 對。\"dMMR/MSI phenotype can be acquired in sporadic CRC (75%) or constitutively… germline mutation (25%). Sporadic [dMMR mostly due to] loss of expression of MLH1 caused by hypermethylation of the MLH1 gene promoter.” \n\n“Most of the germline mutations in Lynch Syndrome occur in MLH1 or MSH2 genes (90%).”\r\n(Ref: Evrard C. et al, Cancers (Basel). 2019;11(10):1567)\n\n\r\n(D) 對。 \r\nPembrolizumab vs ChT in MSI mCRC (ref N Engl J Med 2020;383:2207-2218)\r\n👉mPFS 8.2 vs 16.5 mo (HR 0.6)\r\n👉DoR 10.6 vs 75.4 mo\r\n👉mOS 36.7 vs 77.5 (HR 0.73), 5yr OS 54 vs 44%\n\n\r\n(E) 錯。\n👉KEYNOTE-177 trial（pembrolizumab vs. Chemotherapy）顯示，PD-L1 表現與 PFS 或 ORR 無顯著相關。(ref. N Engl J Med 2020;383(23):2207-2218) \n\n👉CheckMate-142 試驗（nivolumab ± ipilimumab 在 dMMR/MSI-H mCRC 的研究）也顯示，PD-L1 表現與 ORR 或 PFS 並無顯著關聯。(ref. Lancet Oncol 2017;18(9):1182-1191.)\r\n\r\n👉It is important to note that there is currently no role for PD-L1 testing in CRC, outside a clinical trial, and that PD-L1 testing is not recommended. (ref. Colon Cancer NCCN V1 2025, MS-50)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/045/explain_figures/σ£ûτëç 1.png",
      "/qabank/045/explain_figures/σ£ûτëç 2.png",
      "/qabank/045/explain_figures/σ£ûτëç 3.png"
    ]
  },
  {
    "id": 46,
    "question": "一位 48 歲的男性，因貧血發現升結腸惡性腫瘤，胸腹部電腦斷層發現多顆肝臟轉移，經切片病理組織檢測為 pMMR、BRAFV600E、RASwt 之大腸癌，ECOG PS 為 0。下列關於此病患 治療的選擇，何者錯誤？",
    "options": [
      "病患不可選擇 dabrafenib + trametinib 做為 BRAFV600E的實體腫瘤的治療。",
      "此病患可使用 FOLFIRI + bevacizumab 做為轉移第一線治療。",
      "此病患在一線治療無效後，可根據 BEACON study，選擇 encorafenib + binimetinib 治療。",
      "若病患之肝轉移在接受化學治療有效縮小，可考慮請外科醫師將肝臟腫瘤及原發腫瘤 同時切除。",
      "若此病患之 BRAF 不為 V600E mutation，可考慮使用 anti-EGFR 的治療。"
    ],
    "correctAnswer": 2,
    "explanation": "(A) 對。\r\nFailed: Dabrafenib in combination with trametinib is not indicated for patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.這個組合在melanoma, glioma, NSCLC, thyroid, solid tumor basket trial(NCI-MATCH trial, BELIEVE trial, ROAR trial; ORR 80%) \n(ref. J Clin Oncol. 2015 Dec 1;33(34):4023-31)\r\n\n\n\r\n(B) 對。\nBRAF V600E預期對化療效果會比較差，所以體力可行的話FOLFOXIRI會比Doublet好，依據BEACON trial, BRAF V600E TKI目前二線才有角色，但目前FDA已經accelerated approval encorafenib+ cetuximab + mFOLFOX6在一線使用。在一線治療時，Cetuximab 跟 Panitumumab 這類anti-EGFR藥物依目前研究比較偏向不適合使用(ref. NCCN V1.2025, MS-48)\n\n\r\n(C) 錯。\nBEACON study是BRAF V600E 二線治療，結論是:\n1.EC(Encorafenib+Cetuximab or Panitumumab)+/- Binimetinib比FOLFIRI+Cetuximab好;\n2. EC+B可能沒有比EC好到哪(沒有統計power) 且severe AE較多(58% vs 50%); 後來有ANCHOR phase 2 study是挑戰BRAF V600E 一線治療，用EC+Binimetinib看起來ORR不錯，現在要等Breakwater phase 3看一線EC+chemotherapy挑戰有沒有成功，目前初步結果ORR was 61% (95% CI: 52%, 70%) in the encorafenib+ cetuximab, + mFOLFOX6 arm and 40% (95% CI: 31%, 49%) in the control arm. Median DoR was 13.9 months (95% CI: 8.5, not estimable) and 11.1 months (95% CI: 6.7, 12.7) in the respective arms，FDA 已在2024/12 accelerated approval.\r\n(ref. Scott Kopetz. et al. N Engl J Med 2019;381:1632-1643, BEACON trial)\n\r\n \r\n(D) 對。 \r\nStudies of selected patients undergoing surgery to remove colorectal liver metastases have shown that cure is possible in this population and should be the goal for a substantial number of these patients.\r\n•  可切除（Resectable）肝轉移 → 直接考慮手術 +/- 輔助治療\r\n•  潛在可切除（Potentially resectable）肝轉移 → 先接受轉化性化療（conversion therapy），若腫瘤縮小到可切除標準，則考慮手術\r\n•  不可切除（Unresectable）肝轉移 → 以**全身性治療（化療、標靶、免疫治療**為主\n(ref. NCCN V1.2025, MS-29, 37-43, ESMO guideline)\r\n\n\r\n(E) 對。 \r\nBRAF 非 V600E 突變（Non-V600E BRAF mutations）\r\nBRAF 非 V600E 突變（如 BRAF D594G, G469A 等）與 BRAF V600E 在分子機制上不同：\r\n.Class 2 突變（如 K601E, L597V）：增強 ERK 訊號傳導，對 anti-EGFR 可能反應不佳，但目前證據有限。\r\n.Class 3 突變（如 D594G, G469A）：屬於「kinase-dead」突變，會依賴 EGFR 活化，因此對 anti-EGFR 可能有效。\n\r\n研究顯示：BRAF 非 V600E 突變患者可能對 anti-EGFR 單獨或合併治療有反應，尤其是「Class 3 突變」。因此，若患者BRAF 非 V600E 突變，則可考慮使用 anti-EGFR 治療。\n(ref. NEJM, 381(17), 1632-1643, Cancer Cell, 33(1), 125-136.e3, NCCN V1.2025, MS-48 49)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/046/explain_figures/σ£ûτëç 1.png",
      "/qabank/046/explain_figures/σ£ûτëç 2.png",
      "/qabank/046/explain_figures/σ£ûτëç 3.png",
      "/qabank/046/explain_figures/σ£ûτëç 4.png",
      "/qabank/046/explain_figures/σ£ûτëç 5.png",
      "/qabank/046/explain_figures/σ£ûτëç 6.png",
      "/qabank/046/explain_figures/σ£ûτëç 7.png",
      "/qabank/046/explain_figures/σ£ûτëç 8.png",
      "/qabank/046/explain_figures/σ£ûτëç 9.png"
    ]
  },
  {
    "id": 47,
    "question": "關於大腸癌的手術後輔助性化學治療(adjuvant chemotherapy)，下列敘述何者正確？",
    "options": [
      "在 70 歲以上，第二期且無 high risk factors 的大腸癌病患，使用 5-FU/LV 加上 Oxaliplatin 並可顯著提升 Overall survival。",
      "根據 MOSAIC trial，第三期大腸癌病患在術後接受六個月的 oxaliplatin + 5-FU/LV 相較 於單用 5-FU/LV 有無法顯著延長 disease free survival(DFS)。",
      "根據 IDEA collaboration，high-risk stage III 的大腸癌病患使用三個月 FOLFOX的DFS不劣於(non-inferior)使用六個月的FOLFOX。",
      "承上，low-risk stage III 的大腸癌病患使用三個月的 CAPOX，其 DFS 不劣於使用六個月的CAPOX。",
      "Poorly differentiation 並有 mismatch repair deficiency 的 stage II 大腸癌病患可單獨使用 5-FU/LV 作為輔助性化學治療。"
    ],
    "correctAnswer": 3,
    "explanation": "(A) 錯。\r\nPatients with low-risk stage II disease that is MSS or pMMR can be observed without adjuvant therapy or considered for capecitabine or 5-FU/LV. Based on results of the MOSAIC trial, and the possible long-term sequelae of oxaliplatin-based chemotherapy, the Panel does not consider FOLFOX (infusional 5-FU, LV, oxaliplatin) to be an appropriate adjuvant therapy option for patients with stage II disease without high-risk features. \r\n\nHigh risk for systemic recurrence: \u000b- T4 tumors (stage IIB/IIC); poorly differentiated/undifferentiated histology; lymphovascular invasion; PNI; tumor budding; bowel obstruction; lesions with localized perforation or close, indeterminate, or positive margins; or inadequately sampled nodes.\r\n(ref. Colon Cancer NCCN V1 2025 MS-17)\n\n\r\n(B) 錯。\nMOSAIC trial，第三期大腸癌病患在術後接受六個月的 oxaliplatin + 5FU/LV 相較於單用 5FU/LV 有更長的 Disease free survival(DFS)，但 overall survival並沒有顯著差異 (HR=0.90, 95% CI 0.71-1.13)。\r\n\n但2009年JCO發表了8年的追蹤結果，並把stage II和stage III分開來看，在stage II的OS沒有差別；但是stage III中兩組OS就有顯著差異 (FL+oxaliplatin vs FL, HR:0.80 (0.65-0.97), p=0.023)\r\n\n如下圖：Fig.2 Overall survival by treatment arm and by stage\r\n(ref: J Clin Oncol. 2009 Jul 1;27(19):3109-16.)\r\n\n\r\n(C)錯 \n根據 IDEA collaboration， 三個月 FOLFOX 的DFS劣於(inferior) 使用六個月的 FOLFOX。臨床實驗結果細項：\r\n在分析了超過12,800名stage III colon cancer患者和3,263例疾病復發或死亡事件的數據後，研究發現3個月的adjuvant chemotherapy在整體人群中並非非劣效於6個月(hazard ratio, 1.07; 95% confidence interval [CI], 1.00 to 1.15)。\n\r\n然而，在一項探索性分析中，發現對於CAPOX，較短的療程在Stage III Colon Cancer是非劣效的(hazard ratio, 0.95; 95% CI, 0.85 to 1.06)，但對於FOLFOX則不是(hazard ratio, 1.16; 95% CI, 1.06 to 1.26)。\n\r\n原則上，adjuvant chemotherapy在低風險大腸癌症患者（T1、T2或T3和N1）中，3個月的治療是非劣效於6個月。相反，在高風險大腸癌症患者（T4、N2或兩者兼有）中，6個月的療程優於3個月。\n\r\n結論：\r\n這項研究表明，對於第三期大腸癌患者，3個月的治療與標準的6個月相比，在整體上並非非劣效。然而，對於接受CAPOX治療的患者，3個月的治療與6個月一樣有效，特別是在低風險亞組中。\n(ref. N Engl J Med 2018;378:1177-88)\n\n\r\n(D )對\n解釋同上一選項 (ref. N Engl J Med 2018;378:1177-88)\n\n\r\n(E) 錯。\r\ndMMR or MSI-H tumor status may be a predictive marker of decreased benefit and possibly a detrimental impact from adjuvant therapy with a fluoropyrimidine alone in patients with stage II disease. \n\nA retrospective study involving long-term follow-up of patients with stage II and III disease evaluated according to MSI tumor status showed that those characterized as MSI-L or MSS had improved outcomes with 5-FU adjuvant therapy. However, patients with tumors characterized as MSI-H did not show a statistically significant benefit from 5-FU after surgery, instead exhibiting a lower 5-year survival rate than those undergoing surgery alone. Similarly, results from another retrospective study of pooled data from adjuvant trials by Sargent et al. showed that in tumors characterized as dMMR, adjuvant 5-FU chemotherapy seemed to be detrimental in patients with stage II disease, but not in those with stage III disease\n(ref. Colon cancer NCCN V1 2025 MS-20)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/047/explain_figures/σ£ûτëç 1.png",
      "/qabank/047/explain_figures/σ£ûτëç 2.png"
    ]
  },
  {
    "id": 48,
    "question": "關於 small bowel adenocarcinoma，下列敘述何者錯誤？",
    "options": [
      "小腸癌相較於大腸癌，病患診斷時的年齡較輕，診斷的期別較晚期，其中最常見的轉移部位是肝臟及腹膜轉移。",
      "若病患為 RASwt轉移性小腸癌，使用 cetuximab 或是 panitumumab 加上化學治療做為 第一線治療並沒有明顯的治療效果。",
      "第一線化學治療可使用 FOLFOX，而後線治療可使用 FOLFIRI 或是 Taxane-based chemotherapy。",
      "當化學治療皆失敗時，2024 年 NCCN 治療指引不建議根據大腸癌後線治療方式，即使用 regorafenib 或是 trifluridine-tipiracil。",
      "小腸癌 HER2 陽性及 dMMR/MSI-H, PD-L1 高表現及 TMB-H 的機率較大腸癌低。"
    ],
    "correctAnswer": 4,
    "explanation": "**Answers in Small Bowel Adenocarcinoma NCCN Guideline**\n\r\n[A]對。**答案寫在V2 2025 MS-4。小腸癌的診斷年齡大約是66歲，值得注意的是發生率在近年是上升的，與大腸癌相反。30-40%小腸癌是adenocarcinoma，其餘的是GIST, lymphoma, neuroendocrine tumor。疾病表現為腸阻塞跟腹痛，所以發現是通常是晚期。危險因子跟大腸癌一樣(inflammatory bowel disease, lynch syndrome等等)。(ref. NCCN 2.2025, MS-2)\r\nPatients with SBA tend to be younger at diagnosis and often present with a higher stage and grade compared to those with CRC.40 SBA often presents with a local complication of the tumor, most often gastric outlet obstruction in the case of a duodenal SBA or cramping abdominal pain in the case of a jejunal or ileal SBA.36,41,42 Occult gastrointestinal bleeding is another common presentation for SBA, occurring in approximately one-quarter to one-third of cases. (ref. NCCN V2.2025, MS-4)\r\nApproximately 32% of patients diagnosed with SBA have stage IV (distant metastatic) disease.40 The most common sites for metastatic spread include the peritoneal cavity and liver, consistent with other gastrointestinal malignancies.(ref. NCCN V2.2025, MS-10). \n\n\r\n[B] 對 \r\nA 2017 retrospective analysis reported that the efficacy of cetuximabcontaining chemotherapy for RAS wild-type SBA was inconclusive.124 Subsequently, a phase II trial published in 2018 showed that panitumumab has no clinically meaningful activity in RAS wild-type SBA125; therefore, cetuximab or panitumumab should not be used for treatment of SBA.(ref. NCCN V2.2025, MS-12) \n\n\r\n[C,D]對。\r\n要注意bevacizumab可以考慮加上去使用，是因為被證實在小腸癌是安全的，但效果到底好不好不知道。下列處方幾乎都是從大腸癌trial撈出小腸癌患者衍伸出來的，那第一線治療也幾乎是FOLFOX base。另外在BRAFV600E 就跟大腸癌不同，是基於dabrafenib/trametinib basket ROAR study建議，不是BEACON\r\n \n(ref. NCCN V2.2025, MS-12-17)\n\n\r\n[E] 錯**答案從NCCN可以直接找到\r\nImportantly, human epidermal growth factor receptor 2 (HER2) alterations, MSI-H/dMMR, programmed death-ligand 1 (PD-L1) expression, and tumor mutational burden-high (TMB-H) are enhanced in SBA compared to CRC and may reveal greater importance of targeted or immunotherapeutic treatments compared to current CRC treatment algorithms. One study showed higher rates of PD-L1 positivity in SBA associated with Crohn’s or celiac disease, compared with sporadic SBA. (ref. NCCN V2.2025, MS-11,12)\n\r\n(下圖JAMA Oncol 2017;3:1546-1553)，老實說PD-L1有沒有比較高表現就沒有很好證據。另外，MSI-H/dMMR在第二期小腸癌是個prognostic factor，這些病人預後較好，但是不是個藥物的predictive marker還不明確(QUASAR study, CALGB 9581 and 89803 trials)，所以能不能用這個決定要不要接受adjuvant therapy還不明確。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/048/explain_figures/σ£ûτëç 1.png",
      "/qabank/048/explain_figures/σ£ûτëç 2.png",
      "/qabank/048/explain_figures/σ£ûτëç 3.png"
    ]
  },
  {
    "id": 49,
    "question": "ASPEN (American Society for Parenteral and Enteral Nutrition) has guidelines for “Nutritional Support Therapy During Anticancer Treatment”. Which of the followings statement about the guidelines is incorrect?",
    "options": [
      "Nutrition support should not be used routinely in patients undergoing head and neck, abdominal, or pelvic irradiation.",
      "Nutrition support therapy should not be used routinely as an adjunct to chemotherapy.",
      "Nutrition support therapy is beneficial in cancer patients if administered for 7-14 days preoperatively.",
      "Omega-3 fatty acid supplementation may help stabilize weight in cancer patients on oral diets experiencing progressively, unintentional weight loss.",
      "Omega-3 fatty acid supplementation may help stabilize weight in cancer patients on oral diets experiencing progressively, unintentional weight loss."
    ],
    "correctAnswer": 2,
    "explanation": "The ASPEN Clinical Guidelines developed a section for cancer patients aiming to \"examine the literature and develop guidelines only for NST\" (nutritional support therapy) \"in adult cancer patients.\" \n\nQuestion 49 is derived from guideline recommendations seen in Table 2 at the bottom of this page.\n\n(A) Nutrition support should not be used routinely in patients undergoing head and neck, abdominal, or pelvic irradiation.\n--> Correct; Table 2, Point 5\n\n(B) Nutrition support therapy should not be used routinely as an adjunct to chemotherapy.\n--> Correct; Table 2, Point 4 \n\n**(C) Nutrition support therapy is beneficial in cancer patients if administered for 7-14 days preoperatively.\n--> Incorrect; the above statement needs to be qualified, see Table 2, Point 3\nPre-OP NST may benefit \"moderately or severely malnourished\" cancer patients, but we must weigh the pros and cons, lest we delay surgery itself. \n\n(D) Patients should not use therapeutic diets to treat cancer.\n--> Correct; Table 2, Point 9 \n\n(E) Omega-3 fatty acid supplementation may help stabilize weight in cancer patients on oral diets experiencing progressively, unintentional weight loss.\n--> Correct; Table 2, Point 8\n\n\nTable 2. Nutrition Support Therapy During Anticancer Treatment\n--------------------------\nGuideline Recommendations\n--------------------------\n\n1. Patients with cancer are nutritionally-at-risk and should undergo nutrition screening to identify those who require formal nutrition assessment with development of a nutrition care plan. Grade D\n\n2. Nutrition support therapy should not be used routinely in patients undergoing major cancer operations. Grade A\n\n3. Perioperative nutrition support therapy may be beneficial in moderately or severely malnourished patients if administered for 7-14 days preoperatively, but the potential benefits of nutrition support must be weighed against the potential risks of the nutrition support therapy itself and of delaying the operation. Grade A\n\n4. Nutrition support therapy should not be used routinely as an adjunct to chemotherapy. Grade B\n\n5. Nutrition support therapy should not be used routinely in patients undergoing head and neck, abdominal, or pelvic irradiation. Grade B\n\n6. Nutrition support therapy is appropriate in patients receiving active anticancer treatment who are malnourished and who are anticipated to be unable to ingest and/or absorb adequate nutrients for a prolonged period of time(see Guideline 6 Rationale for discussion of “prolonged period of time”). Grade B\n\n7. The palliative use of nutrition support therapy in terminally ill cancer patients is rarely indicated. Grade B\n\n8. ω-3 Fatty acid supplementation may help stabilize weight in cancer patients on oral diets experiencing progressive, unintentional weight loss. Grade B\n\n9. Patients should not use therapeutic diets to treat cancer. Grade E\n\n10. Immune-enhancing enteral formulas containing mixtures of arginine, nucleic acids, and essential fatty acids maybe beneficial in malnourished patients undergoing major cancer operations. Grade A\n\nReference: August DA, et al. JPEN J Parenter Enteral Nutr. 2009 Sep-Oct;33(5):472-500.",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 50,
    "question": "下列關於下肢淋巴水腫(lymphedema)的敘述,何者錯誤?",
    "options": [
      "常見有下肢淋巴水腫的癌症主要是泌尿道癌、婦癌及黑色素癌,約有 20%此類癌症病人有下肢淋巴水腫問題。",
      "Chronic venous insufficiency 也會導致下肢淋巴水腫。",
      "肥胖為下肢淋巴水腫的危險因子。",
      "Complete decongestive therapy (CDT)可以使下肢淋巴水腫的體積下降 31-73%,並且效果持續久。",
      "手術方式如 lymphovenous anastomosis 或 vascularized lymph node transfer,可以使下肢淋巴水腫的體積下降 42-59%。"
    ],
    "correctAnswer": 3,
    "explanation": "The following responses/statements are sourced from \"Up to Date\" articles discussing peripheral lymphedema. \n\n(A) 常見有下肢淋巴水腫的癌症主要是泌尿道癌、婦癌及黑色素癌,約有 20%此類癌症病人有下肢淋巴水腫問題。\n--> Correct; numbers vary widely by study! (Ref 1)\n\n“overall incidence of lymphedema was 15.5% and varied by malignancy (P < .001): melanoma, 16% (upper extremity,5%; lower extremity, 28%); gynecologic, 20%; genitourinary, 10%; head/neck, 4%; and sarcoma, 30%. Increasedlymphedema risk was also noted for patients undergoing pelvic dissections (22%) and radiation therapy (31%).\" \n\n(B) Chronic venous insufficiency 也會導致下肢淋巴水腫。\n--> Correct; Table 1 from Ref 2 \n\t\n**Primary lymphedema\n-Congenital\n-Precox (adolescence) \n-Tarda (adulthood)\n\n**Secondary lymphedema \n-Cancer and cancer treatment\n-Lymph node dissection\n-Lymph node irradiation\n-Obesity\n-Chronic venous insufficiency\n-Infection/chronic inflammation (eg, recurrent cellulitis filariasis)\n\n(C) 肥胖為下肢淋巴水腫的危險因子。\n--> Correct; See answer (B)\n\n(D) Complete decongestive therapy (CDT) 可以使下肢淋巴水腫的體積下降 31-73%,並且效果持續久。\n--> Incorrect; Volume reduction by 31-73% is correct, but effects may not last forever. (Ref 2)\n\nUpper extremity lymphedema: CDT may reduce limb volume by 28-70%. \nQuality of life and functional indicators are also significantly improved.\n\nLower extremity lymphedema: CDT may reduce limb volume by 31-73%. There are fewer studies for this. \n\n\"Patient compliance with treatment is important for achieving and maintaining a successful outcome...\n[but] can be difficult... As such, lymphedema can progress despite conservative treatment measures.\"\n\n(E) 手術方式如 lymphovenous anastomosis 或 vascularized lymph node transfer,可以使下肢淋巴水腫的體積下降 42-59%。\n--> Correct; However, volume reduction varies widely by study (Ref 3)\n\nReferences: \n1. Cormier JN, et al. Cancer. 2010 Nov 15;116(22):5138-49\n2. Mehrara B, et al. Management of peripheral lymphedema. In: UptoDate, Connor RF (Ed), Wolters Kluwer. (Accessed on March 3, 2025.)\n3. Mehrara B, et al. Surgical treatment of primary and secondary lymphedema. In: UptoDate, Connor RF (Ed), Wolters Kluwer. (Accessed on March 3, 2025.)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/050/explain_figures/Screenshot 2025-03-03 at 1.19.48 PM.png"
    ]
  },
  {
    "id": 51,
    "question": "Which is not the complication of erythropoiesis stimulating agents used?",
    "options": [
      "Thrombocytopenia",
      "Hypertension",
      "Seizure",
      "Thromboembolism",
      "Pure red cell aplasia"
    ],
    "correctAnswer": 0,
    "explanation": "Contraindications:\n-Uncontrolled hypertension\n-Pure red cell aplasia (PRCA)\n-Severe allergic reactions\n-Hypersensitivity to non-human mammal-derived products\n-Neonates, permpartum mothers, breastfeeding mothers (if containing benzyl alcohol --> gasping syndrome)\n\nWarning and Precautions:\n-Thromboembolic events\n-Pure red cell aplasia \n-Seizures\n-Allergic reactions\n-Severe cutaneous adverse drug reactions\n-Potential for abuse\n-Dialysis monitoring \n\n(A) Thrombocytopenia\n--> Incorrect; however, this is still seen in some multi center studies...  \n\n(B) Hypertension\n--> Correct \n\n(C) Seizure\n--> Correct \n\n(D) Thromboembolism\n--> Correct \n\n(E) Pure red cell aplasia\n--> Correct \n\n\nReference: \n1. Schoener B, Borger J. Erythropoietin Stimulating Agents. [Updated 2024 Jul 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536997/",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 52,
    "question": "合併化學治療與放射線治療,是目前侷限性小細胞型肺癌的標準治療。關於目前已發表的兩個重要第三期隨機性臨床試驗(CONVERT 試驗和 CALGB30610 試驗)之化學藥物、放射治療劑量和臨床預後描述,下到何者錯誤?",
    "options": [
      "CONVERT 試驗,其使用的化學藥物是 cisplatin 和 etoposide。",
      "CONVERT 試驗,證實每天一次放射治療(總劑量 66 Gy),與每天兩次放射治療(總劑量45 Gy),其整體存活率兩組相同。",
      "CALGB30610 試驗,證實每天一次放射治療(總劑量 70 Gy),比每天兩次放射治療(總劑量45 Gy),提高更好的整體存活率。",
      "上述兩種臨床試驗,放射治療建議在化學治療的第一個或第二個 cycle 開始給予。",
      "CALGB30610 大部分處方是 cisplatin 和 etoposide,部分處方是 carboplatin 和 etoposide。"
    ],
    "correctAnswer": 2,
    "explanation": "This question asks us to compare two Phase III trials on CCRT for limited-stage small cell lung cancer and answer if \"twice daily RT better is than once daily RT in CCRT for limited stage SCC patients.\"\n\nSee below for summary of both trials. \n\n--------------------------------------------------\n\n(A) CONVERT 試驗,其使用的化學藥物是 cisplatin 和 etoposide。\n--> Correct; cisplatin + etoposide for 4-6 cycles every 3 weeks \nFor CALGB 30610: 4 cycles platinum + etoposide \n\n(B) CONVERT 試驗,證實每天一次放射治療(總劑量 66 Gy),與每天兩次放射治療(總劑量 45 Gy),其整體存活率兩組相同。\n--> Correct \ntwice daily OS = 30 months; once daily OS = 25 months\nHazard ratio of death = 1.18 (95% CI 0.95-1.45); p=0.14\n2-year OS = 56% vs 51% \n\n**(C) CALGB30610 試驗,證實每天一次放射治療(總劑量 70 Gy),比每天兩次放射治療(總劑量 45 Gy),提高更好的整體存活率。\n--> Incorrect\nTwice daily OS = 28.5 months; once daily OS = 30.1\nHazard ratio of death = 0.94 (95% CI 0.76-1.17); p=0.594 \n\n(D) 上述兩種臨床試驗,放射治療建議在化學治療的第一個或第二個 cycle 開始給予。\n--> Correct\nCONVERT trial: begin at D22 after beginning Cisplatin + etoposide\nCALGB 30610: starting with either 1st or 2nd chemotherapy cycle \n\n(E) CALGB30610 大部分處方是 cisplatin 和 etoposide,部分處方是 carboplatin 和 etoposide。\n--> Correct \nCisplatin: total 81.3%, 45 Gy 80.5%, 70 Gy 82.2%\nCarboplatin: total 18.7%, 45 Gy 19.5%, 70 Gy 17.8% \n\n--------------------------------------------------\n\n[CONVERT Trial] * chemo: Cisplatin + Etoposide q3w \n\nQuestion: is twice daily RT better than once daily RT in CCRT for limited stage SCC patients? \n\nP: limited-stage SCC patients\nI: Twice daily RT (45 Gy / 30 bid of 1.5 Gy)\nC: Once daily RT (66 Gy / 33 Fx of 2 Gy)\nO: primary outcome is OS (superiority study) \n\nResults: no difference in OS (30 vs 25 months)\n\n--------------------------------------------------\n\n[CALGB 30610 (Alliance) / RTOG 0538] * initially only Cisplatin + Etoposide --> amendment to include carbo in 2015 \nRT begins at 1st or 2nd chemotherapy cycle \n\nQuestion: is twice daily RT better than once daily RT in CCRT for limited stage SCC patients? \n\nP: limited stage SCC patients \nI: Twice daily RT (45 Gy)\n   Concomitant boost RT (61.2 Gy) --> this arm is discontinued due to toxicity \nC: Once daily RT (70 Gy)\nO: primary outcome is OS in ITT \n\nResults: no difference in OS (28.5 vs 30.1 months) \n\nReference:\n1. Faivre-Finn C, et al. Lancet Oncol. 2017 Aug;18(8):1116-1125\n2. Bogart J, et al. J Clin Oncol. 2023 May 1;41(13):2394-2402",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 53,
    "question": "第三期隨機性臨床試驗已經證實低分次全乳房放射線治療 (hypofractionated radiotherapy) 與傳統式分式全乳房放射線治療，在早期乳癌之臨床預後和副作用相似。 根據 2018 年美國放射腫瘤學會標準建議，有關乳癌保留手術後之低分次全乳房放射線治療之適應症，下列敘述何者正確？",
    "options": [
      "年齡要大於 50 歲才考慮。",
      "之前接受術後化學治療則不適合。",
      "不需要照射局部淋巴區域才考慮。",
      "不須注意乳房組織的放射腫瘤劑量。",
      "不建議使用在 HER2 陽性病人。"
    ],
    "correctAnswer": 2,
    "explanation": "(A) 年齡要大於50歲才考慮。\u000b=>根據ASTRO指南，年齡不再是低分次全乳房放射治療的重要限制條件，因此不需一定大於50歲才考慮使用。\r\n(B) 之前接受術後化學治療則不適合。\u000b=>先前接受過術後化學治療並非低分次治療的禁忌條件。\r\n(C) 不需要照射局部淋巴區域才考慮。\u000b=>根據ASTRO建議，當治療區域僅為乳房而非區域淋巴結（regional lymph nodes）時，低分次才被建議使用。如果需要同時治療區域淋巴結，通常不使用低分次**會使用50Gy/25fx的傳統分次來照射**。因此此選項正確。\r\n(D) 不須注意乳房組織的放射腫瘤劑量。\u000b=>放射腫瘤劑量的分佈（dose homogeneity）仍須仔細注意，以避免過量照射乳房組織。\r\n(E) 不建議使用在HER2陽性病人。\u000b=>HER2陽性並非低分次治療的禁忌證。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/053/explain_figures/figure 1.png"
    ]
  },
  {
    "id": 54,
    "question": "關於 explanatory 臨床試驗、pragmatic 臨床試驗的比較，下列何者是錯誤的？",
    "options": [
      "explanatory:日常醫療工作 \r\npragmatic:資源豐富，理想場景",
      "explanatory:高選擇性病人族群，有嚴格的納入、排除條件 \r\npragmatic:有興趣的臨床適應症，極少的納入、排除條件",
      "explanatory:強的順從性嚴格執行 \r\npragmatic:有彈性，允許修改",
      "explanatory:通常是代理的滿足點（例如：客觀反應率、無惡化存活時間） \r\npragmatic:跟受試者、社區、醫療照顧提供者直接相關（例如：客觀反應率、總存活時間）",
      "explanatory:間接 \r\npragmatic:直接"
    ],
    "correctAnswer": 0,
    "explanation": "題源:INT J TUBERC LUNG DIS 15(7):862–870, Table 2 改寫\r\n就算不知道什麼是Explanatory Trial & Pragmatic Trial，看完每個選項就知道A跟其他幾個選項都相反了\r\n\r\n1967 年，Schwartz 跟 Lellouch 描述了兩種隨機分派試驗的模式，pragmatic 或explanatory\r\nexplanatory，解釋型的隨機試驗，目的是探討一個介入帶來的影響，其它變數必須盡量嚴格控制\r\npragmatic trial 務實研究，仍是隨機分派試驗，但儘量降低介入，模擬現實狀況。Pragmatic 或許有些抽象，但把這個字改成 practice 就好懂多了，practice trial，探討實際應用的研究；因為許多研究的當下環境，在實際情況很難重現，比如說有人盯著你吃藥，規律的抽血追蹤等",
    "questionFigures": [
      "/qabank/054/question_figures/figure 1.png"
    ],
    "explainFigures": []
  },
  {
    "id": 55,
    "question": "Schrag D, et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med 389:322-34, 2023 是一個比較 neoadjuvant chemotherapy 和 neoadjuvant chemoradiotherapy 的 non-inferiority randomized controlled trial。關於 non-inferiority randomized controlled trials，下列敘述何者是錯誤的？",
    "options": [
      "在 noninferiority trials，研究者想要證明新的治療不劣於標準治療。",
      "不劣於標準治療的新的治療通常是毒性較小或較為方便。",
      "樣本數的考量跟 superiority trials 一般而言是類似的。",
      "樣本數的考量跟 superiority trials 的一個重要例外是 targeted treatment effect 在 non-inferiority trials 通常比較小，導致 non-inferiority trials 的樣本數較大。",
      "在 noninferiority trials，intention-to-treat 的原則也要嚴格遵守。"
    ],
    "correctAnswer": 2,
    "explanation": "題源:這題是考古題112-63\r\n通常非劣性試驗的目標效應較小，因此需要更大的樣本量來達到統計的顯著性。\r\nAlthough noninferiority trials typically have smaller sample sizes than active-controlled superiority trials, they can have considerably larger sample sizes than placebo-controlled trials. This is because the equivalence margin is often smaller than the treatment difference for which a placebo-controlled trial is powered. In addition, the sample size of a noninferiority trial is very sensitive to the assumed effect of the new treatment relative to the active control; the sample size can be considerably larger if the two treatments are assumed to be slightly more effective than the active control. \r\n\r\nREF: Snapinn SM. Curr Control Trials Cardiovasc Med. 2000;1(1):19-21",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 56,
    "question": "關於癌症臨床試驗滿足點（endpoint），下列何者是錯誤的？",
    "options": [
      "以 overall survival 為主要滿足點，如果對照組效果很好，會導致試驗規模很大、追蹤時間很長。",
      "以 overall survival 為主要滿足點，如果實驗組、對照組不能 crossover，會看不出 2 組overall survival 的差別。",
      "以 overall survival 為主要滿足點，如果有 competing mortality（例如：輔助性化學治療用於年紀大病患的臨床試驗），會稀釋實驗組的治療效果，可以考慮從分析 overallsurvival、改成分析 disease-specific survival。",
      "以 progression-free survival 為主要滿足點，如果試驗是 unblinded，一個可能的 bias 是assessment time bias。",
      "以 progression-free survival 為主要滿足點，如果試驗是 unblinded，可以考慮 blinded independent central review。"
    ],
    "correctAnswer": 1,
    "explanation": "題源:112-65\r\n即使實驗組和對照組沒有 crossover（即患者不會從一組轉到另一組），仍然可以觀察到 overall survival 的差別。Crossover 可能會影響結果的解讀，但不是唯一的無法比較整體生存率的因素。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 57,
    "question": "下列化療或標靶藥物可能造成interstitial lung disease (ILD) or pneumonitis，何者為**非**？",
    "options": [
      "Trastuzumab deruxtecan",
      "Pembrolizumab",
      "Abemaciclib",
      "Trastuzumab emtansine (TDM1)",
      "Bleomycin"
    ],
    "correctAnswer": 3,
    "explanation": "57.  下列化療或標靶藥物可能造成interstitial lung disease (ILD) or pneumonitis，何者為**非**？ \r\n        (A) Trastuzumab deruxtecan  \r\n        (B) Pembrolizumab  \r\n        (C) Abemaciclib \r\n        (D) Trastuzumab emtansine (TDM1) \r\n        (E) Bleomycin \r\n\r\n解答: D\r\n\r\n說明:\r\n(A) Trastuzumab deruxtecan 造成 Interstitial lung disease 為 13.6%\r\n(B) Pembrolizumab 造成  Pneumonitis 為 5.8%\r\n(C) Abemaciclib 造成 Pneumonitis 為 2.7%, placebo 為 1.3%\r\n(D) Trastuzumab emtansine (TDM1) 無 lung fibrosis 毒性, 其他嚴重副作用為liver toxicity, decrease LVEF \r\n(E) Bleomycin 是長期已知的lung fibrosis危險因子,發生率接近10%\r\n\r\n\r\n參考:\r\n(A) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer\r\n    https://www.nejm.org/doi/full/10.1056/NEJMoa1914510\r\n\r\n(B) Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer\r\n    https://www.nejm.org/doi/full/10.1056/NEJMoa1606774\r\n\r\n(C) Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)\r\n    https://ascopubs.org/doi/10.1200/JCO.20.02514?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed\r\n\r\n(D) Overview and Management of Drug-Induced Interstitial Lung Disease With Novel Treatments in HER2+ Breast Cancer, Lung Cancers, and Gastrointestinal Cancers\r\n    https://www.onclive.com/view/overview-and-management-of-drug-induced-interstitial-lung-disease-with-novel-treatments-in-her2\r\n\r\n(E) Bleomycin-Induced Lung Injury\r\n    https://onlinelibrary.wiley.com/doi/full/10.1155/2013/480608",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 58,
    "question": "健保署在2024年7月已經開放NGS檢測，針對肺癌，下列何者**非**ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) evidence tier I marker及其對應藥物(ready for routine use)？",
    "options": [
      "BRAF V600E: Dabrafenib plus trametinib",
      "MET exon 14 skipping mutation: Capmatinib",
      "gPALB2 mutation: Talazoparib",
      "ALK translocation: Crizotinib",
      "EGFR exon 20 insertion mutation: Amivantamab"
    ],
    "correctAnswer": 2,
    "explanation": "58.  健保署在2024年7月已經開放NGS檢測，針對肺癌，下列何者**非**ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) evidence tier I marker及其對應藥物(ready for routine use)？ \r\n        (A) BRAF V600E: Dabrafenib plus trametinib \r\n        (B) MET exon 14 skipping mutation: Capmatinib \r\n        (C) gPALB2 mutation: Talazoparib \r\n        (D) ALK translocation: Crizotinib \r\n        (E) EGFR exon 20 insertion mutation: Amivantamab\r\n\r\n解答: C\r\n\r\n詳解:\r\n(A) BRAF V600E: Dabrafenib plus trametinib : Capmatinib ESCAT 為 IB 級 (2023 ESMO NSCLC)\r\n(B) MET exon 14 skipping mutation: Capmatinib ESCAT 為 IB 級 (2023 ESMO NSCLC)\r\n(C) gPALB2 mutation: Talazoparib 不在2023 ESMO NSCLC名單上,在 2020 ESCAT為 IIIA 級\r\n(D) ALK translocation: Crizotinib ESCAT 為 IB 級 (2023 ESMO NSCLC)\r\n(E) EGFR exon 20 insertion mutation: Amivantamab ESCAT 為 IB 級 (2023 ESMO NSCLC)\r\n\r\n參考:\r\nRecommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group\r\nhttps://www.annalsofoncology.org/article/S0923-7534(20)39971-3/fulltext\r\n\r\nOncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\r\nhttps://www.annalsofoncology.org/article/S0923-7534(22)04781-0/fulltext",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/058/explain_figures/Image 1.jpg",
      "/qabank/058/explain_figures/Image 2.jpg"
    ]
  },
  {
    "id": 59,
    "question": "有關Poly (ADP-ribose) polymerase (PARP) inhibitor治療相關敘述及臨床試驗，下列敘述何者**錯誤**？",
    "options": [
      "Phase III OlympiA trial 證實 adjuvant olaparib 在high risk gBRCA mutation (TNBC or Luminal BC手術後) 有EFS及OS befefit.",
      "Four different PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) have now received regulatory approval in the United States for the treatment of ovarian cancer, breast, prostate, and pancreatic cancers with BRCA1 or BRCA2 mutations and in some cases other defects in DNA repair by homologous recombination.",
      "The FDA has approved rucaparib and olaparib for men with metastatic castration-resistant prostate cancer (mCRPC) who have certain genetic mutations based on the EMBRACA trials.",
      "PARP 抑制 IC50: olaparib > rucaparib > talazoparib.",
      "In NOVA trial, niraparib has demonstrated survival benefit in platinum-sensitive, recurrent ovarian cancer, regardless of the presence or absence of gBRCA mutations or homologous recombination deficiency (HRD) status."
    ],
    "correctAnswer": 2,
    "explanation": "有關Poly (ADP-ribose) polymerase (PARP) inhibitor治療相關敘述及臨床試驗，下列敘述何者**錯誤**？ \r\n(A) Phase III OlympiA trial 證實 adjuvant olaparib 在high risk gBRCA mutation (TNBC or Luminal BC手術後) 有EFS及OS befefit. \r\n(B) Four different PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) have now received regulatory approval in the United States for the treatment of ovarian cancer, breast, prostate, and pancreatic cancers with BRCA1 or BRCA2 mutations and in some cases other defects in DNA repair by homologous recombination. \r\n(C) The FDA has approved rucaparib and olaparib for men with metastatic castration-resistant prostate cancer (mCRPC) who have certain genetic mutations based on the EMBRACA trials. \r\n(D) PARP 抑制 IC50: olaparib > rucaparib > talazoparib.    \r\n(E) in NOVA trial, niraparib has demonstrated survival benefit in platinum-sensitive, recurrent ovarian cancer, regardless of the presence or absence of gBRCA mutations or homologous recombination deficiency (HRD) status. \r\n\r\n解答: C\r\n\r\n詳解:\r\n\r\n(A) [Image 1]\r\nTNBC or Luminal BC手術後, adjuvant olaparib 3y DFS 為 85.9 vs. 77.1%, HR 0.58, p<0.001; OS 為 92.0% vs. 88.3%, HR 0.68, p=0.02\r\n\r\n(B)\r\nolaparib was approved for ovarian, breast, pancreatic and prostate cancer\r\nrucaparib was approved for ovarian and prostate cancer\r\nniraparib was approved for ovarian cancer\r\ntalazoparib was approved for breast and prostate cancer\r\n\r\n(C) EMBRACA trial 研究對象為 Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation\r\n\r\n(D)\r\nOlaparib IC 50 = 68.5 uM\r\nrucaparib IC 50 = 53.7 uM\r\nTalazoparib IC 50 =  8.40 uM\r\n\r\n(E) [Image 2]\r\ngBRCA cohort, mPFS 21.0m vs. 5.5m, HR 0.27, p<0.001\r\nnon-gBRCA cohort, mPFS 9.3m vs. 3.9m, HR 0.45, p<0.001\r\n\r\n\r\n參考:\r\nAdjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer\r\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa2105215\r\n\r\nFDA aprroved for olaparib, rucaparib, niraparib, and talazoparib\r\nhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf\r\nhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s011lbl.pdf\r\nhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf\r\nhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217439s000lbl.pdf\r\n\r\nTalazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation\r\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa1802905\r\n\r\nolaparib, rucaparib, talazoparib IC50\r\nhttps://www.cancerrxgene.org/compound/Olaparib/1017/overview/ic50\r\nhttps://www.cancerrxgene.org/compound/Rucaparib/1175/overview/ic50\r\nhttps://www.cancerrxgene.org/compound/Talazoparib/1259/overview/ic50?screening_set=GDSC1\r\n\r\nNiraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer\r\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa1611310",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/059/explain_figures/Image 1.jpg",
      "/qabank/059/explain_figures/Image 2.jpg"
    ]
  },
  {
    "id": 60,
    "question": "Reprogramming energy metabolism is one of the hallmakers of cancer, one of the following descriptions is **incorrect**?",
    "options": [
      "Otto Warburg first observed an anomalous characteristic of cancer cell energy metabolism that cancer cells could use glycolysis without using oxygen.",
      "The reprogramming includes upregulation of glucose transporters, notably GLUT1.",
      "The reprogramming is associated with activated oncogenes (e.g., RAS, MYC) and mutant tumor suppressors (e.g., TP53)",
      "Glycolysis allows the diversion of glycolytic intermediates into various biosynthesis of nucleosides and amino acids.",
      "Other than Warburg’s effect, cancer cells still could use mitochondrial oxidative phosphorylation to generate fuel (ADP)."
    ],
    "correctAnswer": 4,
    "explanation": "Reprogramming energy metabolism is one of the hallmakers of cancer, one of the following descriptions is incorrect ?  \r\n(A) Otto Warburg first observed an anomalous characteristic of cancer cell energy metabolism that cancer cells could use glycolysis without using oxygen. \r\n(B) The reprogramming includes upregulation of glucose transporters, notably GLUT1. \r\n(C) The reprogramming is associated with activated oncogenes (e.g., RAS, MYC) and mutant tumor suppressors (e.g., TP53)  \r\n(D) Glycolysis allows the diversion of glycolytic intermediates into various biosynthesis of nucleosides and amino acids. \r\n(E) Other than Warburg’s effect, cancer cells still could use mitochondrial oxidative phosphorylation to generate fuel (ADP).\r\n\r\n解答: E\r\n\r\n詳解: 考的是文章的原文\r\n\r\n(A)\r\nOtto Warburg first observed an anomalous characteristic of cancer cell energy metabolism (Warburg, 1930, 1956a, 1956b): even in the presence of oxygen, cancer cells can reprogram their glucose metabolism, and thus their energy production, by limiting their energy metabolism largely to glycolysis, leading to a state that has been termed ‘‘aerobic glycolysis.’’\r\n\r\n(B)\r\nThey do so in part by upregulating glucose transporters, notably GLUT1, which substantially increases glucose import into the cytoplasm\r\n\r\n(C)\r\nGlycolytic fueling has been shown to be associated with activated oncogenes (e.g., RAS, MYC) and mutant tumor suppressors (e.g., TP53) \r\n\r\n(D)\r\nincreased glycolysis allows the diversion of glycolytic intermediates into various biosynthetic pathways, including those generating nucleosides and amino acids;\r\n\r\n(E)\r\nOne subpopulation consists of glucose-dependent (‘‘Warburg-effect’’) cells that secrete lactate, whereas cells of the second subpopulation preferentially import and utilize the lactate produced by their neighbors as their main energy source, employing part of the citric acid cycle to do so.\r\n\r\n參考:\r\nHallmarks of Cancer: The Next Generation\r\nhttps://www.cell.com/fulltext/S0092-8674(11)00127-9",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 61,
    "question": "The current standard genetic testing for identifying HER2 amplification is by",
    "options": [
      "Real-time polymerase chain reaction",
      "Sanger sequencing",
      "Next-generation sequencing",
      "Fluoresce in situ hybridization",
      "Genomic microarray"
    ],
    "correctAnswer": 3,
    "explanation": "根據guideline，現行HER2檢驗是使用Fluoresce in situ hybridization。\r\nReference:\r\nHuman Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society\r\nof Clinical Oncology/College of American Pathologists Clinical Practice Guideline\r\nFocused Update. J Clin Oncol 2018;36:2105-2122.\r\n\r\n校稿:這個與現行HER2陽性認定有關，懶得看Paper原文可快速掃過以下加深印象\r\n\r\nHER2的檢驗方式\r\n目前以免疫化學染色法（Immunohistochemitry IHC）及螢光原位雜交法（Fluorescence in situ hybridization FISH）為主。免疫化學染色法的檢測，由病理醫師根據細胞膜上之HER2第二型人類上皮細胞生長因子接受器染色強弱及其佔乳癌細胞比例，結果以0、1＋、2＋、3＋呈現，HER2基因位於人類第17對染色體上，約四分之一的乳癌腫瘤細胞會有很多HER2基因的重複片段，這些過度的HER2基因就會製造出更多的細胞膜上HER2接受器，螢光原位雜交法的檢測的原理就是利用不同螢光去偵測HER2基因以及第17對染色體中心粒及HER2基因的重複片段，算出HER2基因相對第17對染色體中心粒螢光染色之比率，以拷貝倍數(copy number)來呈現。目前以免疫化學染色法3+或螢光原位雜交法的檢驗陽性(拷貝倍數2.0或2.2以上)才能被確定為HER2陽性。HER2免疫化學染色法2+的乳癌，以螢光原位雜交法再確認，約有20%~40%的乳癌的檢驗結果會是陽性。兩種檢驗方式中，螢光原位雜交法（FISH）為量化的檢驗方式，較無偽陽性及偽陰性的問題；缺點是價格較高。對於HER2免疫化學染色法2+的乳癌，目前臺灣健保局給付螢光原位雜交檢驗。\r\n\r\n出處:https://www.canceraway.org.tw/page.php?IDno=1131",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 62,
    "question": "Which of the following descriptions of cell death is INCORRECT?",
    "options": [
      "Apoptosis is a type of cell death in which a dying cell contracts into an almost-invisible corpse that is soon consumed by its neighbors, and it is non-immunogenic.",
      "Necroptosis is a type of cell death in which necrotic cells become bloated and explode, releasing their contents into the local tissue microenvironment, and it is immunogenic.",
      "Ferroptosis is a type of cell death caused by excessive production of reactive oxygen species (ROS) and insufficient capability to eliminate ROS.",
      "Pyroptosis is a type of cell death in which formation of pores causes cell membrane rupture and release of cytokines as well as damage-associated molecular pattern (DAMP) molecules out of the cell, and it is immunogenic.",
      "Apoptosis does not release proinflammatory signals into the surrounding tissue microenvironment, whereas necroptosis and pyroptosis release proinflammatory molecules out of the cell."
    ],
    "correctAnswer": 0,
    "explanation": "(A)(B)(E)選項的敘述出自Hallmarks of cancer: the next generation，但Apoptosis並非皆是non-immunogenic，故選(A)選項不正確。\r\nReference\r\nHanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013\r\n\r\n\r\n校稿:本題有爭議，為考古，可見112考古詳解統整的120題更完整\r\n112年詳解，1234對應ABDE四個選項皆正確，但Apoptosis is less immunogenic than necroptosis or pyroptosis並非完全沒有，原本A選項就有爭議。\r\n113年多了C選項，邏輯上應該C為錯誤選項，但對應PAPER敘述，並未找到C選項有甚麼明顯錯誤\r\nFerroptosis is a new type of cell death that was discovered in recent years and is usually accompanied by a large amount of iron accumulation and lipid peroxidation during the cell death process; the occurrence of ferroptosis is iron-dependent. Ferroptosis-inducing factors can directly or indirectly affect glutathione peroxidase through different pathways, resulting in a decrease in antioxidant capacity and accumulation of lipid reactive oxygen species (ROS) in cells, ultimately leading to oxidative cell death.\r\n出處:Cell Death & Disease volume 11, Article number: 88 (2020)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 63,
    "question": "Which of the following statements about cancer pain control are (is) correct? \r\n(1) For an opioid-naïve patient suffering from moderate pain, start with short-acting opioid every 3-4 hours, like morphine 7.5 mg, hydromorphone 2 mg or oxycondone immediate release 2 mg orally. \r\n(2) For an opioid-tolerant patient suffering from moderate pain, increase the long-acting opioid dose of 30-100%. \r\n(3) Use fentanyl patch on in patients tolerant to opioid therapy. \r\n(4) Short-acting opioid (50% of the 24-hour total of long-acting opioid) can be used as a rescue dose.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1) 相同敘述可見於DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 12th Edition，第1798頁，藥物換算可以依據第1796頁，Table 98.5。雖然Oxycodone的劑量換算有點奇怪。\r\n(2) 敘述錯誤，根據NCCN Guidelines Version 3.2024-Adult Cancer Pain的PAIN-4那一頁，是建議Titrate short-acting opioid (may require dose increase of 30%–100%)\r\n(3) 無明顯錯誤。\r\n(4) 錯誤，rescue opioids劑量應為5%到15%的24小時總劑量，第1798頁，Breakthrough pain is best managed with the use of a rescue medication, which is a short-acting opioid given on an as-needed basis in addition to the baseline regimen for patients on a fixed opioid schedule. In general, the dose required for rescue opioids is 5% to 15% of the total (or “basal”) daily requirement of opioid in 24 hours.\r\n\r\nReference:\r\nDeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 12th Edition\r\n\r\n校稿:無修正",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 64,
    "question": "以下關於第一線 recurrent and metastatic head and neck squamous cell carcinoma 治療敘述中，正確的有?\r\n(1) 如果病人 PD-L1 CPS ≥20, pembrolizumab monotherapy 為一可以考慮的治療選項。 \r\n(2) 如果病人 PD-L1 CPS < 1, pembrolizumab monotherapy 為一可以考慮的治療選項。 \r\n(3) 如果病人 PD-L1 CPS 介於 1-19, pembrolizumab monotherapy 為一可以考慮的治療選項。 \r\n(4) Pembrolizumab plus platinum/5FU 應僅考慮在 PD-L1 CPS ≥ 1 的族群使用。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "根據NCCN Guidelines Version 1.2025-Head and Neck Cancers，在SYST-A 2 OF 5那頁，first line preferred regimens有 Pembrolizumab/platinum 和 Pembrolizumab，但單用Pembrolizumab需要腫瘤表現PD-L1 with CPS ≥1。所以敘述(2)、(4)錯誤。\r\n\r\n\r\n校稿: 無修正",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 65,
    "question": "以下關於locally advanced head and neck squamous cell carcinoma (HNSCC) CCRT 的敘述中，正確的有?\r\n\r\n(1) 根據 EORTC 22931 以及 RTOG 9501 對於high risk group 的定義，其重疊部分包含：resection margin involvement、 extranodal extension positive、 infiltrative tumor fronts、perineural invasion、lymphovascular invasion。\r\n(2) 對於無法接受platinum 治療的患者，CCRT 時給予avelumab plus cetuximab 相對於 cetuximab alone 並無證據顯示較佳之預後。\r\n(3) In CCRT of HNSCC，weekly cisplatin 30mg/m2 per week is non-inferior to standard cisplatin 100mg/ m2 every three weeks。\r\n(4) In CCRT of HNSCC，weekly cisplatin 40mg/m2 per week is non-inferior to standard cisplatin 100mg/ m2 every three weeks。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 2,
    "explanation": "(1) 根據 EORTC 22931 以及 RTOG 9501 對於high risk group 的定義，其重疊部分包含：\r\nresection margin involvement、 extranodal extension positive、 infiltrative tumor fronts、perineural invasion、lymphovascular invasion。\r\n\r\n錯誤，請見figure 1，僅下列三條重疊\r\n• SCC of oral cavity, oropharynx, larynx, hypopharynx\r\n• Surgical margins microscopic involved\r\n• Extracapsular extension in positive LN\r\n出處:International Journal of Head and Neck Surgery, May-August 2010;1(2):93-96的整理表格\r\n\r\n(2) 對於無法接受platinum 治療的患者，CCRT 時給予avelumab plus cetuximab 相對於 cetuximab alone 並無證據顯示較佳之預後。\r\n\r\n結論：正確\r\n\r\n此選項為REACH study的結論，整理如下:\r\n• open-label、隨機分派的第三期試驗。\r\n• 收錄口腔、口咽、下咽及喉部之局部侵犯性頭頸鱗狀細胞癌之患者。\r\n• 以 1:1 隨機分配至以下各組：\r\n第一組 Fit for high dose cisplatin:\r\n✓ Arm A: 放療 70 Gy/33 Fraction，化療為順鉑 100 mg/m2 Q3W for 3 cycles\r\n✓ Arm B: 放療 70 Gy/33 Fraction，合併 Avelumab 10 mg/kg Q2W 以及 Cetuximab QW，放療結束後維持 Avelumab 10 mg/kg 一年。\r\n▪ Non-fit for high dose cisplatin:\r\n✓ Arm C: 放療 70 Gy/33 Fraction，合併 Avelumab 10 mg/kg Q2W 以及 Cetuximab QW，放療結束後維持 Avelumab 10 mg/kg 一年。\r\n✓ Arm D: 放療 70 Gy/33 Fraction，同步給予 Cetuximab QW。\r\n• Primary endpoint: PFS 療效\r\n• 在 cisplatin-fit 組別，interim analysis 顯示實驗組之一年 PFS 為 64%，對照組為 73%，HR=1.27 (95% CI: 0.83-1.93)，此組別因無療效性 (futility) 而中止。\r\n• 在 cisplatin-unfit 組別，實驗組之兩年無惡化存活率為 44%，對照組為 31%, HR=0.85, p=0.15。此外，實驗組之兩年存活率為 58%，對照組為54% (HR=1.08, p=0.69)。\r\n\r\n在局部侵犯性頭頸癌的病人族群，使用同步放療合併 Avelumab/Cetuximab 相比傳統同步放化療合併cisplatin並無法改善PFS。使用同步放療合併Avelumab/Cetuximab 相比同步放療合併 Cetuximab 則有改善 PFS 的趨勢，但未能達到顯著。\r\n\r\n出處:台灣頭頸癌免疫藥物治療指引\r\n\r\n此外NCCN guideline也未提及合併avelumab plus cetuximab之治療方式，avelumab的腳色僅有axitinib可考慮合併avelumab用於治療salivary gland tumors.\r\nUse of certain tyrosine kinase inhibitors such as axitinib (with or without avelumab) and sorafenib have been evaluated in nonrandomized phase II trials734-736 and are recommended by the panel as category 2B options for patients with unresectable, metastatic, or recurrent salivary gland tumors (useful in certain circumstances).\r\n出處:NCCN Guidelines Version 2.2025 Head and Neck Cancers(MS-58)\r\n\r\n\r\n(3) In CCRT of HNSCC，weekly cisplatin 30mg/m2 per week is non-inferior to standard cisplatin 100mg/ m2 every three weeks。\r\n標準劑量 cisplatin (100 mg/m² 每三週) 是 HNSCC CCRT 的基石。然而，每週低劑量 cisplatin（如 30-40 mg/m²）的非劣效性一直是有爭議的話題。一些研究（如印度 Tata Memorial Hospital 的試驗）顯示每週 30 mg/m² 的 cisplatin 在局部晚期 HNSCC 中可能療效不足，特別是在遠端控制和總生存率上與標準劑量相比有差距。因此，目前多數證據不支持 30 mg/m² 每週劑量與標準劑量具有非劣效性。\r\n\r\n結論：錯誤\r\nNoronha V, Patil V, Menon N, et al. Long-Term Update of a Phase 3 Randomized Study Comparing Once-a-Week Versus Once-Every-3-Weeks Cisplatin Along With Radiation in Head and Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 2025;121(1):128-136. doi:https://doi.org/10.1016/j.ijrobp.2024.07.2315\r\n\r\n(4) In CCRT of HNSCC，weekly cisplatin 40mg/m2 per week is non-inferior to standard\r\ncisplatin 100mg/ m2 every three weeks。\r\n\r\n結論：正確\r\n\r\nIn this multi-institutional open-label phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin (100 mg/m2) or with weekly cisplatin (40 mg/m2) to confirm the noninferiority of weekly cisplatin. \r\nChemoradiotherapy with weekly cisplatin is noninferior to 3-weekly cisplatin for patients with postoperative high-risk LA-SCCHN.\r\n出處:J Clin Oncol. 2022 Mar 1;40(18):1980–1990\r\n\r\n綜上述，正解應為(C) (2),(4)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/065/explain_figures/figure1.jpg"
    ]
  },
  {
    "id": 66,
    "question": "關於 locally advanced nasopharyngeal carcinoma 的治療，下列敘述中正確的有?\r\n(1) T3-T4N0 NPC with high-risk features 可考慮induction chemotherapy followed by CCRT。\r\n(2) Adjuvant chemotherapy 可考慮 cisplatin/5-FU for 6 cycles。\r\n(3) Adjuvant chemotherapy 可考慮 metronomic capecitabine for up to 1 year。\r\n(4) CCRT 後的 EBV copy number 對於 recurrence 預測力不佳。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1) T3-T4N0 NPC with high-risk features 可考慮induction chemotherapy followed by CCRT。\r\n結論：正確\r\n\r\n對於 T3-T4N0 的局部晚期鼻咽癌，尤其是伴隨高風險特徵（如腫瘤體積大、侵襲性或 EBV DNA 高水平），誘導化療 (induction chemotherapy) 後接 CCRT 已成為一種常見策略。諸多臨床試驗（如 NPC-0501 ）以及 NCCN 支持在高風險局部晚期 NPC 中使用 Induction Chemotherapy（如 gemcitabine/cisplatin 或 TPF 方案）以縮小腫瘤並改善遠端控制率。因此，這項敘述符合當前治療共識。\r\n\r\nT3N0M0 NPC : 建議Concurrent systemic therapy/RT\r\n• Consider induction or adjuvant chemotherapy if high-risk features\r\nT4N0-3M0 NPC:Induction chemotherapy followed by systemic therapy/RT\r\n出處:NCCN Guidelines Version 2.2025 Cancer of the Nasopharynx(NASO-2)\r\n\r\nAnne, Roger, Ng W, et al. NPC‐0501 trial on the value of changing chemoradiotherapy sequence, replacing 5‐fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. Cancer. 2020;126(16):3674-3688. doi:https://doi.org/10.1002/cncr.32972\r\n\r\n(2) Adjuvant chemotherapy 可考慮 cisplatin/5-FU for 6 cycles。\r\n\r\n結論：錯誤\r\n\r\nRegimen正確但cycles錯誤。另外現代證據顯示，單純 CCRT 已足夠治療大多數局部晚期 NPC，且額外的輔助 cisplatin/5-FU（特別是長達 6 個 cycles ）並未顯著改善總生存率或無病生存率，且毒性較高，因此，當前指南（如 NCCN 2025）不推薦常規使用如此長期的輔助化療，更多傾向 induction chemotherapy。\r\n\r\nPreferred Regimens\r\n• Cisplatin + RT followed by cisplatin/5-FU\r\n出處:NCCN Guidelines Version 2.2025 Cancer of the Nasopharynx postradiotherapy, chemotherapy with cisplatin 80 mg/m2 on day 1 and fluorouracil 1,000 mg/m2/d on days 1 to 4 was administered every 4 weeks for ‘three’ courses.\r\n出處:J Clin Oncol 1998;16:1310-1317. J Natl Cancer Inst 2005;97:536-539\r\n\r\n(3) Adjuvant chemotherapy 可考慮 metronomic capecitabine for up to 1 year。\r\n結論：正確\r\n可考慮oral metronomic capecitabine (650 mg/m2 BSA twice daily for 1 year)，其 Failure-free survival at 3 years was significantly higher in the metronomic capecitabine group (85·3%) than in the standard therapy group (75·7%), with a HR of 0·50. \r\n\r\nMetronomic capecitabine（低劑量、長療程的口服 capecitabine）作為輔助治療在 NPC 中的應用近年來受到關注。一項關鍵研究 Lancet Oncology 2021 顯示，在 CCRT 後使用 metronomic capecitabine 長達 1 年可顯著降低復發風險並改善無病生存率，特別適用於高復發風險患者（如 EBV DNA 持續陽性者）。此策略因耐受性較好且療效顯著。\r\n\r\n出處:112考古詳解72題，Lancet. 2021 Jul 24;398(10297):303-313\r\n\r\n(4) CCRT 後的 EBV copy number 對於 recurrence 預測力不佳。\r\n\r\n結論：錯誤\r\n\r\nLevels of plasma EBV DNA have been shown to be independently prognostic at baseline and following definitive chemoradiation. After induction chemotherapy, and after radiation, plasma EBV DNA levels are used in some centers as a means of outcome prognostication and residual disease monitoring. \r\n\r\n出處:NCCN Guidelines Version 2.2025 Cancer of the Nasopharynx(MS-37)\r\n\r\n綜上述，正解應為(B) (1),(3)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 67,
    "question": "有關三陰性早期乳癌，目前標準的輔助性治療策略的敘述中，正確的有:\r\n\r\n(1) 若病人並沒有年齡或健康的疑慮，至少應該給予athracycline/cyclophosphamide，續接 taxane 的輔助性(或新輔助性)化學治療，以減少復發及死亡率。\r\n(2) 可以考慮先做新輔助性(neoadjuvant)化學治療，再手術。如果術後病理檢查沒有達成pCR，可以再追加6個月的capecitabine。這樣的治療方式可以增加存活率。\r\n(3) 可以考慮使用免疫治療合併化學治療作為新輔助性(neoadjuvant)治療。相較於傳統的輔助性化學治療，這種方法可以顯著提高pCR rate以及event free survival。\r\n(4) 若沒有germline BRCA1/2 mutation，但病人腫瘤檢體驗出有BRCA 1/2 somatic mutation，應該在化療結束之後追加一年的口服PARP 抑制劑。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "有關三陰性早期乳癌，目前標準的輔助性治療策略的敘述中，正確的有:\r\n\r\n(1) 若病人並沒有年齡或健康的疑慮，至少應該給予athracycline/cyclophosphamide，續接 taxane 的輔助性(或新輔助性)化學治療，以減少復發及死亡率。\r\n\r\n結論：正確\r\n\r\n依NCCN guideline, pT1N0不須接受adjuvant therapy\r\n出處:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-10)\r\n但對TNBC而言，接受Preoperative Systemic Therapy會有Known Benefits \r\n出處:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-L 1 OF 2)\r\n\r\n(2) 可以考慮先做 neoadjuvant 再手術。如果術後病理檢查沒有達成pCR，可以再追加6個月的capecitabine。這樣的治療方式可以增加存活率。\r\n\r\n結論：正確\r\n\r\n可再追加Adjuvant capecitabine (every 3 weeks for six or eight cycles)\r\nAfter standard neoadjuvant chemotherapy containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease-free survival and overall survival among patients with HER2-negative breast cancer who had residual invasive disease on pathological testing. \r\n\r\nCREATE-X 試驗顯示，若新輔助性化療後未達病理完全緩解 (pathologic complete response, pCR)，追加 6-8 周期的 capecitabine（通常為 6 個月）可顯著改善無病生存率 (DFS) 和總生存率 (OS)，特別是在 TNBC 患者中。\r\n\r\n出處:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-16)、N Engl J Med 2017;376:2147-2159\r\n\r\n(3) 可以考慮使用免疫治療合併化學治療作為新輔助性(neoadjuvant)治療。相較於傳統的輔助性化學治療，這種方法可以顯著提高pCR rate以及event free survival。\r\n\r\n結論：正確\r\n\r\nStage II–III Preoperative followed by adjuvant:\r\n• Preoperative pembrolizumab + carboplatin + paclitaxel, followed by preoperative pembrolizumab + cyclophosphamide + doxorubicin or epirubicin, followed by adjuvant pembrolizumab (category 1) \r\n\r\nKEYNOTE-522 試驗證實，對於早期 TNBC，pembrolizumab 聯合化療（包括 taxane、carboplatin 和 anthracycline）可顯著提高 pCR 率（約 65% vs. 51%）並改善無事件生存率 (event-free survival, EFS)。這一策略已成為高風險 TNBC 患者的標準選擇\r\n\r\n出處:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-M 3 OF 10)\r\n\r\n(4) 若沒有germline BRCA1/2 mutation，但病人腫瘤檢體驗出有BRCA 1/2 somatic mutation，應該在化療結束之後追加一年的口服PARP 抑制劑。\r\n\r\n結論：錯誤\r\n\r\nPARP 抑制劑（如 olaparib）在 TNBC 中的應用主要基於 OlympiA 試驗，該試驗顯示，對於攜帶 germline BRCA1/2 突變 的早期 TNBC 患者，化療後追加 1 年 olaparib 可顯著改善 DFS 和 OS。然而，目前證據尚未支持將 PARP 抑制劑常規用於僅有 somatic BRCA1/2 突變（體細胞突變）而無 germline 突變的患者。雖然 somatic BRCA 突變可能提示 PARP 抑制劑的潛在療效，但缺乏大型隨機試驗支持其標準應用。\r\n\r\n依NCCN guideline, 未提及somatic mutation Adjuvant olaparib for 1 year if germline BRCA1/2 mutation (category 1), \r\n出處:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-10)\r\n\r\n但對於轉移性乳癌，有Somatic BRCA1/2 mutations，則建議可使用olaparib(category 2B)\r\n出處:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-Q 8 OF 15)\r\n\r\n綜上述，正解應為(A) (1),(2),(3)，但(1)(3)的文字敘述似乎還是有點 bug",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 68,
    "question": "有關雌激素受體(Estrogen Receptor)陽性HER2陰性早期乳癌患者，目前標準的輔助性治療建議中，正確的有:\r\n\r\n(1) 除非有特殊禁忌症，否則每一個病人在術後都建議給予輔助性內分泌治療5至10年。\r\n(2) 研究顯示對於高復發風險的患者輔助性內分泌治療合併2-3 年的CDK4/6抑制劑 (如abemaciclib or ribociclib)會顯著減少轉移復發率。\r\n(3) 停經前婦女，相較於單獨使用傳統輔助性荷爾蒙治療，合併使用卵巢抑制的藥物 (LHRH agonist)會顯著減少轉移復發率。\r\n(4) 建議先做新輔助性化學治療來增加病理完全緩解率 (pCR rate)。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "有關雌激素受體(Estrogen Receptor)陽性HER2陰性早期乳癌患者，目前標準的輔助性治療\r\n建議中，正確的有:\r\n\r\n(1) 除非有特殊禁忌症，否則每一個病人在術後都建議給予輔助性內分泌治療5至10年。\r\n\r\n結論：正確\r\n\r\n對於 ER+ HER2- 早期乳癌患者，輔助性內分泌治療（如 tamoxifen 或芳香酶抑制劑 [AI]）是標準治療，旨在降低復發風險。根據患者停經狀態和復發風險，治療通常持續 5 年（低風險）至 10 年（高風險），這一點已被 ATLAS 和 aTTom 等試驗證實。因此，除非有明確禁忌症（如嚴重肝病或血栓史），所有患者均應接受此治療\r\n\r\n請直接參考NCCN Guideline,不論PREMENOPAUSAL OR POSTMENOPAUSAL術後都建議給予輔助性內分泌治療\r\n出處:\r\n- NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-6.7.8及BINV-K 2 OF 3、2 OF 3)\r\n- Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet. 2012;381(9869):805-816. doi:https://doi.org/10.1016/s0140-6736(12)61963-1\r\n- Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. Journal of Clinical Oncology. 2013;31(18_suppl):5-5. doi:https://doi.org/10.1200/jco.2013.31.18_suppl.5\r\n\r\n(2) 研究顯示對於高復發風險的患者輔助性內分泌治療合併2-3 年的CDK4/6抑制劑 (如abemaciclib or ribociclib)會顯著減少轉移復發率。\r\n\r\n結：正確\r\n\r\nIn patients with HR-positive/HER2-negative breast cancer, \r\n1) for those with high-risk breast cancer (ie, those with ≥4 positive lymph nodes (confirmed preoperatively and/or at surgery), or 1–3 positive lymph nodes with either grade 3 disease or tumor size≥5 cm (on pre-operative imaging and/or at surgery), 2 years of adjuvant abemaciclibcan be considered in combination with endocrine therapy (category 1, preferred). [VTE risk should be considered when combining abemaciclib with tamoxifen.] \r\n2) For those with any lymph node involvement (excluding microscopic nodal involvement),or if no nodal involvement either tumor size >5 cm, or if tumor size 2–5 cm, either\r\nGrade 2 (and high genomic risk or Ki-67 ≥20%), or Grade 3, 3 years of ribociclib with aromatase inhibitor may be considered (Category 1, preferred). \r\nNotably adjuvant CDK4/6 inhibitors have been studied in patients at high risk who mostly received adjuvant/neoadjuvant chemotherapy; there are limited data in those who did not receive chemotherapy. \r\n\r\n出處:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-K 2 OF 3)\r\n\r\n(3) 停經前婦女，相較於單獨使用傳統輔助性荷爾蒙治療，合併使用卵巢抑制的藥物 (LHRH\r\nagonist)會顯著減少轉移復發率。\r\n\r\n正確\r\nA balanced discussion of the risks and benefits associated with ovarian suppression therapy is critical, including the potential side effects of premature menopause. Aromatase inhibitor or tamoxifen for 5 years plus ovarian suppression should be considered, based on SOFT and TEXT clinical trial outcomes, for premenopausal patients at higher risk of recurrence (ie, young age, high-grade tumor, lymph node involvement).\r\n\r\n對於停經前 ER+ 乳癌患者，SOFT 和 TEXT 試驗證實，單獨使用 tamoxifen 相比，聯合LHRH agnoist (如 goserelin) 加 tamoxifen 或芳香酶抑制劑（如 exemestane）可進一步降低復發風險，特別是在高風險人群（如年輕患者或淋巴結陽性）。這種策略顯著減少遠端轉移復發率\r\n\r\n出處:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-K 2 OF 3)\r\n\r\n(4) 建議先做新輔助性化學治療來增加病理完全緩解率 (pCR rate)。\r\n\r\n錯誤\r\n\r\n參考NCCN Guideline, TNBC or HER2-positive breast cancer會比較有Known Benefits\r\n\r\nKnown Benefits of Preoperative Systemic Therapy\r\n• Facilitates breast conservation\r\n• Can render inoperable tumors operable\r\n• Treatment response provides important prognostic information at an individual patient level, particularly in patients with TNBC or HER2-positive breast cancer\r\n• Identifies patients with residual disease at higher risk for relapse to allow for the addition of supplemental adjuvant regimens, particularly\r\nin patients with TNBC or HER2-positive breast cancer. \r\n\r\n新輔助性化療通常用於三陰性乳癌 (TNBC) 或 HER2+ 乳癌，以縮小腫瘤並提高 pCR 率。然而，對於 ER+ HER2- 早期乳癌，pCR 率通常較低（因其對化療敏感性不如其他亞型），且新輔助性內分泌治療（如 AI）更常被考慮用於停經後患者以評估腫瘤反應。新輔助性化療在 ER+ HER2- 中的應用主要限於特定情況（如腫瘤過大無法手術），但並非標準建議，也非主要目標為提高 pCR。因此，此敘述不符合當前標準。\r\n\r\n出處:NCCN Guidelines Version 2.2025 Invasive Breast Cancer(BINV-L 1 OF 2)\r\n\r\n綜上述，正解應為(A) (1),(2),(3)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 69,
    "question": "關於 BRCA1/2 mutation，以下敘述中，正確的有?\n(1) 具有 germline mutation 的女性，有顯著較高罹患乳癌及卵巢癌風險。\n(2) 預防性卵巢切除，可以減少罹患乳癌的機率。\n(3) 轉移性乳癌，使用 PARP 抑制劑，除了有較佳的無疾病惡化存活期之外，其整體存活期(overall survival)也顯著高於單一化學治療，應優先使用。\n(4) 化療藥品中，鉑金類(platinum)效果相對較佳。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "偷吃步解法：(1), (4) 必選，選(E)\n\n(1) ✓ 正確。BRCA1/2胚細胞系突變確實會顯著增加女性罹患乳癌和卵巢癌的風險。BRCA1突變者一生中罹患乳癌的風險約為65-80%，卵巢癌風險約為39-44%；BRCA2突變者乳癌風險約為45-69%，卵巢癌風險約為11-17%。\n\nKurian AW, Gong GD, John EM, et al. Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: Findings From the Breast Cancer Family Registry - PMC. Journal of Clinical Oncology. 29(34). doi:10.1200/JCO.2010.34.4440\n  \n(2) ✓ 正確。2002 NEJM發表：預防性卵巢切除術(prophylactic oophorectomy)不僅可降低卵巢癌風險，研究也顯示它可減少BRCA突變帶因者乳癌風險約50%，主要是通過降低雌激素水平的機制。\n\nRebbeck TR. Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations. The New England Journal of Medicine. May 23, 2002. Accessed March 6, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa012158\n\n(3) ✓ 正確，PARP抑制劑在BRCA突變的轉移性乳癌患者中提高了無疾病惡化存活期(PFS)，當年尚未證實它們在整體存活期(OS)方面有顯著優勢，但近期 OlympiAD 在2024發表中，在線使用有OS benifit，故正確。\n\nRobson ME, Im SA, Senkus E, et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. European Journal of Cancer. 2023;184:39-47. doi:10.1016/j.ejca.2023.01.031\n  \nRobson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523-533.\n\nLitton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med.\n2018;379(8):753-763.\n\n*關於PARP抑制劑是否具有OS benefit仍具爭議性。在2023年發表的OlympiAD extended follow-up for OS分析中，僅有接受olaparib作為第一線治療的subgroup顯示出相比 chemotherapy 有OS benefit (also not powered for OS in this study)。在整體族群中，olaparib相較於TPC 並未顯示統計上顯著的整體存活優勢。\n此外，在EMBRACA study 中，使用talazoparib相較於化療也未顯著改善overall survival。\n然而，鑑於選項的限制，我們只能選擇 E（1、2、3、4 皆正確)作為最適合的答案。\n\n(4) ✓ 正確。BRCA突變的腫瘤存在DNA修復缺陷，對引起DNA損傷的藥物特別敏感。Cells with BRCA1 pathogenic variant are more sensitive to platinum-based chemotherapeutic agents, which disrupt the DNA structure。\n\n3.Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of BRCA1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol. 2003;22:1169–1173.\n\n4.Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003;88:1285–1291. doi: 10.1038/sj.bjc.6600859IF: 6.4 Q1 .",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/069/explain_figures/fig1.png",
      "/qabank/069/explain_figures/fig2.png"
    ]
  },
  {
    "id": 70,
    "question": "關於轉移性乳癌的 biomarker 及其相對應的藥物，以下 biomarker 中，不必檢驗陽性即可 使用該藥物治療的有?\n(1) PIK3CA mutation: PI3K 抑制劑 (如 alpelisib)\n(2) PI3K/akt/mTOR alteration: mTOR inhibitor (如 everolimus)\n(3) HER2 overexpression (IHC 3+ or FISH positive): trastuzumab, TDM1\n(4) Trop 2 protein expression: anti-Trop2 antibody-drug conjugate (如 sacituzumab govitecan)",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 2,
    "explanation": "(2)(4)\n\n1. PIK3CA mutation: Alpelisib → 需要 PIK3CA 突變陽性才能使用\n2. PI3K/AKT/mTOR alteration: Everolimus → 要 HR+/HER2- ，但 Everolimus 不需要特定 PI3K/AKT/mTOR 改變的檢測\n（但如果今天是 Capivasertib–fulvestrant，則要驗到 PIK3CA/AKT1/PTEN-alterations 才可以用）\n3. HER2 overexpression: Trastuzumab, TDM1 → 需要 HER2 IHC 3+ 或 FISH 陽性 （秒殺）\n4. Sacituzumab govitecan (Trodelvy) 屬於抗 Trop-2 ADC，但目前在治療轉移性三陰性乳癌 (mTNBC) 及 HR+/HER2- 乳癌時，並不需要 Trop-2 陽性檢測結果 才能使用。臨床試驗顯示，大多數乳癌患者都有 Trop-2 表現，因此該藥物可適用於廣泛族群。\n\nRef:\n1. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine. 2021;384(16):1529-1541. doi:10.1056/nejmoa2028485\n\n2. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529. doi:10.1056/NEJMoa1109653\n\n3. Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine. 2023;388(22):2058-2070. doi:10.1056/nejmoa2214131\n\n4. Corti C. Systemic Therapy in Breast Cancer. American Society of Clinical Oncology Educational Book. Published online July 1, 2024.",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/070/explain_figures/fig1.png"
    ]
  },
  {
    "id": 71,
    "question": "有關 HER2 陽性(HER2 overexpression)轉移性乳癌，以下敘述中，正確的有？\n(1) 目前第一線治療建議的是 trastuzumab+pertuzumab 合併紫杉醇。\n(2) 第二線的治療，研究顯示，新一代的 antibody-drug conjugate TDXd (trastuzumab deruxtecan)，效果顯著的優於 TDM1 (trastuzuamb emtansine)。\n(3) Trastuzumab+pertuzumab 合併紫杉醇治療後，產生抗藥性，疾病惡化進展時，更換成下一線的化療藥物時，繼續持續使用 tratuzumab 被證實仍然會加強下一線化療的療效。\n(4) 口服 anti-HER2 標靶藥物 lapatinib 合併 capecitabine，是常用的第三，四線藥物，但是對於腦轉移的患者不建議使用。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "(1) 目前第一線治療建議的是 trastuzumab+pertuzumab 合併紫杉醇。\n✓ 正確。根據臨床實踐指南，HER2 陽性轉移性乳癌的第一線治療確實建議使用 trastuzumab+pertuzumab 加上紫杉醇或 docetaxel 的化療組合。CLEOPATRA 研究證實這種組合可明顯改善總生存期。\n\n(2) 第二線的治療，研究顯示，新一代的 antibody-drug conjugate TDXd (trastuzumab deruxtecan)，效果顯著的優於 TDM1 (trastuzuamb emtansine)。\n✓ 正確。DESTINY-Breast03 研究顯示，在之前接受過 trastuzumab 和紫杉醇治療的患者中，T-DXd 確實顯著優於 T-DM1，PFS和ORR均有顯著改善。\n\n(3) Trastuzumab+pertuzumab 合併紫杉醇治療後，產生抗藥性，疾病惡化進展時，更換成下一線的化療藥物時，繼續持續使用 tratuzumab 被證實仍然會加強下一線化療的療效。\n✓ 正確。多項研究包括 GBG26 及 CEREBEL 研究顯示，即使疾病在 trastuzumab 治療期間進展，繼續使用 trastuzumab 並轉換化療藥物仍可提供臨床效益，支持保持 HER2 阻斷的策略。\n\n(4) 口服 anti-HER2 標靶藥物 lapatinib 合併 capecitabine，是常用的第三，四線藥物，但是對於腦轉移的患者不建議使用。\n✗ 不正確。實際上，lapatinib 是小分子抑制劑，可穿過血腦屏障，與 capecitabine 組合在 HER2 陽性乳癌腦轉移患者中已顯示出臨床活性，因此常被考慮用於此類患者，而非不建議使用。\n\n\n\n1.Swain SM. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. The New England Journal of Medicine. February 19, 2015. Accessed March 6, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa1413513\n\n\n\n2. Cortés J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. New England Journal of Medicine. 2022;386(12):1143-1154. doi:10.1056/nejmoa2115022\n\n\n3.Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer. 47(15):2273-2281. doi:10.1016/j.ejca.2011.06.021\n\n4.Pivot X. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Journal of Clinical Oncology. Published online May 10, 2015.\n\n5. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. The Lancet Oncology. 14(1):64-71. doi:10.1016/S1470-2045(12)70432-1",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 72,
    "question": "有關侵犯性乳癌手術後的輔助性放射治療，以下敘述中，正確的有？\n(1) 若是乳房保留手術之後，建議應該實施。\n(2) 若是腋下淋巴結四顆陽性，建議應該實施。\n(3) 若是病人有接受適當的全身性輔助性治療(systemic adjuvant therapy)，臨床上理學檢查未發現有淋巴結腫大，腋下前哨淋巴結取樣只有一顆陽性，放射治療可以取代腋下淋巴結廓清術。\n(4) 若有其他高風險因子存在，腋下淋巴結只有 1 顆陽性，也建議實施。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1) 正確。乳房保留手術後建議實施輔助性放射治療，這是標準治療流程，可顯著降低局部復發風險。 NCCN: Those who have a positive lymph node have a high risk of recurrence. Therefore, after BCS WBRT is strongly recommended with or without boost to tumor bed for node-positive disease\n\n(2) 正確。當腋下淋巴結有 4 顆或更多呈陽性時，確實建議進行輔助性放射治療，因為這表示疾病已有淋巴結轉移且風險較高。\n\n(3) 正確。根據 ACOSOG Z0011 臨床試驗結果，若病人符合以下條件：接受適當的全身性輔助治療、臨床檢查未發現淋巴結腫大、前哨淋巴結活檢僅有 1-2 顆陽性，則放射治療確實可以取代完整的腋下淋巴結廓清術，且不會影響生存率。\n\n(4) 正確。即使腋下淋巴結僅有 1 顆陽性，若存在其他高風險因素（如腫瘤大小大於 5 公分、分化程度差、年齡小於 40 歲、淋巴血管侵犯等），也建議實施輔助性放射治療以降低復發風險。 NCCN: In the case of cT3N0, high-risk features for considering PMRT include, but are not limited to, young age and/or LVI.\n\n因此，這四個敘述都是正確的。\n\n1.Giuliano MAE. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive. JAMA. 2017;318(10):918-926. doi:10.1001/jama.2017.11470",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 73,
    "question": "關於 breast cancer 的 supportive care，以下敘述中，正確的有?\n(1) Denosumab 治療乳癌骨轉移應注意 osteonecrosis of jaw 可能。\n(2) D-CARE study 中，早期高風險乳癌使用 adjuvant denosumab 顯示可減少骨骼轉移。\n(3) PG2 黃耆多醣體可使用於乳癌治療中癌因性疲憊。\n(4) Megestrol 僅能用於 cancer cachexia，對 ER+ MBC 並無治療效果。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1) 對。Bisphosphonates和 Denosumab 皆與約 2% 的osteonecrosis of the jaw發生率相關。理想情況下，醫師應避免在患者進行或剛完成任何涉及骨骼操作的侵入性牙科手術（如拔牙或植牙）前後使用這些藥物。\n\n(2) 錯。在 D-CARE phase III  RCT試驗中，4509 名具有高風險早期乳癌的premenopausal和postmenopausal女性被隨機分配接受Denosumab 120 mg 皮下注射，每 3 至 4 週一次，持續 6 個月，隨後每 12 週一次，最多 5 年，或接受placebo，並與standard neoadjuvant/adjuvant treatment聯合使用。結果顯示，接受Denosumab治療的患者與接受placebo的患者相比，在bone metastasis-free survival方面沒有顯著差異。\n\nReference: Coleman R, Finkelstein DM, Barrios C, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2020;21:60-72. doi:10.1016/S1470-2045(19)30687-4. PMID: 31806543. \n\n(3) 對。PG2 黃耆多醣體 (Astragalus Polysaccharide PG2) 已獲台灣批准用於治療晚期癌症患者的癌因性疲憊（CRF）。 在一個台灣發表的phase II , double-blind, placebo-controlled RCT試驗中，正在接受adjuvant chemotherapy的 stage II or III 乳癌患者被隨機分配至 PG2 500mg 或placebo組，並於 第 1、3、8 天，每 21 天進行給藥。 研究結果顯示，PG2 結合adjuvant chemotherapy可顯著改善chemotherapy-related fatigue score，並提高患者完成adjuvant chemotherapy的compliance。\n\nReference: Shen WC, Chen SC, Wang CH, Hung CM, Peng MT, Liu CT, Chang YS, Kuo WL, Chou HH, Yeh KY, Wu TH, Wu CF, Chang PH, Huang YM, Yu CC, Lee CH, Rau KM. Astragalus polysaccharides improve adjuvant chemotherapy-induced fatigue for patients with early breast cancer. Sci Rep. 2024 Oct 28;14(1):25690. doi: 10.1038/s41598-024-76627-z. PMID: 39465324; PMCID: PMC11514294.\n\n(4) 錯。Megesterol acetate is listed on the NCCN guidelines as one of the subsequent-line therapy options for the treatment of hormone receptor-positive recurrent unresectable or stage IV breast cancer. 詳見 Figure 1",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/073/explain_figures/Figure 4.png"
    ]
  },
  {
    "id": 74,
    "question": "Based on the latest NCCN guidelines, which of the following statements regarding the descriptions of sarcoma are (is) correct?\n(1) For well-differentiated liposarcoma (with no evidence of de-differentiation) over the extremity,\nsurgical resection with oncologically appropriate margins is adequate for treatment.\n(2) Pleomorphic rhabdomyosarcoma is recommended to be treated like high-grade undifferentiated\npleomorphic sarcoma.\n(3) Immunotherapy could be considered as subsequent lines of therapy for advanced/metastatic\ndisease of cutaneous angiosarcoma.\n(4) Dermatofibrosarcoma protuberans (DFSP) with fibrosarcomatous transformation could be\nconsidered treated with chemotherapy used in soft tissue sarcoma if failed imatinib.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1) 對。Well-differentiated liposarcoma (WDLS) is a low-grade soft tissue sarcoma that arises from adipocytes. Unlike its more aggressive counterpart, de-differentiated liposarcoma (DDLS), WDLS is characterized by local recurrence but lacks metastatic potential. Since WDLS has minimal metastatic risk, adequate surgical resection with oncologic margins is considered definitive treatment. Chemotherapy is ineffective in treating WDLS due to the tumor’s low mitotic activity. 詳見 Figure 1\n\n(2) 對。The incidence of pleomorphic rhabdomyosarcoma (PRMS) increases with age and the overall prognosis in adults is poor. PRMS is usually excluded from rhabdomyosarcoma (RMS) and soft tissue sarcoma randomized clinical trials. PRMS is treated similarly to high-grade undifferentiated pleomorphic sarcoma (UPS) because of their shared histopathological features, aggressive clinical behavior, and poor response to standard rhabdomyosarcoma (RMS) treatments (such as the “VAC” regimen). PRMS is treated using the high-grade soft tissue sarcoma approach, primarily with surgery, radiation, and anthracycline-based chemotherapy. 詳見 Figure 2\n\n(3) 對。Pembrolizumab is approved by U.S. FDA for unresectable or metastatic TMB-H (≥10 mut/Mb) tumors that have progressed following prior treatment and who have no satisfactory alternative options. NCCN guidelines currently list pembrolizumab as a subsequent-line treatment option for patients with certain subtypes of advanced or metastatic soft tissue sarcoma, including myxofibrosarcoma, undifferentiated pleomorphic sarcoma (UPS), cutaneous angiosarcoma, and undifferentiated sarcomas. Cutaneous angiosarcomas often exhibit high TMB, and recently, the combination of ipilimumab and nivolumab showed a response rate of 25% in angiosarcoma with three of five patients with cutaneous angiosarcomas of the scalp and face achieving partial response. 詳見 Figure 3A, 3B\n\n(4) 對。Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing soft tissue sarcoma, but fibrosarcomatous transformation (FS-DFSP) is an aggressive variant with increased metastatic potential and a higher recurrence rate. For unrsectable metastatic or locally advanced FS-DFSP, imatinib is the frontline systemic therapy of choice. For imatinib-resistant FS-DFSP, chemotherapy is considered, such as anthracycline- or gemcitabine-based regimen. 詳見 Figure 4",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/074/explain_figures/Figure 1.png",
      "/qabank/074/explain_figures/Figure 2.png",
      "/qabank/074/explain_figures/Figure 3A.png",
      "/qabank/074/explain_figures/Figure 3B.png",
      "/qabank/074/explain_figures/Figure 4.png"
    ]
  },
  {
    "id": 75,
    "question": "Which of the following statements regarding the treatment of soft tissue sarcoma (STS) are (is) correct?\n(1) In comparison with dacarbazine, eribulin has shown superior activity as a second line\ntherapy for leiomyosarcoma.\n(2) Trabectedin has shown better efficacy than dacarbazine in both leiomyosarcoma and\nliposarcoma.\n(3) Pazopanib has been approved as standard late line therapy for liposarcoma.\n(4) Current recommended treatments for alveolar soft part sarcoma (ASPS) included sunitinib,\npazopanib, pembrolizumab, pembrolizumab in combination with axitinib, and atezolizumab.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 2,
    "explanation": "(1) 錯。A phase 3, randomized, open-label trial showed that eribulin improved OS compared to dacarbazine in patients with previously treated locally advanced or metastatic leiomyosarcoma or liposarcoma. A planned subgroup analysis by sarcoma subtype found a statistically significant improvement in both PFS and OS for liposarcoma patients treated with eribulin versus dacarbazine, with a 1.2-month increase in median PFS and a 7-month increase in OS favoring eribulin. However, no survival benefit was observed for leiomyosarcoma. Notably, dacarbazine is likely more active in leiomyosarcoma than in liposarcoma, so the lack of difference in the leiomyosarcoma group suggests similar efficacy between the two drugs rather than eribulin being ineffective. Based on these findings, the NCCN recognizes eribulin as a standard treatment option for advanced soft tissue sarcomas, not just liposarcoma, regardless of histology. 詳見 Figure 1\n\nReference: Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0IF: 98.4 Q1 . Epub 2016 Feb 10. PMID: 26874885.\n\n(2) 對。Trabectedin is a cytotoxic agent approved by the US FDA for patients with unresectable or metastatic leiomyosarcoma or liposarcoma who have previously received anthracycline-based chemotherapy. In a randomized, open-label, international phase 3 study, trabectedin reduced the risk of sarcoma progression or death by 45% compared to dacarbazine (P < .001). However, overall survival (OS) was not significantly different between the two treatments. Trabectedin is administered as a 24-hour intravenous infusion. The median PFS was 4.2 months with trabectedin, compared to 1.5 months with dacarbazine. Objective response rates remained below 10% and were similar in both treatment groups. Safety monitoring is crucial, as trabectedin was associated with a 1.2% incidence of rhabdomyolysis and a 2.1% incidence of treatment-related death, complications that were not observed in the dacarbazine group. Due to this risk, weekly CPK monitoring, along with standard laboratory tests, is recommended for patients receiving trabectedin. 詳見 Figure 2A, 2B, 2C\n\nReference: Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. doi: 10.1200/JCO.2015.62.4734. Epub 2015 Sep 14. PMID: 26371143; PMCID: PMC5070559.\n\n(3) 錯。Pazopanib is FDA-approved for the treatment of advanced soft tissue sarcomas (STS), excluding liposarcoma, after prior chemotherapy. According to NCCN guidelines, it is recommended as a subsequent-line treatment for non-liposarcoma STS, but not for liposarcoma due to limited efficacy. The Phase 3 PALETTE trial showed that pazopanib significantly improved PFS in advanced STS, but had minimal to no benefit in liposarcoma patients. As a result, pazopanib is not considered a standard late-line treatment for liposarcoma and is not included in its FDA-approved indications. Instead, eribulin and trabectedin are the preferred treatments for advanced liposarcoma after prior therapy. 詳見 Figure 3\n\nReference: van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5. Epub 2012 May 16. PMID: 22595799.\n\n(4 對。Alveolar Soft Part Sarcoma (ASPS) is a rare, slow-growing, but highly metastatic soft tissue sarcoma that frequently affects young adults. For a list of recommended systemic therapy for metastatic or unresectable ASPS by the NCCN. 詳見 Figure 4",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/075/explain_figures/Figure 1.png",
      "/qabank/075/explain_figures/Figure 2A.png",
      "/qabank/075/explain_figures/Figure 2B.png",
      "/qabank/075/explain_figures/Figure 2C.png",
      "/qabank/075/explain_figures/Figure 3.png",
      "/qabank/075/explain_figures/Figure 4.png"
    ]
  },
  {
    "id": 76,
    "question": "Which of the following statements regarding RELATIVITY-047, a study of relatlimab plus nivolumab versus nivolumab alone in patients with advanced melanoma, are (is) correct?\n(1) The hazard ratio of progression-free survival (PFS) favored nivolumab and relatlimab.\n(2) The hazard ratio of overall survival (OS) only marginally favored nivolumab and relatlimab.\n(3) Nivolumab and relatlimab has higher chance of grade 3 or 4 treatment-related adverse\nevents (TRAEs) than nivolumab alone.\n(4) The benefit observed in patients treated with nivolumab plus relatlimab versus nivolumab\nalone was largely consistent across key patient subgroups, including those with BRAF mutations.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1) 對。Checkpoint inhibitors targeting CTLA-4 and PD-1 have transformed the treatment of advanced melanoma, but new combinations are needed to improve efficacy while balancing toxicity. LAG-3, a negative regulator of T-cell activity, is upregulated in melanoma and other tumor types, making it a promising therapeutic target.\nThe RELATIVITY-047 study, a phase 2/3 randomized, double-blind trial, evaluated a novel immune checkpoint combination: relatlimab (a LAG-3–blocking antibody) and nivolumab. Treatment-naive patients were randomized 1:1 to receive either: fixed-dose relatlimab (160 mg) + nivolumab (480 mg) every 4 weeks, or nivolumab monotherapy (480 mg every 4 weeks). At a median follow-up of 13.2 months, the combination significantly prolonged median PFS compared to nivolumab alone (10.1 vs. 4.6 months; HR 0.75; 95% CI, 0.62-0.92; P = .006). Updated data also showed a higher overall response rate (ORR) in the combination arm (43.1% [95% CI, 37.9-48.4]) compared to nivolumab alone (32.6% [95% CI, 27.8-37.7]). This study provided the first phase 3 evidence supporting the clinical benefit of dual LAG-3 and PD-1 pathway inhibition. Based on these results, the FDA approved the fixed-dose relatlimab-nivolumab combination in March 2022 for patients with previously untreated unresectable or metastatic melanoma.\n\nReference: Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. PMID: 34986285; PMCID: PMC9844513.\n\n(2) 對。With an updated median follow-up of 33.8 months, RELATIVITY-047 showed:\n* Median PFS: 10.2 months (nivolumab + relatlimab) vs. 4.6 months (nivolumab alone) (HR: 0.79 [95% CI, 0.66 to 0.95]).\n* Median OS: 51.0 months vs. 34.1 months (HR: 0.80 [95% CI, 0.66 to 0.99]).\n* Objective Response Rate (ORR): 43.7% vs. 33.7%, favoring the combination.\n\nMost subgroups showed a consistent benefit with the combination, and no new or unexpected safety concerns were reported. At 3 years of follow-up, the survival benefit remained sustained, with the upper bound of the OS hazard ratio now < 1, reinforcing the long-term efficacy and manageable safety profile of nivolumab plus relatlimab.\nLong-term overall survival data from Relativity-047 are still awaited.\n\nReference: Tawbi HA, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas H, Lao CD, Janoski De Menezes J, Dalle S, Arance AM, Grob JJ, Ratto B, Rodriguez S, Mazzei A, Dolfi S, Long GV. Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047. J Clin Oncol. 2024 Dec 13:JCO2401124. doi: 10.1200/JCO.24.01124. Epub ahead of print. PMID: 39671533.\n\n(3) 對。Grade 3 or 4 treatment-related adverse events occurred in 18.9% of the patients in the relatlimab–nivolumab group and in 9.7% in the nivolumab group. The most common grade 3 or 4 treatment-related adverse events in the relatlimab–nivolumab group included increased levels of lipase (in 1.7% of the patients), alanine aminotransferase (in 1.4%), and aspartate aminotransferase (in 1.4%), as well as fatigue (in 1.1%).\n\n(4) 對。In prespecified exploratory analyses, progression-free survival also favored relatlimab-nivolumab over nivolumab across key subgroups. The benefit of treatment with relatlimab-nivolumab was observed regardless of patients’ BRAF mutation status. In the subgroup of patients with BRAF mutations, the median PFS was 10.1 months (95% CI, 4.6 to 23.1) in the relatlimab–nivolumab group and 4.6 months (95% CI, 3.0 to 6.5) in the nivolumab group (hazard ratio for progression or death, 0.74 [95% CI, 0.54 to 1.03]); in the subgroup of patients with wild-type BRAF, the median PFS was 10.1 months (95% CI, 5.9 to 17.0) with relatlimab-nivolumab and 4.6 months (95% CI, 2.9 to 6.6) with nivolumab (hazard ratio, 0.76 [95% CI, 0.59 to 0.98]).",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 77,
    "question": "以下哪些是屬於預後較差的原發部位不明轉移癌次族群?\r\n(1) 頸部淋巴結切片診斷為 p16+ squamous cell carcinoma\r\n(2) 分化不好的 small neuroendocrine carcinoma\r\n(3) 女性腋下淋巴結診斷為 ER+ adenocarcinoma\r\n(4) 男性腹膜腫瘤切片診斷為 nonpapillary adenocarcinoma",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 2,
    "explanation": "根據 ESMO 2022 分類出 favorable CUP\r\n\r\n詳見 Figure 圖片\r\n\r\n(1) 頸部淋巴結切片診斷為 p16+ squamous cell carcinoma ⇔ ESMO: Squamous cell carcinoma involving non-supraclavicular cervical lymph nodes \r\n(2) 分化不好的 small neuroendocrine carcinoma ⇔ 非ESMO所列舉的favorable CUP  \r\n(3) 女性腋下淋巴結診斷為 ER+ adenocarcinoma ⇔ ESMO: Women with isolated axillary lymph node metastases (breast-like CUP)\r\n(4) 男性腹膜腫瘤切片診斷為 nonpapillary adenocarcinoma ⇔ 非ESMO所列舉的favorable CUP  \r\n\r\n所以答案應為 (2) (4) 預後較差, 非favorable CUP",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/077/explain_figures/77-Figure 1.jpg"
    ]
  },
  {
    "id": 78,
    "question": "Which of the following statements regarding the differential diagnosis of “round cell tumor”\r\nare (is) correct?\r\n(1) Immunohistochemistry (IHC) staining of CD45 could help to diagnose hematological\r\nmalignancy, such as lymphoma or extramedullary myeloid leukemia.\r\n(2) If melanoma is suspected, one should order IHC staining of S100.\r\n(3) If a tumor shows positive staining of synaptophysin, chromogranin and CD56, one should\r\nconsider neuroendocrine carcinoma or small cell carcinoma.\r\n(4) For a round cell tumor positively stained with NKX3.1, one should consider Ewing sarcoma.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "Figure 1, 2可以大略知道如何運用IHC stain 做 小藍圓tumor的鑑別診斷\r\n\r\n(1)CD45 是白血球共同的marker, 因此在lymphoma 和 leukemia 上都會表現, 其他非血球系列的 tumor 不會表現 CD45, 所以可以用來幫助血液癌症的診斷\r\n\r\n(2)根據上圖可以知道 Melanoma 會表現 S-100 protein, 其餘sarcoma的表現則是variable, 因此若懷疑Melanoma則可以染S-100\r\n\r\n(3)synaptophysin, chromogranin都是神經內分泌細胞會產生的protein, 因此 small cell carcinoma 和 neuroendocrine carcinoma都會表現 (除此之外還有neuroblastoma, pheochromocytoma), 而CD 56 會表現在 NK/T cell 和 神經內分泌細胞, 所以small cell carcinoma 和 neuroendocrine carcinoma也會表現, 所以若是IHC 若synaptophysin, chromogranin, CD 56 皆 positive則需高度考慮small cell carcinoma 和 neuroendocrine carcinoma\r\n\r\n(4)NKX3.1 is a 234 amino acid transcription factor protein that is expressed in the prostate, 所以並非Ewing sarcoma IHC 的表現而是prostate cancer \r\n            \r\n[Ewing sarcoma IHC]\r\nCD99 (strong, diffuse membranous expression in ~90 - 95%) (Am J Surg Pathol 2005;29:1025)\r\nNKX2.2 (high specificity) (Am J Surg Pathol 2012;36:993)\r\nVimentin (80 - 90%)\r\n\r\n所以答案應為 A (1),(2),(3)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/078/explain_figures/78-Figure 1.jpg",
      "/qabank/078/explain_figures/78-Figure 2.jpg"
    ]
  },
  {
    "id": 79,
    "question": "關於 anaplastic thyroid cancer (ATC)的描述中,正確的有?\r\n(1) 預後最差的甲狀腺癌,約<1%,發生率低,對於碘-131 治療通常有反應。\r\n(2) 轉移性 ATC 的病人可檢測是否帶有 BRAF-V600E 基因型突變, 如帶有此基因突變,\r\n可使用 BRAF 抑制劑 dabrafenib 合併 MEK 抑制劑 tremetinib 治療。\r\n(3) 由於 Thyroid stimulating hormone (TSH)會刺激甲狀腺濾泡上皮細胞的生長,因此使用\r\n左旋甲狀腺素(levothyroxine)壓制 TSH,是 ATC 患者的適合治療方法。然而目前對於\r\nTSH 該壓到多少(多低)沒有共識。\r\n(4) 極少的機會可能會測到 NTRK gene fusion, 如果陽性可使用 NTRK 抑制劑治療。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 2,
    "explanation": "(1): 根據 DeVita, anaplastic thyroid cancer rare 發生率 (1% to 2% of all thyroid cancers) 而且預後很差, median OS < 6 months, ATC 是沒有分化的細胞所以不會像濾泡細胞會有Thyroglobulin增加以及碘的吸收, 所以碘-131 並非是ATC合適的治療方式 (2021 ATA guideline 已經提到碘-131不要用在ATC)\r\n\r\n(2): Harrison 提到 ATC 約 20-40% 有 BRAF-V600E mutation, 根據 ESMO 2019 guideline 提到的 trial (DOI: 10.1200/JCO.2017.73.6785), 使用 BRAF inhibitor dabrafenib (150 mg twice daily) 加上 MEK inhibitor trametinib (2 mg once daily) 的16位病人有很高的ORR (69%), 所以在 May 2018, FDA approval for the treatment of locally advanced or metastatic ATC with the BRAF V600E mutation\r\n\r\n(3): ATC 是沒有分化的細胞所以不會有濾泡細胞的表現(例如:Thyroglobulin表現以及碘的吸收), 因此TSH無法影響ATC, 所以使用levothyroxine並非是ATC合適的治療方式, DeVita 和其他治療指引完全沒提到使用 thyroxine\r\n\r\n(4): ESMO, ATA 都提到 NTRK fusion 即使是在ATC也是非常少, 但是都建議ATC若有target drug則建議使用,因為化療response太差\r\n\r\nATA 2019, RECOMMENDATION 23 \r\nIn NTRK or RET fusion ATC patients with stage IVC disease, we suggest initiation of a TRK inhibitor (either larotrectinib or entrectinib) or RET inhibitor (either selpercatinib or pralsetinib), preferably in a clinical trial, if available. \r\n\r\nESMO 2019\r\nExtended molecular profiling of ATCs should be strongly encouraged as it may reveal promising possibilities for targeted therapies.\r\n\r\n所以答案應為(C) (2),(4)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 80,
    "question": "Regarding drug treatment for metastatic renal cell carcinoma patients who previously received\r\nimmune checkpoint and antiangiogenic therapies (LITESPARK-005), which of the following\r\nstatements are (is) correct?\r\n(1) Belzutifan provides better progression-free survival\r\n(2) Belzutifan provides better overall survival\r\n(3) Belzutifan provides better objective responses\r\n(4) No active targeted therapy in the control arm in this study",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "此題考的是 LITESPARK-005 這一trial \r\n\r\n以下為跟答案有關的result\r\n\r\nDual Primary endpoint: PFS and OS \r\nmPFS: HR:0.75, P value < 0.00001\r\nmOS: HR: 0.87, P value: 0.099 (沒有達到統計學上差異)\r\nORR: 21.9% vs 3.5%,  P value < 0.00001\r\n\r\n其餘trial 詳細資料可看 Figure \r\n\r\n所以答案應為 (B) (1),(3)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/080/explain_figures/80-Figure 1 trial design.jpg",
      "/qabank/080/explain_figures/80-Figure 2 characteristics and mPFS.jpg",
      "/qabank/080/explain_figures/80-Figure 3 mPFS and mOS.jpg",
      "/qabank/080/explain_figures/80-Figure 4 ORR and DOR.jpg",
      "/qabank/080/explain_figures/80-Figure 5 safety.jpg"
    ]
  },
  {
    "id": 81,
    "question": "Regarding to the adjuvant treatment for locally advanced renal cell carcinoma after operation,\r\nwhich trials show positive results to improve overall survival, which of the following are (is)\r\ncorrect?\r\n(1) CheckMate 914 (Ipilimumab+Nivolumab)\r\n(2) S-TRAC (Sunitinib)\r\n(3) IMmotion010 (Atezolizumab)\r\n(4) KEYNOTE 564 (Pembrolizumab)",
    "options": [
      "(1),(2),(3)",
      "(1)(3)",
      "(2)(4)",
      "(4)",
      "(1)(2)(3)(4)"
    ],
    "correctAnswer": 3,
    "explanation": "(1)錯誤\r\nCheckMate 914 (Part-A), phase 3, n=816, 1:1, 2017/8-2021/3\r\nCheckMate 914 (Part-B), phase 3, n=825, 2:1:1, 2020/3-2022/3\r\n\r\n<Inclusion criteria>\r\nLocalized RCC (clear-cell or sarcomatoid component), high risk (pT2a Fuhrman Gr 3or4, pT2b-T4 Gr any, pTany Gr any N1) of relapse after OP (radical or partial nephrectomy)\r\nNo clinical/radiologic evidence of residual disease or distant metastases \r\n\r\n<Study design>\r\n[Part A] Nivolumab (240 mg) iv. q2w * 12 +  Ipilimumab (1mg/kg) iv. q6w* 4  \r\n              placebo + placebo\r\nPri. end point : Disease free survival (DFS)\r\nSec end point: OS, safety \r\n\r\n[Part B] Nivolumab (240 mg) iv. q2w * 12 + placebo\r\n              placebo + placebo\r\n              Nivolumab (240 mg) iv. q2w * 12 +  Ipilimumab (1mg/kg) iv. q6w* 4 \r\nPri end point : DFS of Nivo vs. placebo\r\nSec end points: OS of Nivo vs. placebo\r\n                       DFS & OS of Nivo + Ipi and Nivo\r\n\r\n<Results>\r\n[Part A] Nivo + Ipi vs. placebo (Median 37 mo. follow up) \r\n              mDFS: NR vs. 50.7 mo (HR: 0·92, 95% CI 0·71–1·19; p=0·53)\r\n              OS: **NR (The number of events required for OS interim analysis was not reached at the time of the data cutoff, only 61 events occured ) \r\n\r\n[Part B] OS was note tested (The sec end point of OS was to be tested hierarchically, i.e., only if the pri end point of DFS was significant)     \r\n              Pri end point DFS of Nivo vs. placebo was not met (HR=0.87, p = 0.4)              \r\n\r\n[Conclusion] \r\nPart A: OS was not reached (No DFS benefit for adjuvant Nivo + Ipi vs. placebo)\r\nPart B: OS was not tested (DFS of Nivo vs. placebo was not met)\r\n\r\n<Ref>\r\nPart A: Motzer J et al. (2023) The Lancet, Vol 401(10379), 821 - 832\r\nPart B: Motzer J et al. (2024) Journal of Clinical Oncology, Vol43(2), https://doi.org/10.1200/JCO.24.00773\r\n\r\n\r\n(2) 錯誤\r\nS-TRAC, phase 3, n= 615, 1:1, 2007/9-2011/4\r\n\r\n<Inclusion criteria> \r\nNon-metastatic, High-risk (by UISS score: TNM stage III or VI) clear-cell RCC, post resection, treatment naive\r\n\r\n<Study design> \r\n - Sunitinib (50 mg/QD) vs. placebo, 4-weeks-on, 2-weeks-off schedule for 1 year or until PD/intolerance.\r\nPrimary end point: DFS(BICR) \r\nSecondary end point: investigator-assessed DFS, OS, and safety.\r\n\r\nOverall survival data were not mature at the time of data cutoff.\r\n\r\n<Results>\r\nSunitinib vs. placebo (Median 5.4 yrs follow up) \r\nmDFS: 6.8 years vs. 5.6 years (HR: 0.76;  p=0.03) (NEJM Dec.2016)\r\nmDFS benefit of adjuvant sunitinib over placebo was observed across certain high risk subgroups  (Eu Urology Jan 2018)\r\n-T3, no or undetermined nodal involvement, Fuhrman grade ≥2, ECOG PS ≥1, T4 and/or nodal involvement (HR 0.74, 95% CI: 0.55-0.99; p=0.04), \r\n-NLR(neutrophil-to-lymphocyte ratio) ≤3 (HR 0.72, 95% CI 0.54-0.95; p=0.02), \r\n-Fuhrman grade 3/4 (HR 0.73, 95% CI 0.55-0.98; p=0.04). \r\n\r\nOS was not reached in either arm. (HR 0.92, p=0.6) (updated cut off date: 2017/1/31) (Eu Urology Jan 2018)\r\n\r\n[Conclusion] OS was not reached \r\n\r\n<Ref>\r\nMotzer et. al.(2018) European Urology, Vol 73(1),62-68\r\nRavaud et. al.(2016) N Engl J Med, Vol 375(23),2246-2254\r\n\r\n\r\n(3)錯誤\r\nIMmotion010 , phase 3, n=778, 1:1, 2017/1-2019/2\r\n\r\n<Inclusion criteria>\r\nRCC (clear-cell or sarcomatoid component) ,increased risk of recurrence (T2 Gr 4, T3a Gr3/4, T3b-T4 Gr any, TxN+ Gr any or M1rendered free of disease after resection(NED)), after nephrectomy +/- metastasectomy\r\n\r\n<Study design>\r\nAtezolizumab (1200 mg Q3W, IV) vs. placebo (Q3W, IV) for 16 cycles or 1 year.\r\nPri end point: investigator-assessed DFS\r\nSec end point: OS, investigator-assessed DFS by PD-L1 score(IC)\r\n\r\n<Results>\r\nAtezolizumab vs. placebo (Median 44.7 months follow up) \r\nmDFS:  57.2 mo. vs. 49·5 months (HR: 0.93, p=0·50). \r\nmOS: immature at data cutoff\r\n\r\n[Conclusion] OS data was immature\r\n\r\n<Ref>\r\nPal, S. K et. al. Lancet (London, England)(2022), 400(10358), 1103–1116. \r\nhttps://clinicaltrials.gov/study/NCT03024996\r\n\r\n(4)正確\r\nKEYNOTE 564, phase 3, n=994. 1:1, 2017/6-2023/9\r\n\r\n<Inclusion criteria>\r\nLocoregional RCC with clear-cell component, high risk of recurrence (pT2 Gr4 or sarcomatoid differentiationN0, pT3-T4 Gr any N0, pTany Gr any N+ or M1 NED), post partial or radical nephrectomy +/- metastasectomy\r\n\r\n<Study design>\r\npembrolizumab (200 mg Q3W, IV) vs. placebo (Q3W) for up to 17 cycles (approximately 1 year) or until recurrence/intolerance\r\nPri endpoint: investigator-assessed DFS\r\nSec endpoint: OS, safety\r\n\r\n<Results>  \r\npembrolizumab vs. placebo (Median 24.1 months follow-up) \r\n24-month DFS: 77.3% vs. 68.1% (HR: 0.68; P=0.002)\r\n\r\n(Median 57.2 months follow-up) \r\nOS: (HR: 0.62; P=0.005)\r\n(percentage of alive participants) \r\n24 mo: 96.3% vs. 93.9% \r\n36 mo: 93.9% vs. 89.5%\r\n48 mo: 91.2% vs. 86.0% \r\n(See Figure 1)\r\n\r\n[Conclusion] Adjuvant Pembrolizumab after Nephrectomy led to significant improvement in both DFS and OS for high-risk RCC.(NEJM Feb 2024)\r\n\r\n<Ref>\r\nChoueiri, T. K et.al.(2021)  NEJM 385(8), 683–694. https://doi.org/10.1056/NEJMoa2106391\r\nChoueiri, T. K et. al.(2024) NEJM390(15), 1359–1371. https://doi.org/10.1056/NEJMoa2312695",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/081/explain_figures/081 Figure 1.jpg"
    ]
  },
  {
    "id": 82,
    "question": "Which of the following statements about clinical trials in urothelial carcinoma(UC) are (is) correct:\r\n(1) Nivolumab for high-risk recurrence after surgical treatment for UC in patients with tumors expressing PD-L1 ≥1% (CheckMate 274)\r\n(2) Avelumab maintenance after gemcitabine-platinum treatment (JAVELIN Bladder 100, metastatic UC)\r\n(3) Pembrolizumab+ enfortumab vedotin (EV-302/KEYNOTE-A39) for first-line treatment\r\n(4) Nivolumab +gemcitabine-platinum for first-line treatment (CheckMate-901, metastatic UC)",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "此題考臨床試驗收案條件\r\n\r\n(1)正確\r\nCheckMate 274, phase 3, n=790, 1:1, 2016/4-2020/1\r\n\r\n<Inclusion criteria>\r\n-muscle-invasive urothelial carcinoma(MIUC), received radical surgery\r\n-high risk of recurrence (pT3/pT4a, or pN+ ; patients not eligible for/declined adjuvant cisplatin-based chemotherapy who had not received neoadjuvant cisplatin-based chemotherapy; ypT2-ypT4a or ypN+ for patients who received neoadjuvant cisplatin).\r\n\r\n\r\n<Study design>\r\nNivolumab (240mg Q2W, IV) or placebo (Q2W) for up to 1 year\r\nPrimary endpoint : DFS among all patients, DFS among patients with PDL-1≥1%\r\n\r\n<Ref>\r\nBajorin et. al. NEJM 2021;384:2102-2114 \r\n\r\n\r\n(2) 正確\r\nJAVELIN Bladder 100, phase 3, n=700, 1:1, 2016/5-2019/6 \r\n\r\n<Inclusion criteria>\r\nunresectable locally advanced or metastatic urothelial cancer who did not have disease progression with first-line chemotherapy (4-6 cycles of gemcitabine + cisplatin/carboplatin)\r\n\r\n<Study design>\r\nMaintenance avelumab (10 mg/kg, Q2W, IV) vs. Best supportive care\r\nPrimary end points: OS\r\nSecondary end points: PFS, safety\r\n\r\n<Ref>\r\nPowles, T et. al. NEJM, 383(13), 1218–1230. \r\n\r\n\r\n(3) 正確\r\nEV-302, phase 3, n=886, 1:1, 2020/3-2023/8 \r\n\r\n<Inclusion criteria>\r\n-Previously untreated , unresectable locally advanced or metastatic urothelial carcinoma \r\n-Key exclusion : Previous PD-1 or PD-L1 inhibitor therapy or other systemic therapy (except for neoadjuvant or adjuvant chemotherapy after surgery with recurrence >12 months after the completion of therapy)\r\n\r\n<Study design>\r\n-Enfortumab vedotin (1.25 mg/kg IV, days1 & 8, 3-week cycle) + pembrolizumab (200 mg IV, day 1, 3-week cycle) (enfortumab vedotin–pembrolizumab group)\r\n-Gemcitabine + cisplatin/\tcarboplatin  (chemotherapy group). \r\n\r\n<Ref> Powles T, et al. N Engl J Med 2024;390:875-888\r\n\r\n(4)正確\r\nCheckMate-901, phase 3, n=608, 1:1, 2018/1-2022/9\r\n\r\n<Inclusion criteria>\r\n-Previously untreated, unresectable or metastatic urothelial carcinoma \r\n-Eligible to receive cisplatin therapy\r\n-Previous intravesical therapy was permitted if the treatment had been completed at least 4 weeks before the initiation of the trial treatment. \r\n Previous neoadjuvant therapy, RT, or adjuvant platinum-based chemotherapy was permitted with recurrence 12 months or more after the completion of therapy.\r\n\r\n<Study design>\r\n[nivolumab (360 mg) + gemcitabine–cisplatin] Q3W *6 => [nivolumab (480 mg)] Q4W for a maximum of 2 years\r\n[nivolumab (360 mg) + gemcitabine–cisplatin] Q3W *6 => [gemcitabine–cisplatin alone] Q3W *6 cycles \r\nPrimary endpoint: PFS & OS\r\nExploratory endpoint: oRR & safety \r\n\r\n<Ref> van der Heijden MS, et al. N Engl J Med 2023;389:1778-1789",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 83,
    "question": "Nectin 4 is an important target for drug design for urothelial carcinoma. Which of the following statements are (is) correct ?\r\n(1) Nectin 4 is expressed in many cancer cells, such as urothelial carcinoma cells.\r\n(2) Nectin 4 is a membranous protein\r\n(3) Membranous Nectin-4 expression frequently decreases during metastatic spread of urothelial carcinoma\r\n(4) Cancer cells with small cell carcinoma differentiation express less.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1) 正確\r\nNectin-4（Nectin Cell Adhesion Molecule 4）is a cell adhesion molecule of the Nectin and Nectin-like families that is highly abundant in normal embryonic and fetal tissues and poorly expressed in healthy adult tissues. (Normal tissues including skin, salivary glands, bladder and esophagus express only low to medium levels of Nectin-4)\r\nSolid tumors that highly express Nectin-4 include bladder cancer, pancreatic cancer, triple-negative breast cancer, non-small cell lung cancer, gastric cancer, esophageal cancer, ovarian cancer, and many other cancers. (https://www.biochempeg.com/article/288.html)\r\n\r\nNectin-4 is a transmembrane protein involved in making and maintaining adherens junctions. Although it is not expressed in high levels in adult somatic cells, it is upregulated in bladder cancer \r\n(UpToDate: Molecular biology of bladder cancer)\r\n\r\n\r\n\r\n(2) 正確\r\nNectin-4 is a type I membrane glycoprotein that consists of an extracellular region with three Ig domains of Ig V and IgC types. (https://www.biochempeg.com/article/288.html)\r\n(See Figure.1)\r\n\r\nNectin-4 is a transmembrane protein involved in making and maintaining adherens junctions (UpToDate: Molecular biology of bladder cancer)\r\n\r\n\r\n\r\n(3) 正確\r\nKlümper, N. et. al. assessed Membranous NECTIN-4 protein expression (H-score by Immunohistochemistry (IHC)) between primary tumors (PRIM) and patient-matched distant metastases (MET), they noted that membranous Nectin-4 expression significantly decreased during metastatic spread, with 39.4% of MET lacking membranous Nectin-4 expression. (Wilcoxon matched pairs P < 0.001)\r\nThe other multicenter EV-treated cohort (N=47) showed absence or weak membranous Nectin-4 expression (34.0% of the cohort) was associated with a significantly shortened PFS on EV (log-rank P < 0.001).\r\n(Clin Cancer Res (2023) 29 (8): 1496–1505.)\r\n\r\n\r\n\r\n\r\n(4) 正確\r\nImmunohistochemistry for nectin-4 was performed on 169 patients including 83 with non-muscle invasive bladder cancer and 86 patients with muscle invasive bladder cancer.\r\nOverall, 50/86 muscle invasive tumors were positive, including 15/22 (68.2%) urothelial carcinomas, 1/10 (10%) sarcomatoid carcinomas, and 0/15 (0%) small cell carcinomas...etc\r\n\r\nWhole transcriptome RNA sequencing revealed that compared to conventional urothelial carcinomas, most sarcomatoid carcinomas and all but two small cell carcinomas expressed very low levels of nectin-4 mRNA\r\n(Hoffman-Censits et. al.(2021) Appl Immunohistochem Mol Morphol. 1;29(8):619-625.)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/083/explain_figures/083 figure 1.jpg"
    ]
  },
  {
    "id": 84,
    "question": "在 ALK rearrangement 非小細胞肺癌的治療中,下列選項何者正確?\r\n(1) Alectinib, brigatinib, lorlatinib 相較於 crizotinib 是一線治療 ALK-rearranged NSCLC 的preferred regimen。\r\n(2) Immunohistochemistry 使用特定 antibody 可評估 ALK 變異,若 immunohistochemistry 為陽性,不需再進一步使用 FISH 做確認,臨床上可直接使用相關標靶藥物治療。\r\n(3) ALK–rearrangement 非小細胞肺癌 若產生 central nervous system metastases,targettherapy 中 alectinib, ceritinib 或 lorlatinib 相較於 crizotinib 是較佳的選擇。\r\n(4) 副作用表現上, 高血脂較常見於 crizotinib, diarrhea 較常見於 ceritinib, edema 及神經認知功能下降常見於 lorlatinib。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "(1)正確\r\n1st generation ALK TKI: Crizotinib \r\n2nd generation ALK TKI: Ceritinib, Alectinib, Brigatinib, Ensartinib \r\n3rd generation ALK TKI: Lorlatinib \r\n\r\n*2G & 3G ALK TKIs compared to Crizotinib: CROWN trial & ALEX trial & ALTA-1L (See Figure 1.)\r\n=> Alectinib, brigatinib, lorlatinib all showed prominent and superior risk reduction  of disease progression over crizotinib. \r\n(Cathleen Park, MD et.al. ASCO daily news. January 30, 2025)\r\n\r\n\r\n(2)正確\r\nMultiple monoclonal antibodies have been developed for the IHC detection of the ALK fusion oncoprotein (Uptodate: ALK(+) advanced NSCLC)\r\nFDA-approved IHC can be utilized as a stand-alone test, not requiring confirmation by FISH (NCCN-NSCLC-v3.2025. P.97/285) \r\n\r\n\r\n(3) 正確  \r\nkeypoint: For asymptomatic and symptomatic patients, second- or third- generation ALK TKIs should be used, as data exist for each of these drugs regarding brain penetration and central nervous system efficacy\r\n(Uptodate: ALK-positive advanced NSCLC - special considerations regarding treatment - brain metastasis)\r\n\r\nAlthough ceritinib has demonstrated CNS activity, it is less CNS penetrant than alectinib, brigatinib, and lorlatinib, and cross-trial comparisons suggest a lower durability of CNS response with ceritinib\r\n(Uptodate: brain mets in NSCLC - patients with oncogenic drivers - ALK translocation - brain mets at presentation)\r\n\r\nCeritinib has been compared with platinum/pemetrexed chemotherapy in the front-line setting(Phase 3 ASCEND-4 trial) but not with crizotinib.\r\n\r\n==============以下補充=================\r\nThere was one adjusted comparison of studies : ASCEND-1 & 3 vs. PROFILE 1001, 1005, and 1007 had mentioned the better CNS efficacy of ceritinib over crizotinib in \"previosuly treated\" locally advanced or metastatic ALK+  NSCLC : ((2016) J Thorac Oncol, 11(9), 1550–1557.)\r\n\r\n[Total population] \r\nceritinib vs. crizotinib (n = 189 vs. n = 557)\r\n1-year OS rate: 82.6 % vs. 66.0 % ; HR: 0.59 (95% CI: 0.46–0.75) \r\nmPFS : 13.8 mo. vs. 8.3 mo. ; HR=0.56 (95% CI: 0.43–0.73)\r\n\r\n[For baseline brain metastases (excluding PROFILE 1001)] \t\r\nceritinib vs. crizotinib   (n = 189 vs. n = 432)\r\nOS  HR: 0.47 (95% CI: 0.32–0.71), p<0.001\t\r\nPFS HR: 0.53 (0.40–0.69), p<0.001\r\n==============以上補充=================\r\n\r\n(4) 錯誤\r\n=> 高血脂較常見於 lorlatinib, 其他敘述正確\r\n(see figure. 2)\r\n\r\n=> Lorlatinib was designed to accumulate in the CNS, resulting in profound efficacy in the CNS and thus higher CNS toxicities, such as mood disturbances, cognitive impairment, and personality change\r\n\r\n==============以下補充=================\r\n[補充-1] Crizotinib\r\nPROFILE 1014 Clinical trial, Ph 3, n=343, 2011/1-2013/7\r\n<Inclusion criteria>\r\nPreviously untreated advanced ALK-positive nonsquamous NSCLC \r\n\r\n<Study design>\r\n-oral crizotinib 250 mg twice daily \r\n-iv. chemotherapy (Pemetrexed, 500 mg / m2 plus either cisplatin (75mg/m2) or carboplatin AUC 5-6) every 3 weeks for up to six cycles. \r\n\r\n<Results>\r\nCrizotinib vs. chemo\r\n(46 months median follow up)\r\nOS: NR vs. 47.5 mo \r\n(HR: 0.76 , 95% CI: 0.548 to 1.053; two-sided P = .0978)\r\nPFS: 10.9 mo vs. 7.0 mo (HR= 0.45; 95% CI: 0.35 to 0.60; P<0.001). )\r\n=> Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC.\r\n\r\n[補充-2] Ceritinib\r\nASCEND-4 study, phase 3, n=376 (158 (42.0%)Asian), 1:1, 2013/8-2015/5\r\n<Inclusion criteria>\r\nPreviously untreated, stage IIIB or IV ALK+ non-squamous NSCLC, include brain mets. (symptematic or not)\r\n\r\n<Study design>\r\nceritinib 750 mg/day (fasted) QD PO or chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5–6 + pemetrexed 500 mg/m2] q3w => pemetrexed maintenance.\r\nPrimary end point: PFS\r\n\r\n<Results> Mar 2017. Lancet\r\nmedian duration of treatment exposure was 66·4 weeks\r\nmPFS: 16.6 mo vs. 8.1 mo (HR= 0.55 , 95% CI : 0.42–0.73]; p<0.00001). \r\nmPFS (baseline BM+): 10.7 mo.vs. 6.7 mo. (HR= 0.75 , 95% CI : 0.44–1.12)\r\nmPFS (baseline BM-): 26.3 mo.vs. 8.3 mo. (HR= 0.48 , 95% CI : 0.33–0.69)\r\n\r\n*C/T: cisplatin 75 mg/m2 or carboplatin AUC 5–6 + pemetrexed 500 mg/m2, q3w\r\n==============以上補充=================\r\n\r\n<Ref>\r\nShaw AT, et al. N Engl J Med. 2020.\r\nPeters S, et al. N Engl J Med. 2017. \r\nCamidge DR, et al. N Engl J Med. 2018. \r\nSolomon BJ, et al. N Engl J Med. 2014\r\nSolomon BJ, et al. (2018) J. Clin. Oncol. 36(22), 2251–2258. \r\nTan, D. S. et. al. (2016) J Thorac Oncol, 11(9), 1550–1557. \r\nRybarczyk-Kasiuchnicz A, et al. Int J Mol Sci. 2021\r\nCathleen Park, MD et. al. ASCO daily news, January 30, 2025\r\nE Thunnissen et. al. Lung Cancer. 2019 Dec:138:13-18.\r\nNCCN guideline Ver.3 2025 \r\nShaverdashvili et. al. (2022) Default Digital Object Group. \r\nSoria JC et. al. Lancet.2017 Mar 4;389(10072):917-929.",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/084/explain_figures/084 Figure 1.jpg",
      "/qabank/084/explain_figures/084 Figure 2.jpg"
    ]
  },
  {
    "id": 85,
    "question": "下列關於 Malignant pleural mesothelioma 的敘述中,正確的有?\r\n(1) 根據 phase 3 randomized trial (MAPS),在 unresectable malignant pleural mesotheliom病人,bevacizumab 加上 chemotherapy 相較於 chemotherapy alone 可顯著延長 overall survival。\r\n(2) 病理上,malignant pleural mesothelioma 常呈現 positive 的 immunohistochemical marker 為 WT1, calretinin, and D2-40; thyroid transcription factor-1 (TTF-1)常為 negative\r\n(3) 根據 CheckMate 743 trial,immune checkpoint inhibitors 的 overall survival benefit 主要發生在非上皮型(Non-epithelioid)的病人族群。\r\n(4) CheckMate 743 trial 顯示,在 unresectable malignant pleural mesothelioma 病人,nivolumab + chemotherapy 相較於 chemotherapy 可顯著延長 overall survival (OS)",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "(1)正確\r\nMAPS trial: randomized, controlled, open-label, Phase 3 trial. (Lancet 2016;387:1405-1414)\r\n\r\nBackground: assess the effect on survival of bevacizumab when added to the present standard of care, cisplatin plus pemetrexed, as first-line treatment of advanced malignant pleural mesothelioma\r\n\r\nKey inclusion criteria: unresectable malignant pleural mesothelioma, chemotherapy naive, ECOG 0–2, no substantial cardiovascular comorbidity, not amenable to curative surgery\r\n\r\nRegimen:\r\nPCB Q3W (up to 6cycles): pemetrexed (500 mg/m2) + cisplatin (75 mg/m2) + bevacizumab (15mg/kg)\r\nPC Q3W (up to 6cycles): pemetrexed (500 mg/m2) + cisplatin (75 mg/m2) \r\n\r\nFindings\r\nMedian OS: PCB vs.PC\r\n           18.8 vs. 16.1 months\r\n           (HR: 0.77, p-value: 0.0167)\r\n\r\n\r\n(2)正確\r\nUseful IHC markers include: \r\n# positive markers to confirm mesothelial differentiation, such as WT1, calretinin, and D2-40\r\n# negative markers to exclude mimics, such as polyclonal carcinoembryonic antigen (CEA), thyroid transcription factor-1 (TTF-1), and claudin-4.\r\n# One of the caveats is that no individual IHC marker is entirely sensitive and specific.\r\n# Therefore, it is recommended that a panel including at least two mesothelial markers (eg, calretinin, WT1, D2-40) and two carcinoma markers (eg, claudin-4, TTF-1, polyclonal CEA) should be used to establish the diagnosis.\r\n\r\nNCCN guideline v2.2025 – Principles of pathologic review (Page 11/61) \r\n\r\n(3)正確。 epithelioid & non-epithelioid 皆有OS benefit，但non-epithelioid組HR較低且forest plot沒跨過中線 (見explain_figure 1)\r\n(4)錯誤。此trial 為 Nivo + Ipi vs. chemo\r\n\r\nCheckmate-743 trial: a multicenter, randomized, open-label, phase 3\r\nLancet 2021;397:375-386\r\nAnnals of Oncology2022, Volume 33, Issue 5, 488 - 499\r\n\r\nBackground: \r\n– Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy (moderate survival benefit with poor outcomes). \r\n– Nivolumab plus ipilimumab has shown clinical benefit in other tumour types, including 1L NSCLC \r\n– Hypothesis: Nivo + Ipi would improve overall survival in MPM.\r\n\r\nKey inclusion criteria: previously untreated, histologically confirmed, unresectable MPM and ECOG ≤1\r\n\r\nExperimental arm: Nivolumab (3 mg/kg)Q2W + Ipilimumab (1 mg/kg) Q6W for up to 2 years\r\nControl arm: platinum plus pemetrexed chemotherapy, 6 cycles\r\n\r\nFindings: \r\nNivolumab + ipilimumab to prolong OS versus chemotherapy across subgroups, including histology. Median OS of \r\n– All patients: 18.1 vs. 14.1 mo, HR 0.73\r\n– Epithelioid: 18.2 vs. 16.7 mo, HR 0.85\r\n– Non epithelioid: 18.1 vs. 8.8 mo, HR 0.48\n\n<補充：比較MAPS和CM-743>\n值得注意的是MAPS以及CM-743都有排除CNS metastasis\nMAPS中epithelioid以及non-epithelioid似乎都偏向使用cis+alimta+beva，但都沒有達到統計上的顯著差異(Epitheloid HR:0.82(0.64-1.06);non-epitheloid HR:0.64(0.40-1.02))\n而在CM-743中的subgroup analysis, PD-L1>=1%相較於<1%對於使用nivo+ipi在median OS的好處更大(>=1%, HR:0.69(0.55-0.87);<1%, HR:0.94(0.62-1.40))",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/085/explain_figures/explain_figure 1.jpg"
    ]
  },
  {
    "id": 86,
    "question": "一位 56 歲女性,健康檢查意外發現胸部腫塊,電腦斷層顯示 anterior mediastinum mass and suspicious lung and pleural metastases,經切片診斷為 thymoma with lung and pleural metastases,ECOG PS 為 1,與病人討論後決定先讓病人接受第一線 systemic therapy,下列那些(何者)是您會考慮幫病人使用的處方?\r\n(1) Pembrolizumab plus CAP (cisplatin + doxorubicin + cyclophosphamide IV) day 1 every 3 weeks\r\n(2) Pembrolizumab plus cisplatin + etoposide day 1 every 3 weeks\r\n(3) Pembrolizumab plus paclitaxel + carboplatin day 1 every 3 weeks\r\n(4) ADOC (doxorubicin IV day 1 + cisplatin 50 mg/m2 IV day 1 + vincristine IV day3 + cyclophosphamide IV day 4) every 3 weeks",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 3,
    "explanation": "根據NCCN guideline-thymoma&thymic carcinoma v1.2025 (P.13 & 14/46), 1st line chemotherapy for thymoma 建議CAP, CAP+prednisolone, ADOC; pembrolizumab monotherapy 建議在 thymic carcinoma 2nd line 使用。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 87,
    "question": "關於小細胞肺癌的敘述中,正確的有?\r\n(1) 在 limited-stage small cell lung cancer 病患接受過 definitive concurrent chemoradiation 後,若疾病達到緩解,可考慮執行 prophylactic cranial irradiation\r\n(2) 根據 IMpower133 trial & CASPIAN trial,目前 carboplatin + etoposide + atezolizumab 或carboplatin/cisplatin + etoposide + durvalumab 均被 NCCN guideline 列為 extensive-stage small cell lung cancer PD-L1≧1%病患的第一線藥物,PD-L1<1%病患則不建議。\r\n(3) Lurbinectedin, topotecan, and irinotecan 均是 extensive-stage small cell lung cancer 有可能使用的二線藥物。\r\n(4) 根據 PACIFIC trial,limited-stage small cell lung cancer 病患,在接受 definitive concurrent chemoradiation 結束後再加入 Durvalumab/Tremelimumab,可顯著延長 overall survival。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1)正確\r\nNCCN guideline-SCLC - v4.2025 (P. 9,10,12/86)\r\nPrimary treatment 之後達CR or PR的limited stage SCLC，建議durvalumab (category 1)，或考慮prophylactic cranial irradiation\r\n\r\n\r\n(2)錯誤。這兩個trial顯示 treatment outcomes 和 PDL-1 level 無關\r\nImpwer133 trial: double-blind, placebo-controlled, phase 3 \r\nN Engl J Med 2018;379:2220-2229\r\nJ Clin Oncol 39:619-630  (2021)\r\n\r\nBackground: Analyze the synergistic effect and efficacy of combining checkpoint inhibitior with chemotherapy\r\n\r\nKey inclusion criteria: treatment-naive extensive stage SCLC\r\n\r\nExperimental arm: atezolizumab + carboplatin + etoposide\r\nControl arm: placebo + carboplatin + etoposide\r\n\r\nKey findings\r\n– addition of atezolizumab to chemotherapy resulted in significantly longer OS & PFS than chemotherapy alone\r\n– No numerical difference in efficacy outcomes was observed across the PD-L1 IHC subgroups. \r\n– Overall, the data suggest that clinical benefit was observed in patients with extensive stage-SCLC treated with 1L atezolizumab plus carboplatin+etoposide, independent of bTMB(blood-based tumor mutational burden) or PD-L1 biomarker status.\r\n\r\n===================================\r\nCaspian trial:randomised, controlled, open-label, phase 3\r\nThe Lancet 2019, Volume 394, Issue 10212, 1929 - 1939\r\nESMO Open 2022, Volume 7, Issue 2, 100408\r\n\r\nBackground: Assess durvalumab, +/- tremelimumab, in combination with platinum–etoposide in treatment-naive patients with extensive stage-SCLC\r\n\r\nKey inclusion criteria: treatment-naive extensive stage SCLC\r\n\r\nExperimental arm:\r\nDurvalumab+tremelimumab+platinum–etoposide,Durvalumab+platinum–etoposide\r\nControl arm: platinum–etoposide\r\n\r\nKey findings: \r\n– 1st line durvalumab plus platinum–etoposide significantly improved overall survival in patients with ES-SCLC\r\n– To date, no association has been found between outcomes with first-line immunotherapy and PD-L1 expression or tumor mutational burden in extensive stage-SCLC\r\n\r\n\r\n(3)正確 \r\nNCCN guideline-SCLC - v4.2025 (P. 23/86)\r\n三者皆為 subsequent line (無limited stage/extensive stage之分) systemic therapy 可能用藥\r\n\r\n(4)錯誤。Pacific trial 是針對NSCLC；Adriatic trial 才是針對SCLC\r\nPacific trial: \r\n[JCO 40, 1301-1311(2022)]\r\nDurvalumab as consolidation therapy in patients with unresectable, stage III NSCLC and no disease progression after CCRT\r\n\r\nAdriatic trial:\r\n(N Engl J Med 2024;391:1313-1327)\r\nAdjuvant therapy with durvalumab, +/- tremelimumab in patients with limited-stage SCLC and no disease progression after standard platinum-based CCRT\n\n<補充>\n總結來說\n1. Advanced stage: \nCASPIAN trial: dura+/-treme + EP > EP in OS\nIMpower133: atezo + EP > EP in OS\n\n2. Limited stage (adjuvant after CCRT)\nAdriatic trial adjuvant durva+/-treme > placebo\n\n至於CASPIAN以及Adriatic trial中到底要不要除了durva以外還要另外再加上tremelimumab (durva +treme arm)，以現有data來說還不到統計力可以做出差異，因此study group還不願意unblinded結果，尚待更多資料。因此目前guideline仍以+/-tremelimumab作為建議。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 88,
    "question": "Catheter-related infections 是癌症病患常見的感染合併症,包括有 exit site infection、tunnel or pocket infection 及 catheter-related bacteremia or fungemia 等類型。以下為有關 catheter-related infections 診治的敘述中,正確的有:\r\n\r\n(1) Exit site 及 pocket site 感染時的紅、腫、熱、痛等症狀,在有 neutropenia 的病患身上可能較不明顯。\r\n(2) 在判斷病患是否發生catheter-related bacteremia 時,「differential time to positivity」是常用的判斷原則。\r\n(3) 若病患發燒時由 catheter 所做的血液培養發現有gram-positive bacteria,若該菌證實為Corynebacterium spp.或 Staphylococcus aureus,前者較可能為 blood culture contaminant。\r\n(4) Central line-associated blood stream infection 的標準處置是全身性抗生素治療、加上antibiotic lock therapy 以保留此 central line(即”catheter salvage”)",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "(1)正確\r\nTypical clinical signs such as tenderness or purulent discharge at the insertion site, implicating the catheter as the source of infection, are frequently absent during neutropenia \r\n(J Clin Microbiol. 2003 Jan;41(1):118–123.)\r\n\r\nLocal signs are absent in almost 60% of catheter related bloodstream infection(CRBSI), particularly with older age, critical illness, immunosuppression, catheters in place one week or less, and jugular/femoral sites.\r\n(Uptodate: Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis)\r\n\r\n\r\n(2)正確\r\nDifferential time to positivity (DTTP) has been used as a tool for diagnosis of CRBSI, particularly in those with cancer, but the predictive value of this approach is uncertain. \r\nDTTP is interpreted as evidence that the central line is infected if blood obtained from the peripheral vein starts growing bacteria >2 hours after blood obtained from the central line\r\n(Uptodate: Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis)\r\n\r\n\r\n(3)正確\r\nIn the absence of other identifiable sources of infection, the following blood culture results may be attributed to CRBSI\r\n##  ≥1 blood culture bottles positive for S. aureus, enterococci, Enterobacteriaceae, Pseudomonas aeruginosa, Candida species\r\n##  ≥2 blood culture bottles positive for coagulase-negative staphylococci or other common commensals (eg, Corynebacterium species [not Corynebacterium diphtheriae], Cutibacterium species, Bacillus species [not Bacillus anthracis], viridans group streptococci)\r\n(Uptodate: Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis)\r\n\r\n\r\n(4)錯誤。 一般來說，處置包含 catheter removal + systemic antibiotics，除非移除導管不可行，才會考慮catheter salvage(lock therapy + systemic antibiotics) or guidewire exchange of catheter\r\ns\r\nIn general, management of CRBSI consists of catheter removal and systemic antibiotic therapy. If catheter removal is not feasible (eg, there is no alternative access site or sites are limited, the patient has a bleeding diathesis, patient declines removal, or quality of life issues take priority over the need for catheter reinsertion at another site), a decision regarding catheter salvage or guidewire exchange must be made.\r\n(Uptodate: Intravascular non-hemodialysis catheter-related infection: Treatment)\r\n\r\n\r\n**圖片補充: examples of definitions of catheter related infection\r\nJournal of Infection (2005) 51, 267–280",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/088/explain_figures/figure 88.jpg"
    ]
  },
  {
    "id": 89,
    "question": "Superior vena cava syndrome(SVCS)是罹患惡性腫瘤病患常見的急症之一。\n以下為有關 SVCS 病因、診斷及處置的敘述，正確的有:\n(1) 當病人表現 SVCS 典型的症狀，如 venous distention of neck and chest wall, facial\nedema 等，一定是位於縱隔腔的惡性腫瘤壓迫 SVC 所造成的。\n(2) 引發 SVCS 常見的惡性腫瘤為 lung cancer、lymphoma、thymic malignancies 及 germ\ncell tumor 等。\n(3) 經 CT 或 MRI 清楚地顯示有縱隔腔腫瘤後，應立即給予放射線治療，以迅速緩解\nSVCS 相關的症狀。\n(4) SVCS 的處理有賴正確的診斷及腫瘤分期(staging)。但若欲迅速緩解 SVCS，\npercutaneous transluminal angioplasty using balloon dilatation 或 insertion of expandable metal stent 是有效的處置之一",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 2,
    "explanation": "(1)(2)\n任何導致SVC回流不順的病因都能引發SVC syndrome，不論是因為外在腫瘤的壓迫或是血管內產生的血栓都有可能。依照過去統計，約莫60%-86%的SVC syndrome是因為惡性腫瘤所引起(Devita 12th edition)，而其中最常見的是肺癌(尤其是Squamous和small cell lung cancer)、轉移性乳癌、淋巴癌、胸腺瘤以及其他好發於縱隔腔的腫瘤等(Azizi et al, Figure 1.)。但non-neoplastic 引起的SVC syndrome發生率同樣在逐步上升中，絕大多數是因為外來catheter(如CVC, pacemaker等)形成的thrombosis，更少數是因為如Bechet disease、vascular anomalies等易引起血栓的疾病所導致\n(3)(4)\nSVC syndrome的處置方式可以參考圖二(Azizi et al, 2020. Figure 2.)\n若臨床症狀及影像診斷高度懷疑有SVC syndrome時，首要判斷病人是否已有life threatening symptoms。若有立即致命的可能(例如已產生呼吸衰竭、休克、癲癇等症狀），建議除穩定生命徵象外可以考慮進行intravascular stenting或是將以形成的血栓進行thrombolysis等。若情況較不危急，則建議先進行tissue biopsy以及完整腫瘤分級後，再根據癌別及期別進行相對應的治療（化療、放療或手術等)。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/089/explain_figures/Figure 1.png",
      "/qabank/089/explain_figures/Figure 2.png"
    ]
  },
  {
    "id": 90,
    "question": "以下為有關 malignant spinal cord compression (MSCC)的敘述，正確的有:\n(1) 發生 MSCC cancer-specific incidence rate 最高的癌別是 multiple myeloma。\n(2) 發生 MSCC 最常見的部位是胸椎(thoracic spine)。\n(3) 相較於 X 光檢查、CT scan 及同位素骨掃描，MRI 是 MSCC 診斷較佳的影像學檢查\n方式。\n(4) MSCC 的病理組織學檢查，最主要發現是 gray matter 出現 demyelination 或 necrosis。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "(1)以下摘錄自Devita: 在發展出「轉移性脊髓壓迫症（MSCC）」的患者中，最常見的癌症類型包括肺癌（25%）、前列腺癌（16%）、多發性骨髓瘤（11%）和乳腺癌（7%）。在特定癌症發生率最高的癌症中，包括多發性骨髓瘤（15%）、淋巴瘤（14%）和前列腺癌（6%）。總結來說，一個病患若發生MSCC，則最高機率是因爲得到肺癌，然而所有癌症中，multiple myeloma是最容易形成MSCC的癌別。MSCC大多發生在50歲以上的成年病人中，而兒童族群中最有機會產生MSCC的癌症種類則有所不同，為Ewing sarcoma, neuroblastoma, primary vertebral osteosarcoma, germ cell tumors, lymphoma。\n\n(2)胸椎是轉移性脊髓壓迫症（MSCC）最常見的部位（約佔60%的病例，可因相較於頸椎和腰椎，胸椎最多節，因此發生機率也最高）。\n\n(3)MRI為最佳診斷MSCC的工具（軟組織解析度佳、非侵入性、T2 phase下spinal cord顯影清晰）。若病患無法接受MRI檢查，有另一方式是CT myelogram，做法是將顯影劑注入CSF中接著做CT scan來評估是否有壓迫產生，但因侵入性較高非常少做。\n\n(4)MSCC的病生理機轉為：腫瘤壓迫導致epidural venous plexus回流不順導致spinal cord外層white matter edema，若無法減壓在組織病理上可以看到MSCC最具代表性的demyelination or necrosis of white matter，而gray matter會相對完整。\n\n(1)(2)(3)皆正確",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 91,
    "question": "55 歲男性，因為轉移性腎細胞癌 (clear cell renal cell carcinoma) 接受 nivolumab+ipilimumab 並用藥物治療。在接受第二次藥物注射後 10 天因為胸悶與呼吸困難至急診就醫。心電圖 顯示 complete AV block，無明顯 ischemia、超音波顯示微量 pericardial effusion。以下敘述中，\n正確的有?\n(1) 相較於單獨使用 anti-PD1 或 anti-CTLA4 治療，並用 anti-PD1 與 anti-CTLA4 可能增加\nimmune related cardiac toxicity 的機率。\n(2) 可能合併其他 immune related adverse events 例如 myositis 或 myasthenia gravis。\n(3) Cardiac troponin 升高可能伴隨嚴重心臟不良事件 (major adverse cardiac events, MACE)\n的機率升高。\n(4) 如懷疑 immune-related cardiac toxicity 應盡速開始 prednisolone 1-2 mg/kg/ day 治療。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "本題主要在考immunotherapy related toxicity\n\n(1) 以nivolumab + ipilimumab為主的combination therapy在各臨床試驗中可以看到，無論是all grade或是grade 3以上的irAE的比率相較於單用nivolumab或ipilimumab的確較高（如圖一）。值得注意的是nivolumab 1mg/kg+ ipilimumab 3mg/kg相較於nivolumab 3mg/kg+ ipilimumab 1mg/kg的組合來說，毒性的確也較低。\n\n(2)根據題幹描述，此病患已出現complete AV block以及呼吸困難，的確可能已出現心肌炎和重症肌無力的症狀。此二者為相對較為罕見的副作用。ICI引起的神經毒性主要以polyneuropathy為主，罕見情況會出現致命性副作用例如Guillain-Barre和myasthenia gravis，而Myasthenia gravis 致死率高達20%, early onset (median 29 days), 並常常合併myocarditis and myositis，俗稱為Triple M syndrome。 \n\n(3)因此若病患出現疑似心肌炎症狀，ASCO guideline建議需要立即監測troponin以及BNP, 同時檢測CPK已排除myocarditis的可能。\n\n(4)根據ASCO guideline（如圖二），若出現grade 2以上症狀(abnormal cardiac biomarkers、出現mild symptoms以及new ECG abnormalities without conduction delay)，則須立即停止使用ICI並且給予methylprednisolone 1-2mg/kg/d。若無效則考慮給予methylprednisolone pulse therapy (1g/day)，搭配使用MMF、infliximab或是ATG。若出現致命性症狀(grade 4)則考慮額外給予abatacept或alemtuzumab等免疫抑制劑。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/091/explain_figures/Figure 1.png",
      "/qabank/091/explain_figures/Figure 2.png"
    ]
  },
  {
    "id": 92,
    "question": "使用 PET-CT 來評估淋巴癌治療療效的 5 point scale，正確的有:\n(1) Score 1: mild uptake above background\n(2) Score 2: uptake <= mediastinum\n(3) Score 3: uptake > mediastinum, but < spleen\n(4) Score 4: uptake moderately increased compared to liver",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 2,
    "explanation": "Deauville 5 points scale(D5PS)是用來評估FDG-avid nodal lymphoma（如Hogdkin lymphoma, DLBCL等）在PET scan上顯影亮度的量表。詳細評分方式如圖一，其中主要是以mediastinum blood pool以及liver的亮度來當作比較值。除了initial staging以外，D5PS可作為treatment response的評估工具，D5PS 1-3分為metabolic complete response，4-5分則可能為Partial response（但FDG uptake較治療前降低)、stable disease（FDG uptake無變化)、progressive disease（FDG uptake增加或出現new lesions）。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/092/explain_figures/Figure 1.png"
    ]
  },
  {
    "id": 93,
    "question": "以下哪些情況會增加罹患 lymphoma 的風險，正確的有？\n(1) Inherited immunodeficiency states (Chédiak-Higashi syndrome, Ataxia telangiectasia)\n(2) Acquired immunodeficiency states (HIV-1 infection, Multicentric Castleman Disease)\n(3) Autoimmune and inflammatory disorders (Sjögren syndrome, Hashimoto thyroiditis)\n(4) Chemicals and drugs (phenytoin, dioxin, pesticides)",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 65252,
    "explanation": "如附表DeVita, Hellman and Rosenberg's Cancer 12/e (Table 67.1, p. 1372)\n\n不論是inherited 或acquired immunodeficiency都跟增加lymphoma罹患風險有關，接受器官移植的病人罹患NHL的機率約增加100倍(其中約30%是從polyclonal B-cell proliferation發展成clonal B-cell malignancy)，除此之外，一等親患有NHL、HL或CLL的人也觀察到罹患NHL的風險增加，9% 的lymphoma或CLL患者的一等親患有lymphoproliferative disorder (Br J Haematol 2008;143(3):361–368.)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/093/explain_figures/figure1.png"
    ]
  },
  {
    "id": 94,
    "question": "55 歲女性上腹痛 3 個月，診斷胃腺癌第四期，合併肝及腹腔轉移，下列病理組織免疫染色檢查中，非為必須項目的有?\r\n(1) HER2/neu overexpression\r\n(2) MSI/dMMR\r\n(3) PD-L1\r\n(4) FGFR-2 amplification",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 3,
    "explanation": "附圖ESMO academy 2024現行guideline及NCCN guideline\n現行針對advanced unresectable/metastatic gastric adenocarcinoma第一線治療需考慮platinum-fluoropyrimidine doublet ChT治療並檢測HER2, MSI/dMMR, PD-L1來考慮加上標靶或免疫藥物，標準治療下這三項為必要項目。另外一線治療可能可考慮檢驗CLDN18.2(SPOTLIGHT trial, GLOW trial)。\r\nNTRK gene fusions在GI cancers雖然少見(<5%)，目前也有藥物(Entrectinib, larotrectinib, repotrectinib)可以使用，在一線或後線病人無法標準治療的患者可以考慮檢驗。\r\n胃癌中FGFR-2 amplification約佔3%–10% ，但目前相關的FGFR-TKI(Futibatinib, AZD4547…)還沒有看到明顯好處(phase II SHINE study)。\r\n💡胃癌一線IO健保給付條件：\r\n(1)胃癌（不含胃腸基質瘤及神經內分泌腫瘤/癌）：限以nivolumab 120mg 規格量品項併用fluoropyrimidine（5-FU或 capecitabine）及oxaliplatin，用於第一線治療晚期或轉移性且不具有 HER2過度表現的胃癌病人。(113/4/1、113/6/1)\r\n(2)CPS≧5",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/094/explain_figures/figure1.png",
      "/qabank/094/explain_figures/figure2.png"
    ]
  },
  {
    "id": 95,
    "question": "關於前導性治療在局部晚期胃癌病患的角色，下列描述中，正確的有?\r\n(1) 使用配方應優先考慮 fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)或fluoropyrimidine and oxaliplatin。\r\n(2) 胃癌的前導性 chemoradiotherapy 已完全不建議使用。\r\n(3) MSI-H/dMMR 病患可以考慮 pembrolizumab 作為前導性治療。\r\n(4) FLOT 加上免疫藥物(MATTERHORN study or KEYNOTE-585)已證實比 FLOT 可以增加 pCR rate,disease-free survival 及 overall survival。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1)Landmark trial Phase III MAGIC study證明手術前後加上ECF不僅不增加手術相關M&M還能downstaging和增加R0 resection rate，並且帶來 5-year OS benefit(36% vs 23, HR 0.75, P = 0.009)，但只有42%病人有完成術後的三次療程．後續 ACCORD 07-FFCD 9703 study(僅25% pure gastric cancer),比較 perioperative CF regimen也有看到相似好處 (5-year OS 38% vs 24%, HR 0.69, P = 0.02)。ACCORD 07 研究結果顯示，不含epirubicin的doublet chemotherapy可能已足夠。類似的數據亦來自 CALGB 8010195 和 OE0596 試驗，因此ECF被 FOLFOX取代成為perioperative chemotherapy的首選。\r\n後續FLOT4 phase III study比較 perioperative ECF/ECX和FLOT，FLOT 的pCR明顯優於 ECF/ECX (16% vs 6%, P = 0.02)，且 FLOT 達成 R0 resection的比例較高(85% vs. 78%，P = 0.02)。此外ECF/ECX 組耐受性較差，有 40% 的患者出現至少一次Severe AE，而 FLOT 組則為 25%。FLOT 有較佳mDFS(30 vs. 18 months; P = 0.0036), 較佳mOS (50 vs. 35 months; HR, 0.77, P = 0.012). 3-yr OS(57% vs. 48%)，且FLOT組的術後治療完成率較高 (50% vs. 37%)。因此，FLOT 被視為局部晚期胃癌與 EGJ 腺癌圍手術期治療的標準療法(SoC)。\r\n🎈FLOT 適用於patients with very good performance status, lack of comorbidities, and younger age\r\n🎈FOLFOX 則較適合 patients with good to moderate performance status in the presence of comorbidities or older age\r\n\r\n(2)在Gastric cancer(非EGJ)雖然因為證據不足，目前大多Guideline沒有建議(ESMO)或已將Preoperative chemoradiation的建議刪除(NCCN)，但這議題還沒有一個定論(後續還有Neo-CRAG, PREACT, CRITICS-II studies還在進行中)：\r\n因為CROSS study排除沒有 involving EGJ的胃癌病人，僅在其中EGJ adenocarcinoma病人看到 neoadjuvant chemoradiotherapy 比起直接手術有OS 好處: mOS 43.2 vs. 27.1 months(HR 0.73; P = 0.038), 10-yr OS (36% vs. 26%)， 針對EGJ tumors 的preoperative chemoradiotherapy vs. chemotherapy比較在後續Neo-AEGIS study中並沒有看到OS好處，trial也因此提早終止。\r\n後續TOPGEAR intergroup study直接比較G/GEJ病人接受Pre-OP CRT vs. peri-OP chemotherapy，看到Pre-OP CRT 雖然有較高 pCR rate和較多 tumor downstaging，但沒有survival和PFS好處。\r\n\r\n(3)(4)如NCCN guideline更新。\r\nKEYNOTE-585 加上neoadjuvant+adjuvant pembrolizumab 有較好的pCR(12.9 vs. 2%, p<0.00001)，EFS也有看到較長的趨勢(median 44.4 vs. 25.3 mo; HR 0.81; 95% CI, 0.67-0.99; P=0.0198)但沒有達到顯著(其threshold設在0.0178，statistical failure:α loss & multiplicity due to multiple interim analyses)。\r\nMATTERHORN trial 雖然在interim analysis看到FLOT再加上Durvalumab可以增加pCR(19 vs. 7%, ORR 3.08, p<0.00001)，最近(2023-3-7)也有發新聞稿宣稱EFS達到statistically significancy但是正式的EFS, OS好處都還未經證實。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/095/explain_figures/figure1.png",
      "/qabank/095/explain_figures/figure2.png",
      "/qabank/095/explain_figures/figure3.png"
    ]
  },
  {
    "id": 96,
    "question": "關於胃癌的輔助性化學治療，下列描述中，正確的有?\r\n(1) CLASSIC trial 證明 oxaliplatin plus capecitabine 比 capecitabine 單獨使用有更好的 overall survival and disease-free survival。\r\n(2) ACTS-GC 證明使用一年 TS-1 比使用半年 TS-1 有更好的 overall survival and disease-free survival。\r\n(3) JACCRO GC-07 trial 證明胃癌三期病患使用 TS-1 plus paclitaxel 比 TS-1 單獨使用有更好 的 overall survival and disease-free survival。\r\n(4) ARTIST trial 次族群分析顯示 node positive 胃癌病患術後使用 capecitabine plus cisplatin加上 radiotherapy 比不加 radiotherapy 的 3-year disease-free survival 好，但對於 overall survival 無統計差異。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 3,
    "explanation": "(1)CLASSIC study: 接受D2 gastrectomy的病人在術後接受adjuvant CAPOX(6 months)治療對比surgery only有5y-DFS及5y-OS benefit，並非比較oxaliplatin plus capecitabine  vs. capecitabine。\r\n(2)ACTS-GC study: adjuvant S-1(1 year)對比 surgery only有 5-yr OS benefit(71.7 vs. 61.1%, HR  0.68, P = 0.003)，並非比較TS-1用半年或一年的效果。\r\n(3) JACCRO GC-07 study: 比較stage III gastric cancer 接受D2 gastrectomy後接受adjuvant docetaxel (18 wks) plus S-1(1 yr)和S-1(1 yr) alone的效果，有看到3-yr RFS(68 vs. 57%, HR 0.715)和OS(78 vs. 71%, HR 0.742)。並非加上paclitaxel。\r\n(4) ARTIST I study: 比較D2 gastrectomy後接受postoperative XP 中間加上 RT(XRT) 或XP alone的效果，整體雖沒有看到 DFS和OS的顯著好處，但subgroup analysis有看到在node-positive disease 病人有DFS顯著好處(77.5 vs. 72.3%, p-0.0365)，也才有後續ARTIST II study比較術後node-positive disease 病人接受S-1 vs. SOX vs. SOXRT有無好處差異，但沒有看到postoperative chemoradiation的DFS benefit。",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 97,
    "question": "關於第一線系統性治療(systemic therapy)在食道癌的角色，下列描述中，正確的有? \r\n(1) CheckMate 648 trial顯示nivolumab plus chemotherapy or ipilimumab對於chemotherapy alone 有更佳的tumor response rate、progressive-free survival and overall survival，尤其是PD-L1 expression (TPS≥1 or CPS≥10)的病患有更顯著的臨床療效。\r\n(2) KEYNOTE-590 trial顯示pembrolizumab plus chemotherapy對於chemotherapy 有更佳的 tumor response rate、progressive-free survival and overall survival，尤其是PD-L1 expression (CPS≥10)的病患有更顯著的臨床療效。\r\n(3) KEYNOTE-590 trial subgroup analysis顯示pembrolizumab對於鱗狀上皮癌的療效優於腺癌患者。\r\n(4) CheckMate 648 trial subgroup analysis顯示nivolumab對於鱗狀上皮癌的療效優於腺癌患者。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "考first-line treatment of advanced or metastatic esophageal cancer。\r\n\r\nCheckMate 648\r\n*收錄對象主要是SCC，翻trial的protocol，把adenocarcinoma列為exclusion criteria (figure 1)。\r\n*在OS方面，nivolumab+CT 在整體或PD-L1 expression≥1%都優於單打CT；nivo+ipi在整體或PD-L1 expression≥1%也都優於單打CT (figure 2)。\r\n*在PFS方面，nivolumab+CT in PD-L1 expression≥1%優於單打CT，但在整體病人中PFS沒有達統計學差異；nivo+ipi vs. CT in PD-L1 expression≥1%沒有統計學差異，nivo+ipi vs. CT在整體病人中沒有統計數字 (figure 3)。\r\n*在tumor response rate方面，在PD-L1 expression≥1%病人中，nivolumab+CT與nivo+ipi的ORR都優於單打CT；在整體病人中，nivolumab+CT的ORR優於單打CT，nivo+ipi與單打CT的ORR差不多 (figure 4)。\r\n\r\n\r\nKEYNOTE-590\r\n*收錄對象有ESCC也有EAC (figure 5)。\r\n*在OS方面，pembolizumab+CT在整體、ESCC、CPS≥10都優於單打CT，尤其在ECC CPS≥10病人中表現更好 (figure 6)。\r\n*在PFS方面，pembolizumab+CT在整體、ESCC、CPS≥10都優於單打CT，尤其在CPS≥10病人中表現更好 (figure 7)。\r\n*在tumor response rate方面: all randomised patients: 45.0% vs. 29.3%, estimated percentage difference (15.8% [95% CI 9.0–22.5]; p<0.0001)。\r\n*pembolizumab+CT 在ESCC跟EAC的比較-> OS: ESCC 12.6個月, EAC 11.6個月；PFS: ESCC 6.3個月, EAC 6.3個月 (figure 8)。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/097/explain_figures/figure1.jpg",
      "/qabank/097/explain_figures/figure2.jpg",
      "/qabank/097/explain_figures/figure3.jpg",
      "/qabank/097/explain_figures/figure4.jpg",
      "/qabank/097/explain_figures/figure5.jpg",
      "/qabank/097/explain_figures/figure6.jpg",
      "/qabank/097/explain_figures/figure7.jpg",
      "/qabank/097/explain_figures/figure8.jpg"
    ]
  },
  {
    "id": 98,
    "question": "45歲女性因健康檢查意外發現胰臟頭有小腫瘤，經胃鏡超音波切片檢查顯示well differentiated neuroendocrine tumor、Grade 1、Ki67 <3%，病人的其他影像檢查並沒有遠端或淋巴轉移。根據NCCN Guidelines 2024，下列後續治療建議中，合宜的有？\r\n(1) 若病人是非功能性的，且腫瘤 < 1cm，可以先觀察。\r\n(2) 若病人是功能性的(有carcinoid syndrome)，且腫瘤 < 1cm，也可以先觀察或打 somatostatin analog。\r\n(3) 若病人是非功能性的，且腫瘤 > 2cm，建議pancreatectomy。\r\n(4) 若病人是MEN1，不管腫瘤大小，都建議pancreatectomy。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "參考NCCN Guideline - Neuroendocrine Tumors of the Pancreas (Well-Differentiated Grade 1/2)\r\n\r\n(1) 若病人是非功能性的，且腫瘤 < 1cm，可以先觀察 (figure 1)。\r\n(3) 若病人是非功能性的，且腫瘤 > 2cm，建議pancreatectomy (figure 1)。\r\n(2) functional panNET: 不管大小，都建議切除。(figure 2-7)\r\n(4) PanNET with MEN1 建議手術的情況: functional tumor, 對藥物治療無效、tumor 大於2公分、tumor在6-12個月間長太快 (figure 8)。\r\n順手複習MEN1, MEN2 (figure 9)。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/098/explain_figures/figure1.jpg",
      "/qabank/098/explain_figures/figure2.jpg",
      "/qabank/098/explain_figures/figure3.jpg",
      "/qabank/098/explain_figures/figure4.jpg",
      "/qabank/098/explain_figures/figure5.jpg",
      "/qabank/098/explain_figures/figure6.jpg",
      "/qabank/098/explain_figures/figure7.jpg",
      "/qabank/098/explain_figures/figure8.jpg",
      "/qabank/098/explain_figures/figure9.jpg"
    ]
  },
  {
    "id": 99,
    "question": "Which of the following statements about management of advanced or metastatic gastrointestinal stromal tumor (GIST) are (is) correct?\r\n(1) Imatinib is the standard first line therapy, and could achieve a progression-free survival (PFS) around 2-3 years and an overall survival (OS) around 5-6 years.\r\n(2) Avapritinib is highly effective in GIST patients with PDGFRA exon 18 D842V mutation.\r\n(3) Sunitinib is the standard second line therapy and is effective against tumors with KIT exon 13/14 mutant.\r\n(4) Ripretinib is the standard fourth line therapy.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1) 從UpToDate的一段，引用自Mohammadi M, IJzerman NS, Hollander DD, et al. Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data. Target Oncol. 2023;18(3):415-423.“Subsequent retrospective registry studies of patients with advanced GIST treated with imatinib have reported a median progression-free survival of 33 months and overall survival of 68 months.”\r\n\r\n(2) 有PDGFRA exon 18 D842V，要用avapritinib，對imatinib有抗藥性 (figure 1)。\r\n\r\n(3) 第二線: sunitinib (figure 1)。對於secondary KIT exon 13/14 mutations的效果優於secondary KIT exon 17/18 mutations。\r\nHeinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26(33):5352-5359. “Both PFS and OS were significantly longer for patients with secondary KIT exon 13 or 14 mutations than for those with exon 17 or 18 mutations (PFS: 7.8 vs. 2.3 months; OS: 13 vs. 4 months).”\r\n\r\n(4) 第四線: ripretinib (figure 1)。\r\n<校稿補充> Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:923-934.\r\n-- 收錄病人: Advanced GIST, progression on at least imatinib, sunitinib, and regorafenib or documented intolerance to any of these treatments\r\n-- Ripretinib比起安慰劑，明顯改善mPFS、有acceptable safety. \r\n significantly improved median progression-free survival compared with placebo and had an acceptable safety profile in patients with advanced gastrointestinal stromal tumours who were resistant to approved treatments.",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/099/explain_figures/figure1.jpg"
    ]
  },
  {
    "id": 100,
    "question": "Regarding the diagnosis and staging of biliary tract cancer, which of the following statements are (is) correct?\r\n(1) For resectable intrahepatic cholangiocarcinoma, resection and regional lymphadenectomy is necessary for accurate staging and treatment.\r\n(2) For isolated intrahepatic mass (imaging characteristics consistent with malignancy but not consistent with hepatocellular carcinoma), tumor biopsy is mandatory for diagnosis and molecular testing.\r\n(3) Testing for MSI or MMR deficiency is recommended in patients with unresectable or metastatic gallbladder cancer, intrahepatic CCA.\r\n(4) Comprehensive molecular profiling is recommended for patients with unresectable or metastatic BTC who are candidates for systemic therapy.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1)(2) 詳見figure 1, 2。\r\n(3) 從表格建議的molecular testing，不論是gallbladder cancer、intrahepatic CCA或extrahepatic CCA，都建議測MSI-H/dMMR。FGFR fusion/rearrangement和IDH1 mutation在gallbladder cancer 不建議測，因為發生率很低 (figure 3, 4)。\r\n(4) 直接複製貼上guidedline上的文字敘述 (figure 5)。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/100/explain_figures/figure1.jpg",
      "/qabank/100/explain_figures/figure2.jpg",
      "/qabank/100/explain_figures/figure3.jpg",
      "/qabank/100/explain_figures/figure4.jpg",
      "/qabank/100/explain_figures/figure5.jpg"
    ]
  },
  {
    "id": 101,
    "question": "Regarding the treatment choice of advanced pancreatic adenocarcinoma, which of the following statements are (is) correct?\r\n(1) Induction chemotherapy preferred 4-6 months followed by chemoradiation in selected locally advanced without systemic metastatic disease.\r\n(2) Recommended adjuvant therapy options apply to patients who do not receive prior neoadjuvant therapy.\r\n(3) First line treatment for metastatic disease could be FOLFIRINOX or NALIRIFOX (liposomal irinotecan, oxaliplatin, leucovorin, and fluorouracil).\r\n(4) For known BRCA1/2 or PALB2 mutation first line treatment for metastatic disease could be gemcitabine + albumin-bound paclitaxel.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "(1) Induction chemotherapy preferred 4-6 months followed by chemoradiation in selected locally advanced without systemic metastatic disease.\r\nCorrect\r\n*NCCN Guidelines Version 2.2025. PANC-6 (Figure1)\r\n-In patients with locally advanced, unresectable disease \r\n-- Good or intermediate performance status\r\n--> initial systemic chemotherapy for 4-6 months \r\n--> In selected patients (good performance status+ no systemic metastases): consolidation chemoradiation or SBRT\r\n-- Poor PS: single agent chemotherapy or palliative RT \r\n\r\n參考trial\r\n*LAP07 Trial (Hammel et al., JAMA Oncology, 2016): no clear survival benefit with the addition of conventional chemoradiation following gemcitabine monotherapy. Chemoradiation may improve local control and delay the need for resumption therapy\r\n\r\n\r\n(2) Correct, Recommended adjuvant therapy options apply to patients who do not receive prior neoadjuvant therapy.\r\n*NCCN Guidelines Version 2.2025. PANC-6、PANC-8、PANC-F (2 OF 13) (Figure2)(Figure3)\r\n- Recommended adjuvant therapy options apply to patients who did not receive prior neoadjuvant therapy.\r\n-- For those who received prior neoadjuvant therapy, the adjuvant therapy options are dependent on the response to neoadjuvant therapy and other clinical considerations.\r\n(建議的輔助治療選項適用於未接受neoadjuvant的患者、對於曾接受neoadjuvant的患者，輔助治療選項需考慮對neoadjuvant的反應以及其他臨床考量因素。)\r\n- Adjuvant treatment should be administered to patients who have adequately recovered from surgery; treatment should be initiated ideally within 12 weeks\r\n\r\n(3) Correct, First line treatment for metastatic disease could be FOLFIRINOX or NALIRIFOX (liposomal irinotecan, oxaliplatin, leucovorin, and fluorouracil).\r\n*NCCN Guidelines Version 2.2025. PANC-F 5 OF 13\r\n- recommended first line therapy\r\n--•FOLFIRINOX (category 1) or modified FOLFIRINOX (*a)\r\n--•Gemcitabine + albumin-bound paclitaxel (category 1) (*b)\r\n--•NALIRIFOX (category 1) (*c)\r\n\r\n參考trial (3篇)\r\n*a Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825. \r\n*a-1 研究方法 \r\n-- 隨機分配 342 名ECOG 0 或 1 的患者，接受 FOLFIRINOX 或 gemcitabine 治療。\r\n(FOLFIRINOX= oxaliplatin, 85 mg/m2; irinotecan, 180 mg/m2; leucovorin, 400 mg/m2; and fluorouracil, 400mg/m2 bolus + 2400mg/m2 46-hour連續輸注, Q2wks)\r\n(Gemcitabine 1000 mg/m2 Qwk, 7 of 8 weeks and then Qwk for 3 of 4 weeks) 每週給藥7周、第8周休息，再來每週給藥3周、第4周休息\r\n-- 療程6個月(who had a response)\r\n-- The primary end point= overall survival.\r\n*a-2 研究結果\r\n-- mOS: FOLFIRINOX 組為 11.1 個月，Gemcitabine 組為 6.8 個月(hazard ratio for death, 0.57，P<0.001)(Figure4)\r\n-- mPFS: FOLFIRINOX 組為 6.4 個月，Gemcitabine 組為 3.3 個月(hazard ratio for disease progression, 0.47，P<0.001)(Figure5)\r\n-- ORR: FOLFIRINOX 組為 31.6%，Gemcitabine 組為 9.4% (P<0.001)\r\n-- 不良事件: FOLFIRINOX 組較多，其中 5.4% Febrile Neutropenia \r\n-- 6個月時的生活品質明顯下降: FOLFIRINOX 組31%，而 gemcitabine 組則為 66% (hazard ratio, 0.47; P<0.001).(Figure6)\r\n*a-3 結論\r\nAs compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status.\r\n\r\n\r\n*b Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-1703.\r\n*b-1 研究方法 \r\n隨機分配 Karnofsky performance-status 70 分以上的metastatic pancreatic cancer患者接受 nab-paclitaxel+gemcitabine 或是gemcitabine monotherapy\r\n(nab-paclitaxel 125 mg/m2與 Gemcitabine 1000 mg/m2，於每 4 週的第 1、8 和 15 天給予)\r\n(Gemcitabine 1000 mg/m2單用，在第 1 個療程中，每週打，7 週後停1週，從第 2 個療程起，每 4 週的第 1、8 和 15 天給予)\r\n-- 療程打到disease progression\r\n-- The primary end point= OS.\r\n-- The secondary end point= PFS and overall response rate.\r\n\r\n*b-2 研究結果\r\n-- 431 vs 430人\r\n-- mOS: Nab-paclitaxel–gemcitabine 組 8.5 個月，Gemcitabine 組則為 6.7 個月(hazard ratio for death, 0.72；P<0.001)(Figure7)\r\n--1 年OS：nab-paclitaxel–gemcitabine 組為 35%，Gemcitabine 組為 22%。\r\n--2 年OS：nab-paclitaxel–gemcitabine 組為 9%，Gemcitabine 組為 4%。\r\n-- mPFS: Nab-paclitaxel–gemcitabine 組 5.5 個月，Gemcitabine 組則為 3.7 個月(hazard ratio for disease progression or death, 0.69；P<0.001)(Figure8)\r\n-- ORR: Nab-paclitaxel–gemcitabine 組為 23%，Gemcitabine 組為 7%（P<0.001）\r\n-- 3 級或以上最常見的不良事件：Nab-paclitaxel–gemcitabine 組比較多 --> Neutropenia (38% vs. 27%)、Fatigue (17% vs7%)、Neuropathy(17% vs1%)\r\n-- 其他不良事件: Febrile neutropenia(3% vs. 1%)\r\n\r\n*b-3 結論\r\nIn patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased.\r\n\r\n\r\n\r\n*c Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 2023;402:1272-1281.\r\n*c-1 研究方法\r\n-- randomised, open-label, phase 3 study\r\n-- mPDAC，且ECOG 0 或 1。患者以 1:1 的比例隨機分配至NALIRIFOX 組或Nab-paclitaxel + Gemcitabine 組\r\n(NALIRIFOX 組：Liposomal irinotecan 50 mg/m², Oxaliplatin 60 mg/m², Leucovorin 400 mg/m², Fluorouracil 2400 mg/m² 46 小時持續輸注。每 28 天週期的第 1 天與第 15 天)\r\n(Nab-paclitaxel + Gemcitabine 組：Nab-paclitaxel 125 mg/m², Gemcitabine 1000 mg/m²。每 28 天週期的第 1、8 和 15 天給予)\r\n-- The primary end point= OS.\r\n\r\n*c-2 研究結果\r\n-- 383 vs 387人\r\n-- mOS: NALIRIFOX 11.1 個月、Nab-paclitaxel + Gemcitabine 組 9.2 個月、(hazard ratio for death, 0.83；p=0.036)(Figure9)(Figure10)\r\n-- 3 級或以上治療相關不良事件: NALIRIFOX 組 87%、Nab-paclitaxel + Gemcitabine 組 86% \r\n-- 治療相關死亡（Treatment-related deaths）：兩組均為2%\r\n\r\n*c-3 結論\r\nThe use of the NALIRIFOX regimen as a possible reference regimen for first-line treatment of mPDAC.\r\n\r\n\r\n\r\n(4) Incorrect, For known BRCA1/2 or PALB2 mutation first line treatment for metastatic disease could be gemcitabine + albumin-bound paclitaxel.\r\n應修正為Gem-Cis\r\n*NCCN Guidelines Version 2.2025. PANC-F 5 OF 13 (Figure11)\r\n- Only for known BRCA1/2 or PALB2 mutations:\r\n--•FOLFIRINOX (category 1) or modified FOLFIRINOX (見選項3的*a trial)\r\n--•Gemcitabine + cisplatin (*d)\r\n\r\n參考trial\r\n*d O'Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020;38:1378-1388.\r\n\r\n*d-1 研究方法\r\n-- 未經治療的gBRCA/PALB2 陽性 pancreas adenocarcinoma with measurable stage III to IV, ECOG 0 to 1.\r\n-- 分別接受 A 組 Cisplatin+Gemcitabine 另一組 B 組 Cis+Gem+Veliparib 80mg\r\n(A 組Cisplatin 25 mg/m² + Gemcitabine 600 mg/m²，於 第 3 天和第 10 天給藥)\r\n(B 組與 A 組相同，再加上 Veliparib 80 mg，每日口服兩次，從第 1 天至第 12 天，每3 週為 1 個治療週期)\r\n-- The primary end point= response rate (RR)\r\n-- Secondary end points: PFS, disease control rate (DCR), OS, safety, and correlative analyses.\r\n\r\n*d-2 研究結果\r\n-- RR: 74.1% vs 65.2% (P = 0.55) 兩組均超過預先設定的療效閾值。(Figure12)\r\n-- DCR: 100% vs 78.3%(P = 0.02)\r\n-- mPFS: 10.1 個月 vs 9.7 個月(P = 0.73)\r\n-- mOS: 15.5 個月 vs 16.4 個月(P = 0.6)\r\n-- 2yr OS(entire cohort) 30.6%、3yr OS(entire cohort) 17.8% \r\n-- 3 至 4 級血液學毒性 A 組較多: Neutropenia 13(48%) vs 7(30%)、Thrombocytopenia 15(55%) vs 2(9%)、Anemia 14(52%) vs 8(35%)\r\n\r\n*d-3 結論\r\nCisplatin and gemcitabine is an effective regimen in advanced gBRCA/PALB2+ PDAC. Concurrent veliparib did not improve RR.",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/101/explain_figures/Figure1.jpg",
      "/qabank/101/explain_figures/Figure10.jpg",
      "/qabank/101/explain_figures/Figure11.jpg",
      "/qabank/101/explain_figures/Figure12.jpg",
      "/qabank/101/explain_figures/Figure2.jpg",
      "/qabank/101/explain_figures/Figure3.jpg",
      "/qabank/101/explain_figures/Figure4.jpg",
      "/qabank/101/explain_figures/Figure5.jpg",
      "/qabank/101/explain_figures/Figure6.jpg",
      "/qabank/101/explain_figures/Figure7.jpg",
      "/qabank/101/explain_figures/Figure8.jpg",
      "/qabank/101/explain_figures/Figure9.jpg"
    ]
  },
  {
    "id": 102,
    "question": "Regarding the treatment of advanced hepatocellular carcinoma, which of the following statements are (is) correct?\r\n(1) Preferred first line treatment choice for Child Pugh A HCC patient is atezolizumab + bevacizumab or tremelimumab + durvalumab.\r\n(2) Subsequent-line systemic therapy for disease progression option could be cabozantinib, regorafenib, lenvatinib or sorafenib.\r\n(3) Subsequent-line systemic therapy for disease progression could be ramucirumab for those with AFP ≥400 ng/mL.\r\n(4) Immune checkpoint inhibition has shown clinical benefit in HCC patients without selection for microsatellite instability (MSI), mismatch repair (MMR), tumor mutational burden (TMB), or programmed death ligand 1 (PD-L1) testing status.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1) Preferred first line treatment choice for Child Pugh A HCC patient is atezolizumab + bevacizumab or tremelimumab + durvalumab.\r\nCorrect! (for unresectable HCC)\r\n*NCCN Guidelines Version 4.2024,  HCC-5、 HCC-I 1 OF 2 (Figure1)\r\n-First-Line Systemic Therapy\r\n--Preferred Regimens\r\n--• Atezolizumabd + bevacizumab (category 1) (*a: Updated IMbrave150)\r\n--• Tremelimumab-actl + durvalumab (category 1) (*b: HIMALAYA trial) \r\n-- Caution: 所列的治療方式在 Child B or C liver function 的safety data很有限\r\n\r\n*相關trial (2篇)\r\n*a Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76:862-873.\r\n*a-1研究方法\r\n-- open-label, phase III study\r\n-- 未接受過全身性治療且不可切除的HCC\r\n-- 2:1的比例隨機分配至：Atezolizumab+bevacizumab 或是 Sorafenib組別\r\n(Atezolizumab 1,200 mg + Bevacizumab 15 mg/kg Q3wk)\r\n(Sorafenib 400 mg BID)\r\n-- Co-primary endpoints= OS and PFS\r\n-- Secondary efficacy endpoints= objective response rates(ORR)、exploratory subgroup efficacy analyses.\r\n\r\n*a-2研究結果\r\n--共501病人(ITT)，A+B(n = 336)、Sorafenib(n = 165)(Figure2)\r\n--mOS: 19.2 個月 vs 13.4 個月，HR 0.66, descriptive p <0.001\r\n--mPFS: 6.9 個月 vs 4.3 個月，HR 0.65, descriptive p <0.001\r\n--治療相關的 3/4 級AE: 143 人(43%，n = 329) vs 72 人(46%，n = 156)\r\n--治療相關的 5 級AE: 6 人(2%) vs 1 人(<1%)\r\n--Objective response: 97人(30%) vs 18人(11%)(Figure3)\r\n\r\n*a-3結論\r\nIMbrave150 (Published May 13, 2020 N Engl J Med 2020;382:1894-1905)的主要分析顯示，A+B相較於Sorafenib，在advanced HCC 患者中具有顯著更大的療效優勢，但當時survival data尚未成熟。在12 個月後進行的更新分析中，顯示A+B組的mOS較 Sorafenib 組延長 5.8 個月，且治療相關AE的嚴重程度與先前結果相似。這些更新結果進一步確認，A+B已成為advanced HCC的一線標準治療\r\n\r\n*b Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022;1:EVIDoa2100070.\r\n*b-1研究方法\r\n-- open-label, phase 3 trial\r\n-- 未接受過全身性治療且不可切除的HCC\r\n-- 隨機分配至3組: Tremelimumab+Durvalumab、單用durvalumab、Sorafenib\r\n(Tremelimumab 300 mg 單次給藥+ Durvaluma 1500 mg q4wks)= STRIDE (Single Tremelimumab Regular Interval Durvalumab) \r\n(單用durvalumab 1500 mg q4wks)\r\n(Sorafenib 400 mg BID)\r\n-- The primary endpoint= OS for STRIDE vs Sorafenib\r\n-- The secondary objective= Noninferiority for OS for Durvalumab versus Sorafenib\r\n\r\n*b-2研究結果\r\n--N=1171：STRIDE(n = 393)、Durvalumab(n = 389)、或Sorafenib(n = 389)\r\n--mOS: 16.43個月 vs 16.56 個月 vs 13.77 個月 (Figure4)\r\n--> STRIDE 比起 Sorafenib，OS的HR= 0.78、P=0.0035\r\n--> Durvalumab monotherapy不亞於 (noninferior to) sorafenib (HR, 0.86; 95.67% CI, 0.73 to 1.03; noninferiority margin, 1.08)\r\n--Overall survival at 36 months: 30.7% vs 24.7% vs 20.2%\r\n--mPFS: 三組沒有差異(Figure5)\r\n--治療相關的 3/4 級AE: 50.5% vs 37.1% vs 52.4%\r\n \r\n*b-3結論\r\nFor unresectable HCC\r\n--STRIDE significantly improved OS versus sorafenib. \r\n--Durvalumab monotherapy was noninferior to sorafenib.\r\n\r\n\r\n(2) Subsequent-line systemic therapy for disease progression option could be cabozantinib, regorafenib, lenvatinib or sorafenib.\r\nCorrect! \r\n*NCCN Guidelines Version 4.2024, HCC-I 1 OF 2\r\n- Subsequent-Line Systemic Therapy if Disease Progression\r\n-- Options \r\n-- • Cabozantinib (category 1) (*c)\r\n-- • Regorafenib (category 1) (*d) \r\n-- • Lenvatinib \r\n-- • Sorafenib\r\n-- 1線治療之後，目前缺乏比較數據來確定最佳治療選擇\r\n\r\n\r\n*相關trial (2篇)\r\n*c Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379:54-63.\r\n*c-1研究方法\r\n-- Randomized, double-blind, phase 3 trial\r\n-- 收錄曾接受Sorafenib治療，用過1-2線全身治療後progression的病人\r\n-- Cabozantinib 抑制tyrosine kinases (包含VEGFR 1, 2, and 3, MET, and AXL)\r\n-- N= 707, 隨機2:1分配至 Cabozantinib (60 mg QD) 或 Placebo\r\n-- The primary end point= OS\r\n-- The secondary end point= PFS, ORR\r\n\r\n*c-2研究結果\r\n--mOS: 10.2 個月 vs 8.0 個月 (HR for death, 0.76; P=0.005)(Figure6)\r\n--mPFS: 5.2 個月 vs 1.9 個月 (HR for disease progression or death, 0.44; P<0.001)(Figure7)\r\n--ORR: 4% vs <1% (P=0.009)\r\n--Grade 3 or 4 AEs: Cabozantinib多於安慰劑組別 68% vs 36%\r\n--> palmar–plantar erythrodysesthesia (17% vs. 0%), hypertension (16% vs. 2%), AST上升 (12% vs. 7%), fatigue (10% vs. 4%), and diarrhea (10% vs. 2%).\r\n\r\n*c-3結論\r\n--在先前接受過治療的advanced HCC, Cabozantinib 比起安慰劑有更長的OS與PFS，但也有更多的high-grade AE (約為2倍)\r\n\r\n\r\n*d Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomized, double blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.\r\n\r\n*d-1研究方法\r\n--Randomised, double-blind, parallel-group, phase 3 trial\r\n--收錄under Sorafenib治療(≥400 mg/day for ≥20 of last 28 days of treatment)，卻PD的病人，需 Child-Pugh A\r\n--隨機2:1分配至 口服 Regorafenib 或 另一組 安慰劑 ，兩組都有最佳支持治療(BSC)\r\n(Regorafenib 160 mg QD，吃三周休一周，4周為一循環)\r\n-- The primary end point= OS\r\n\r\n*d-2研究結果\r\n--N=573隨機分配，Regorafenib 379、Placebo 194 (For efficacy analyses)\r\n--N=567接受治療，Regorafenib 374、Placebo 193 (For safety analyses)\r\n--mOS: 10.6 個月 vs 7.8 個月 (HR 0.63;one-sided p<0·0001) (Figure8)\r\n--AEs: 100% vs 93%\r\n--Grade 3 or 4 AEs: Regorafenib組多於Placebo\r\n--> hypertension 57(15%) vs 9(5%)， hand–foot skin reaction 47(13%) vs 1(1%), fatigue 34(9%) vs 9(5%), and diarrhoea 12(3%) vs 0\r\n--治療相關死亡(Grade 5 AE): 共發生88例(50 vs 38)，其中有9例被認為與試驗藥物相關，Regorafenib 組 7 例(2%)、安慰劑組 2 例(1%、為肝衰竭)\r\n\r\n*d-3Interpretation\r\nRegorafenib is the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafenib treatment.\r\n\r\n(3) Subsequent-line systemic therapy for disease progression could be ramucirumab for those with AFP ≥400 ng/mL.\r\nCorrect!\r\n*NCCN Guidelines Version 4.2024, HCC-I 1 OF 2 (Figure9)\r\n- Subsequent-Line Systemic Therapy if Disease Progression\r\n-- Useful in Certain Circumstances\r\n-- • Ramucirumab (AFP ≥400 ng/mL) (category 1) (*e =REACH-2 trial)\r\n-- • Nivolumab \r\n-- • For MSI-H/dMMR tumors: Dostarlimab-gxly (category 2B) \r\n-- • For RET gene fusion-positive tumors: Selpercatinib (category 2B)\r\n\r\n*相關trial (1篇)\r\n*e Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:282-296.\r\n\r\n*e-1研究方法\r\n--Randomised, double-blind, placebo-controlled, phase 3 trial\r\n--符合條件需要年滿 18 歲，並且具備以下條件：\r\n--1.經組織學或細胞學確診為HCC，或肝硬化合併 HCC\r\n--2.BCLC B 期或 C 期疾病\r\n--3.Child-Pugh A 級肝功能\r\n--4.ECOG 0 或 1\r\n--5.AFP ≥400 ng/mL\r\n--6.曾接受 Sorafenib 一線治療\r\n--隨機分配2:1至 Ramucirumab 組(8 mg/kg Q2wks)或 安慰劑組，兩組均有最佳支持治療(BSC)\r\n--The primary end point= OS\r\n--The secondary endpoints= PFS、ORR、time to radiographic progression, safety, time to deterioration in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8), and time to deterioration in ECOG\r\n--此研究還合併分析了 REACH-2 及 REACH(NCT01140347)試驗中 AFP 濃度 ≥400 ng/mL 的患者個體數據\r\n\r\n*e-2研究結果\r\n--N=292, Ramucirumab 197、Placebo 95\r\n--Ramucirumab 組相較於安慰劑組，OS和PFS均顯著改善\r\n--mOS: 8.5 個月 vs 7.3 個月，HR 0.710、p = 0.0199 (Figure10)\r\n--PFS: 2.8 個月 vs 1.6 個月，HR 0.452、p < 0.0001\r\n--ORR未達統計學差異: 9 人(5%) vs 1 人(1%)、p = 0.1697\r\n--FHSI-8 總分惡化時間未達統計學差異: 3.7 個月 vs 2.8 個月、HR 0.799、p = 0.238\r\n--ECOG 惡化時間未達統計學差異: HR 1.082、p = 0.77\r\n--3 級以上治療相關不良事件(發生率 ≥5%): 高血壓 25 例(13%) vs 5 例(5%)、低鈉血症 11 例(6%) vs 0 例、AST升高 6 例(3%) vs 5 例(5%)\r\n--任何級別的嚴重不良事件(SAEs，無論原因): 68 例(35%) vs 28 例(29%)\r\n--與治療相關的死亡事件: Ramucirumab 組有3例判定為與試驗治療相關：AKI、hepatorenal syndrome、Renal failure \r\n \r\n*e-3結論\r\n--Ramucirumab 相較於安慰劑能改善 曾接受 Sorafenib 治療且 AFP 濃度至少 400 ng/mL 之HCC患者的OS。\r\n--Ramucirumab was well tolerated, with a manageable safety profile\r\n\r\n\r\n(4) Immune checkpoint inhibition has shown clinical benefit in HCC patients without selection for microsatellite instability (MSI), mismatch repair (MMR), tumor mutational burden (TMB), or programmed death ligand 1 (PD-L1) testing status.\r\nCorrect!\r\n-In Nivolumab, 相關trial=CheckMate 040 指出 All responses occurred early in treatment. Responses were observed regardless of baseline etiology and PD-L1 status.(Figure11)\r\n-In A+B, 相關trial=IMbrave150 指出 The predictive value of PDL1 status for the efficacy of PDL1 and PD1 inhibitors or combination therapies has not been clearly shown in the case of HCC.\r\n-MSI and MMR Deficiency: MSI-high tumors在HCC不常見(<3%)，MSI is not a practical biomarker for predicting responses to ICIs in HCC patients. (Figure12)\r\n-TMB: HCC通常表現low tumor mutational burden (TMB). This low TMB suggests that it is unlikely to serve as a relevant biomarker for ICI response in the majority of HCC patients. (Figure13)\r\n*相關trial\r\n--CheckMate 040: Efficacy and Safety of Nivolumab + Ipilimumab in Patients With Advanced HCC Previously Treated With Sorafenib \r\n--IMbrave150 \r\n--Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma, Curr. Oncol. 2023, 30(9), 8665-868",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/102/explain_figures/Figure1.jpg",
      "/qabank/102/explain_figures/Figure10.jpg",
      "/qabank/102/explain_figures/Figure11.jpg",
      "/qabank/102/explain_figures/Figure12.jpg",
      "/qabank/102/explain_figures/Figure13.jpg",
      "/qabank/102/explain_figures/Figure2.jpg",
      "/qabank/102/explain_figures/Figure3.jpg",
      "/qabank/102/explain_figures/Figure4.jpg",
      "/qabank/102/explain_figures/Figure5.jpg",
      "/qabank/102/explain_figures/Figure6.jpg",
      "/qabank/102/explain_figures/Figure7.jpg",
      "/qabank/102/explain_figures/Figure8.jpg",
      "/qabank/102/explain_figures/Figure9.jpg"
    ]
  },
  {
    "id": 103,
    "question": "Regarding the treatment choice of unresectable and metastatic biliary tract adenocarcinoma, which of the following statements are (is) correct?\r\n(1) Durvalumab + gemcitabine + cisplatin or pembrolizumab + gemcitabine + cisplatin is preferred first-line systemic therapy regimens.\r\n(2) The most common therapeutic targets (more than 10%) are FGFR2 fusion or rearrangement and IDH1 mutation in common bile duct adenocarcinoma.\r\n(3) For MSI-H/dMMR tumors pembrolizumab treatment could be recommended.\r\n(4) Germline testing is recommended for all patients with unresectable or metastatic BTC who are candidates for systemic therapy.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1) Durvalumab + gemcitabine + cisplatin or pembrolizumab + gemcitabine + cisplatin is preferred first-line systemic therapy regimens.\r\nCorrect!\r\n*NCCN Guidelines Version 6.2024, BIL-C 2 OF 5 (Figure1)\r\n-Primary Treatment for Unresectable and Metastatic Disease\r\n--Preferred Regimens\r\n--• Durvalumab + gemcitabine + cisplatin (category 1) (*a=TOPAZ-1 trial)\r\n--• Pembrolizumab + gemcitabine + cisplatin (category 1) (*b=KEYNOTE-966)\r\n--補充\r\n--> Durvalumab + gemcitabine + cisplatin 也適用於在根治性手術後超過6個月且adjuvant therapy 完成後超過6個月復發的患者\r\n--> 若作為後線治療使用，應限於未曾接受過checkpoint inhibitor治療的患者，因為目前缺乏針對已接受checkpoint inhibitor後再使用immunotherapy的相關數據。\r\n\r\n\r\n相關trial (2篇)\r\n*a Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022;1:EVIDoa2200015. \r\n*a-1研究方法\r\n--double-blind, placebo-controlled, phase 3 study\r\n--先前未接受治療的不可切除或轉移性膽道癌患者，或復發性疾病患者\r\n--1:1 隨機分配，接受Durvalumab 或安慰劑，兩組均合併gemcitabine + cisplatin治療，最多八個週期，隨後單獨使用durvalumab 或安慰劑until disease progression or unacceptable toxicity.\r\n--The primary objective= OS\r\n--The secondary end points= PFS, ORR, Safety.\r\n\r\n*a-2研究結果\r\n--N=685，Durvalumab組(n=341)、Placebo組(n=344)\r\n--Data cutoff時，Durvalumab 組198名患者(58.1%)和安慰劑組226名患者(65.7%)已死亡\r\n--mOS: 12.8個月 vs 11.5個月，HR for OS= 0.80，P=0.021 (Figure2)\r\n--mPFS: 7.2個月 vs 5.7個月，HR for PFS= 0.75，P=0.001\r\n--ORR: 26.7% vs 18.7% (Figure3)\r\n--3或4級AE: 75.7% vs 77.8%\r\n\r\n*a-3結論\r\n--Durvalumab + chemotherapy顯著提高OS，也改善PFS and ORR. 兩組的safety profiles沒有差異\r\n\r\n\r\n*b Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401:1853-1865.\r\n*b-1研究方法\r\n--Randomised, double-blind, placebo-controlled, phase 3 trial\r\n--收錄滿18歲、未接受過治療的、不可切除的locally advanced or metastatic膽道癌；ECOG 0 或 1\r\n--依 1:1 隨機分配至Pembrolizumab組 或 安慰劑組，兩者均Q3wks (最多 35 個療程)，且兩組均合併Gemcitabine+Cisplatin\r\n(Pembrolizumab 200mg Q3wk)\r\n(Gemcitabine 1000 mg/m²，於第 1 天和第 8 天給予，Q3wks，無最高治療限制)\r\n(Cisplatin 25 mg/m²，於第 1 天和第 8 天給予，Q3wks，最多 8 個療程)\r\n--The primary objective= OS (ITT)\r\n--The secondary endpoint= Safety (as-treated)\r\n\r\n*b-2研究結果\r\n--N=1069，Pembrolizumab組(n=533)、Placebo組(n=536)\r\n--mOS: 12·7個月 vs 10·9個月，HR= 0·83，one-sided p=0·0034 [significance threshold, p=0·0200] (Figure4)\r\n--3或4級AE: 420(79%) vs 400(75%)\r\n--Treatment-related 3或4級AE: 369(70%) vs 367(69%)\r\n--因為AE而死亡: 31(6%) vs 49(9%) [其中 8(2%) vs 3(1%) 被認定與治療相關]\r\n\r\n*b-3結論\r\n--Pembrolizumab plus gemcitabine and cisplatin改善OS，且沒有新的safety signals--> a new treatment option for patients with previously untreated metastatic or unresectable BTC.\r\n\r\n\r\n(2) The most common therapeutic targets (more than 10%) are FGFR2 fusion or rearrangement and IDH1 mutation in common bile duct adenocarcinoma.\r\nIncorrect! FGFR2 fusion or rearrangement, IDH1 mutation均是在 intrahepatic CCAs多，其他subsites為rare表現\r\n*NCCN Guidelines Version 6.2024, BIL-B 1-3 OF 8\r\n-Molecular profiling in BTCs: Comprehensive molecular profiling is recommended for patients with unresectable or metastatic BTC who are candidates for systemic therapy. If tissue is too scant or not available, consider repeat biopsy depending on tumor accessibility, safety, and clinical context. A cell-free DNA (cfDNA) test may also be considered for identifying gene mutations. This technique may not reliably identify gene fusions or rearrangements depending on the panel used and the specific partner gene. \r\n(Figure5,6,7)\r\n--NTRK fusion: <1%\r\n--MSI-H/dMMR: 1%–3%\r\n--TMB-H: <5%\r\n--BRAF V600E mutation: 1%–5% \r\n--FGFR2 fusion or rearrangement: 9%–15% of intrahepatic CCAs and rare in other subsites\r\n--IDH1 mutation: 10%–20% of intrahepatic CCAs and rare in other subsites\r\n--HER2 (ERBB2) overexpression and/or amplification: 5%–20% of CCAs, 15%–30% of gallbladder cancer\r\n--RET fusion: <1%\r\n--KRAS G12C mutation: 1%\r\n\r\n\r\n(3) For MSI-H/dMMR tumors pembrolizumab treatment could be recommended.\r\nCorrect!\r\n*NCCN Guidelines Version 6.2024, BIL-B 4 OF 8, BIL-C 3 OF 5 (Figure8)\r\n-在unresecatble or metastatic gallbladder cancer, intrahepatic CCA, or extrahepatic CCA 建議要驗MSI/dMMR\r\n-- 若為MSI-H/dMMR tumors，第一線Targeted Tx建議Pembrolizumab、Subsequent-Line 建議Pembrolizumab、Dostarlimab-gxly (category 2B)\r\n\r\n相關trial (2篇)\r\n*c Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1-10.\r\n*c-1研究方法\r\n--Histologically/cytologically confirmed MSI-H/dMMR\r\n--Advanced noncolorectal cancer + 先前治療失敗\r\n--符合上述條件的病人接受pembrolizumab 200 mg Q3wks for 2 years (或直到PD、無法耐受的toxicity、病人withdrawal)\r\n--Median follow up was 13.4 months. \r\n--The primary end point= ORR\r\n\r\n*c-2研究結果\r\n--N=233, 子宮內膜癌、胃癌、膽管癌和胰腺癌最為常見 (全部27種tumor types)\r\n--ORR= 34.3% (Figure9)\r\n--mPFS= 4.1個月、mOS= 23.5個月\r\n--TRAE= 151=(64.8%)\r\n--- Gr3-5= 34(14.6%)、無其他與治療相關的致命不良事件\r\n\n-- Cholangiocarcinoma cohort: \n-- ORR= 40.9%, mPFS= 4.2個月、mOS= 24.3個月\n\r\n*c-3結論\r\n--對於先前接受治療的不可切除或轉移性MSI-H/dMMR非結直腸癌患者，Anti–PD1 (pembrolizumab) 具有臨床益處。其毒性與之前使用pembrolizumab的經驗一致。\r\n\r\n\r\n*d Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: Updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022;33:929-938.\r\n*d-1研究方法\r\n--與前一篇均為KEYNOTE-158 study\r\n--Longer follow-up: previously treated advanced MSI-H/dMMR noncolorectal cancers\r\n--Median time from first dose to database cut-off 37.5 個月\r\n\r\n*d-2研究結果\r\n--ORR= 30.8%(Figure10)\r\n--mPFS= 3.5 個月、mOS= 20.1 個月個月\r\n--Median duration of response= 47.5 months\r\n--TRAE= 227(64.7%)\r\n--- Gr3-4= 39(11.1%)、Gr5= 3(0.9%)\r\n\n-- Cholangiocarcinoma cohort: \n-- ORR= 40.9%, mPFS= 4.2個月、mOS= 19.4個月\n\r\n*d-3結論\r\n--Pembrolizumab demonstrated clinically meaningful and durable benefit, with a high ORR of 30.8%, long median duration of response of 47.5 months, and manageable safety across a range of heavily pretreated, advanced MSI-H/dMMR noncolorectal cancers, providing support for use of pembrolizumab in this setting.\r\n\r\n\r\n(4) Germline testing is recommended for all patients with unresectable or metastatic BTC who are candidates for systemic therapy.\r\nIncorrect!\r\n*NCCN Guidelines Version 6.2024, BIL-B 1 OF 8\r\n Recommendations:\r\n--Germline testing in hepatobiliary cancers\r\n--> 是否行germline testing尚無足夠證據可用於制定明確的標準，也無證據支持進行universal germline testing。\r\n--> 若患者具備以下任一特徵，可以考慮檢測：診斷時年齡較輕、個人或家族癌症病史顯著、無已知liver disease危險因子，或腫瘤基因檢測中發現可能為germline alterations。\r\n--> 已知攜帶與cancer predisposing syndrome相關的germline mutation的患者（如Lynch syndrome or hereditary breast and ovarian cancer syndrome），目前仍缺乏足夠證據支持針對膽道惡性腫瘤進行篩檢。\r\n\r\n(原文: Evidence remains insufficient for definitive recommendations regarding specific criteria to guide genetic risk assessment in hepatobiliary cancers or for universal germline testing in these tumors. In BTCs, genetic counseling referral and potential germline testing should be considered in patients with any of the following characteristics: young age at diagnosis; a strong personal or family history of cancer; no known risk factors for liver disease; or presence of mutations identified during tumor testing that are suspected to be possible germline alterations. For patients who do harbor a known germline mutation associated with a cancer predisposing syndrome (ie, Lynch syndrome or hereditary breast and ovarian cancer syndrome), there is currently insufficient evidence to support screening for biliary tract malignancies.)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/103/explain_figures/Figure1.jpg",
      "/qabank/103/explain_figures/Figure10.jpg",
      "/qabank/103/explain_figures/Figure2.jpg",
      "/qabank/103/explain_figures/Figure3.jpg",
      "/qabank/103/explain_figures/Figure4.jpg",
      "/qabank/103/explain_figures/Figure5.jpg",
      "/qabank/103/explain_figures/Figure6.jpg",
      "/qabank/103/explain_figures/Figure7.jpg",
      "/qabank/103/explain_figures/Figure8.jpg",
      "/qabank/103/explain_figures/Figure9.jpg"
    ]
  },
  {
    "id": 104,
    "question": "下列關於大腸直腸癌HER2-amplification的敘述，正確的有？\r\n(1) 在大腸直腸癌，HER2高表現的病患約有2-5%，且可能與anti-EGFR 藥物使用的抗藥性有關。\r\n(2) 在兩線化學治療失敗後，在HER2高表現，RAS-wild type 的大腸直腸癌病患，可考慮使用trastuzumab + tucatinib。\r\n(3) 根據DESTINY-CRC02，單獨使用T-DXd無論RAS-mutant或wild type，其response rate 約為35%。\r\n(4) 根據DESTINY-CRC01，在low HER2 (IHC2+/ISH-或IHC1+) 的病患使用T-DXd依然有約40%的response rate。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": null,
    "explanation": "(1) 在大腸直腸癌，HER2高表現的病患約有2-5%，且可能與anti-EGFR 藥物使用的抗藥性有關。\r\nCorrect!\r\n*NCCN Guidelines Version 1.2025 MS-49 (Figure1)\r\n--HER2 is rarely amplified/overexpressed in CRC(approximately 3% overall), but the prevalence is higher in RAS/BRAF–wild type tumors (reported at 5%–14%).\r\n--目前無證據證實 HER2 overexpression在預後的角色\r\n--除了是HER2-targeted therapy的predictive marker, HER2 amplification/overexpression也與EGFR-targeting monoclonal antibodies的抗藥性有關!\r\n\r\n*參考trial: Raghav K, Loree JM, Morris JS, et al. Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology 2019:1-13. \r\n--研究對象：98 名 RAS/BRAF–wild type mCRC\r\n--不使用 EGFR inhibitor時，無論 HER2 狀態如何，median PFS相似。\r\n--使用 EGFR inhibitor時，HER2 amplification患者的 PFS 顯著較短(2.8 個月 vs. 8.1 個月)。\r\n--HR：7.05(95% CI, 3.4–14.9)。\r\n--P < .001\r\n--結論：in RAS/RAF wild-type mCRC，HER2 amplification與anti-EGFRab therapy的抗藥性/療效有關。\r\n\r\n(2) 在兩線化學治療失敗後，在HER2高表現，RAS-wild type 的大腸直腸癌病患，可考慮使用trastuzumab + tucatinib。\r\nCorrect!\r\n*NCCN Guidelines Version 1.2025, COL-D 2 OF 12 (Figure2)\r\n\r\n*參考trial: Strickler JH, Cercek A, Siena S, et al. Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC [abstract]. Ann Oncol 2022;33:S808-S869.\r\n-研究方法\r\n--收錄18歲以上、chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic CRC\r\n--Cohort A: Tucatinib (300 mgBID) + intravenous trastuzumab(8 mg/kg loading, then 6 mg/kg Q3wks)->打到progression\r\n--中途有擴大招募: 以4:3分至兩組\r\n--> Cohort B= tucatinib + trastuzumab \r\n--> Cohort C= tucatinib monotherapy\r\n--The primary endpoint= objective response rate for cohorts A and B combined and was assessed in patients in the full analysis set (ie, patients with HER2-positive disease who received at least one dose of study treatment).\r\n-結果\r\n--114 人 HER2 陽性並接受治療(Cohort A: 45, B: 39, C: 30)\r\n--ORR: 38.1%(Figure3)\r\n--AE: \r\n--> A+B: 腹瀉(64%)、3 級以上：高血壓(7%)、3%(3/86) tucatinib 相關嚴重不良事件（急性腎損傷、結腸炎、疲勞)\r\n--> C: 腹瀉(33%)、3 級以上：ALT、AST 升高(各 7%)、1 人(3%) tucatinib 相關嚴重不良事件（藥物過量）、\r\n\r\n-結論\r\n--Tucatinib+trastuzumab: FDA approved for mCRC and is an important new treatment option for chemotherapy-refractory HER2-positive mCRC.\r\n\r\n(3) 根據DESTINY-CRC02，單獨使用T-DXd無論RAS-mutant或wild type，其response rate 約為35%。\r\nIncorrect! 在subgroup分析中，RAS-Wild-type的ORR優於RAS-mutant，可以看直接下方**Subgroup研究的資料 (Figure4,5,6)\r\n\r\n*相關trial: Kanwal Raghav, et al.Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial, The Lancet Oncology,Volume 25, Issue 9, 2024,1147-1162 \r\n-目的: 探討 Trastuzumab deruxtecan 不同劑量(5·4 mg/kg and 6·4 mg/kg)在先前治療過的HER2(+), RAS wild-type or mutant mCRC，找出適合的劑量\r\n-方法\r\n-- 收錄年滿 18 歲或 20 歲(依地區而定)、先前治療過的unresectable,recurrent, or metastatic HER2-positive, and RAS wild-type or mutant colorectal cancer (先前治療chemotherapy, and anti-EGFR, anti-VEGF, or anti-PD-L1 therapy)\r\n-- Stage 1: 1:1 的比例被隨機分配至接受 5.4 mg/kg 或 6.4 mg/kg 的 trastuzumab deruxtecan, Q21d\r\n-- Stage 2: 所有患者均被分配至 5.4 mg/kg 的治療組\r\n-- The primary endpoint= ORR\r\n-研究結果\r\n-- The confirmed ORR= 37·8% (5·4 mg/kg) vs 27·5% (6·4 mg/kg)\r\n-- Gr3 以上drug-related AE 34 (41%) vs 19 (49%) \r\n-- **Subgroup研究\r\n--> 在5·4 mg/kg組別的ORR: 39.7% (RAS wild-type) vs 28.6% (RAS mutant)\r\n--> 在6·4 mg/kg組別的ORR: 32.4% (RAS wild-type) vs 0% (RAS mutant)\r\n-結論: 在先前治療過的HER2-positive mCRC (有包含RAS mutations, 或先前接受anti-HER2 therapy)，trastuzumab deruxtecan 單用，5·4 mg/kg是最佳的劑量\r\n\r\n(4) 根據DESTINY-CRC01，在low HER2 (IHC2+/ISH-或IHC1+) 的病患使用T-DXd依然有約40%的response rate。\r\nIncorrect! ORR為0\r\n*相關trial: Salvatore Siena MD, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. The Lancet Oncology,Volume 22, Issue 6, 2021,779-789\r\n\r\n-目的: 探討 Trastuzumab deruxtecan的anti-tumor activity與安全性，在HER2(+)的mutant mCRC\r\n-方法\r\n-- 需年滿 18 歲（日本為 20 歲以上）\r\n-- HER2-expressing metastatic colorectal cancer、且已接受兩種以上先前治療後惡化(可接受除了trastuzumab deruxtecan以外的HER2-targeted therapies)、且 RAS and BRAFV600E wild-type\r\n-- 依照 HER2 表現程度 分為3個cohort\r\n--> Cohort A：HER2 陽性（即 IHC3+ 或 IHC2+ 且 ISH 陽性）\r\n--> Cohort B：HER2 低表現（IHC2+ 且 ISH 陰性）\r\n--> Cohort C：HER2 低表現（IHC1+）\r\n-- 所有患者接受 6.4 mg/kg trastuzumab deruxtecan Q3wk，直至疾病進展、出現不可接受的不良反應、withdrawal，或死亡。\r\n--The primary endpoint= ORR in cohort A、safety\r\n\r\n-研究結果\r\n-- ORR= 24(45.3%) in cohort A\r\n-- 3 or worse treatment-emergent adverse events that occurred in at least 10% of all participants\r\n-- **對於Cohort B and Cohort C的分析 (Figure7)\r\n--> 均無患者達到客觀緩解(ORR)\r\n--> mPFS 在cohort B and C相似: 1.3 個月 and 1.4 個月\r\n--> mOS 在cohort B and C: not reached\r\n--> PD or Death: Cohort B (4名)、Cohort C (14名)\r\n----\r\n\r\n此題覺得答案為(1)(2)\n(審稿附議)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/104/explain_figures/Figure1.jpg",
      "/qabank/104/explain_figures/Figure2.jpg",
      "/qabank/104/explain_figures/Figure3.jpg",
      "/qabank/104/explain_figures/Figure4.jpg",
      "/qabank/104/explain_figures/Figure5.jpg",
      "/qabank/104/explain_figures/Figure6.jpg",
      "/qabank/104/explain_figures/Figure7.jpg"
    ]
  },
  {
    "id": 105,
    "question": "一位 47 歲病患診斷為 cT3N2M1 之 sigmoid colon adenocarcinoma，有多處肺轉移及肝臟 轉移，為無法手術之疾病(unresectable)，病理檢測為 RASwt、BRAFwt、pMMR，病患之 ECOG PS 0 且無腸阻塞、出血等症狀。下列對於此病患的治療建議中，正確的有? \r\n\r\n(1)  根據 FIRE-3 study，cetuximab + FOLFIRI 相較於 bevacizumab + FOLFIRI，其 OS benefit 只有在 RAS-wild type 且腫瘤位於左側大腸時才顯著。 \r\n(2)  Cetuximab + FOLFIRI 在 RAS-wild type 且腫瘤位於左側大腸的病患，其 response rate 約為 7 成，且其 early tumor shrinkage 及 depth of response 皆優於 bevacizumab + FOLFIRI。 \r\n(3)  當病患在一線使用 bevacizumab + FOLFOX，可在疾病惡化時使用 FOLFIRI 加上 ramucirumab 或是繼續使用 bevacizumab。 \r\n(4)  Panitumumab 相較於 cetuximab 有較多的 Grade 3 以上的 infusion reaction，但有較少 的 hypomagnesaemia 風險。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "(1)(2) 正確，在 FIRE-3 的後續報告中，RAS wild type mCRC 的 median OS 在左大腸且接受 FOLFIRI + Cetuximab 的組別可達到 38.2 個月， FOLFIRI + Bevacizumab 只有 28.2 個月。“FOLFIRI plus cetuximab resulted in a significantly higher ORR and longer OS compared to FOLFIRI plus bevacizumab among patients with left-sided tumours” (fig1)\r\n \r\n參考同篇論文 appendix，RAS-wild type left-sided mCRC，在 FOLFIRI + Cetuximab 的組別比起 FOLFIRI + Bevacizumab 有較佳的 ORR (69% vs 62%), early tumor shrinkage (71% vs 50%), depth of response (50% vs 33%)。(fig2)\r\n \r\nRef: British Journal of Cancer (2021) 124:587–594; https://doi.org/10.1038/s41416-020-01140-9 \r\n\r\n(3) 正確，根據 NCCN guideline ver. 1.2025 Colon cancer“Another meta-analysis showed an OS and PFS benefit to continuing an anti-angiogenic agent after progression on an anti- angiogenic agent in first-line “，在 MS-68 中內文提到幾個 clinical trial 研究 contiuation of bevacizumab plus another chemotherapy regimen following progression on bevacizumab\r\n“Overall, these data (along with data from the VELOUR trial, discussed below) show that the continuation of VEGF blockade in second-line therapy offers a very modest but statistically significant OS benefit. “\r\nRamucirumab 的部分，則參考 phase III RAISE study，OS 有達到統計學上顯著差異，FOLFIRI + Ramucirumab versus FOLFIRI + placebo (13.3 vs 11.7個月; HR: 0.844)。(fig3)(fig4)\r\n \r\n\r\n(4) 錯誤，此選項可以從藥物機轉刪除。“Cetuximab and panitumumab are monoclonal antibodies directed against EGFR that inhibit its downstream signaling pathways. Panitumumab is a fully human monoclonal antibody, whereas cetuximab is a chimeric monoclonal antibody. ”“ Administration of either cetuximab or panitumumab has been associated with severe infusion reactions, including anaphylaxis, in 3% and 1% of patients, respectively. “\r\n由於 Cetuximab 是 chimeric antibody，帶有不同物種的分子，因此較容易造成過敏反應，給藥時容易有輸注反應 (infusion reaction)；相較 panitumumab 都是人類的分子，過敏的機率就低很多。\r\n至於anti-EGFR monoclonal antibody 造成的低血鎂，有文獻指出這與 blockade of the EGFR in the kidney 相關。沒有找到兩種藥物 head to head 比較的臨床試驗，不過是有找到一篇 systematic reivew 當中 pooled analysis，看到 cetuximab 發生低血鎂的比例比起 panitumumab 還要高。(fig5)\r\n \r\nRef: \r\n1. NCCN guideline v1.2025 Colon cancer MS-61\r\n2. Petrelli, F. et al. (2011) ‘Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies’, Expert Opinion on Drug Safety, 11(sup1), pp. S9–S19. doi: 10.1517/14740338.2011.606213.",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/105/explain_figures/fig1.png",
      "/qabank/105/explain_figures/fig2.png",
      "/qabank/105/explain_figures/fig3.jpg",
      "/qabank/105/explain_figures/fig4.png",
      "/qabank/105/explain_figures/fig5.png"
    ]
  },
  {
    "id": 106,
    "question": "下列關於 Appendiceal neoplasm 的敘述，正確的有? \r\n(1)  病理下可分為 low-grade/high-grade mucinous neoplasm, appendiceal adenocarcinoma 及 neuroendocrine tumor。 \r\n(2)  Signet ring mucinous adenocarcinoma 的預後很差。 \r\n(3)  若腹膜轉移的病患可使用 PCI (peritoneal cancer index)評估是否可手術切除，若可手術切除，可在術前接受六個月的前導性化學治療並隨後加上 HIPEC (hyperthermic intraperitoneal chemotherapy)。 \r\n(4)  無法手術的病患，應接受與大腸癌相同的基因檢測(RAS, BRAF, MMR, HER2)及治療選擇。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "這段文字出自 NCCN version 1.2025 colon cancer MS-9～MS-13\r\n(1) 正確，”Appendiceal neoplasms can be histopathologically classified as neuroendocrine neoplasms (NENs), mucinous neoplasms, goblet cell adenocarcinomas (GCAs), colonic-type adenocarcinomas (non- mucinous), and signet ring cell carcinomas (epithelial origin).”\r\n\n(2) 正確，”It has been well-established that the presence of signet ring cells leads to a poorer prognosis; 10% to 40% of patients with G3 (poorly differentiated) mucinous adenocarcinoma with signet ring cells have a 5-year OS.”\r\n\n(3) 正確，”In select patients diagnosed with metastatic spread to the peritoneum, CRS and HIPEC have the potential to be curative.”\r\n“The intent of CRS is to achieve maximum cytoreduction before the initiation of HIPEC. Because of this, presurgical evaluation of peritoneal involvement is recommended and can be achieved through laparoscopy and the peritoneal carcinomatosis index (PCI) scoring system. The PCI quantifies the distribution of tumors throughout 13 regions of the abdomen and pelvis along with a lesion size score.” “Once an individual is deemed a candidate for CRS/HIPEC they should continue chemotherapy for up to 6 months, preferably in the neoadjuvant setting.”\r\n\n(4) 正確，”Cytotoxic chemotherapy with efficacy against CRC is used to treat AA. It is reasonable to use other targeted therapy options for MSI-high (MSI-H), BRAF mutation, or HER2 status, which is consistent with recommendations within the NCCN Guidelines for Colon Cancer and NCCN Guidelines for Rectal Cancer. There is no clear evidence for anti-epidermal growth factor receptor (EGFR) therapy even if the patient’s tumor is RAS/RAF wild-type.”",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 107,
    "question": "42 歲男性，經診斷肛門緣上 1.5cm Low rectal adenocarcinoma, cT4aN2aM0, circumferential resection margin involved, stage IIIC，IHC 發現 MLH1/PMS2 loss, preserved MSH2/6，RASwt 及 BRAFwt，此病患之 ECOG PS 為 0，無阻塞或出血症狀，關於此病患的治療建議， 下列敘述中，正確的有? \r\n(1)  病患可先使用 dostarlimab 六個月並根據評估後決定是否接受 chemoradiation (CRT) 及手術。 \r\n(2)  在 CRT 後接受化學治療並後手術，相較於先接受化學治療後 CRT 再手術，有更高的 pCR 機率。 \r\n(3)  clinical CR 的定義為:內視鏡下腸壁光滑且 MRI T2W 下只有 dark signal 且無>5mm lymph node。 \r\n(4)  對於 Total neoadjuvant therapy 後達到 cCR 的病患，可考慮 watch-and-wait 而不進行手術。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1) 正確，病患為 dMMR locally advanced stage IIIC rectal cancer，根據 NCCN guideline 可以先進行 neoadjuvant immune chekcpoint inhibitor 六個月，評估療效。(fig1)\r\n \r\n(2) 正確，CAO/ARO/AIO-12 這篇 randomized phase II trial，回應了optimal sequence of chemoradiotherapy (CRT) and chemotherapy before total mesorectal excision surgery for total neoadjuvant therapy in rectal cancer。\r\n\r\nThis secondary analysis of a randomized clinical trial showed that CRT followed by chemotherapy resulted in higher pathological complete response without compromising disease-free survival, toxicity, QoL, or stool incontinence and is thus proposed as the preferred total neoadjuvant therapy sequence if organ preservation is a priority.\n\r\nRef:  JAMA Oncol. 2022;8(1):e215445. doi:10.1001/jamaoncol.2021.5445\r\n\r\n(3) 正確，Clinical complete response，根據NCCN version 2025.1 colon cancer page REC-H 1 OF 2 的定義如 fig2。\r\n \r\n(4) 正確，在接受 total neoadjuvant therapy 後如果達到 clinical complete response，可以考慮 active surveillance (fig3)，目的是減少手術後可能伴隨的功能喪失，例如 incontinence, permanent colostomy 等等。目前支持 active surveillance 的研究多半是 phase II trial。",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/107/explain_figures/fig1.png",
      "/qabank/107/explain_figures/fig2.png",
      "/qabank/107/explain_figures/fig3.png"
    ]
  },
  {
    "id": 108,
    "question": "下列關於大腸直腸癌 RAS 突變的敘述，錯誤的有?\r\n(1) 最常見的 KRAS 突變為 KRAS G12D。\r\n(2) 在 FIRE-3 臨床試驗中，次族群分析發現 RAS 突變之大腸癌病患接受 cetuximab + FOLFIRI 相較於 bevacizumab + FOLFIRI 有更差的PFS。\r\n(3) 在 CodeBreaK300 中，sotorasib + panitumumab 相較於 triflufluridine- tipiracil 或 regorafenib 有較佳的 PFS。\r\n(4) 在 KRYSTAL-1 中，adagrasib + cetuximab 相較於 triflufluridine-tipiracil 或 regorafenib 有較佳的 PFS。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 3,
    "explanation": "(1) 正確，根據 NCCN v.2025.1 MS-47 colon cancer 的描述\r\n“Studies have reported that around 40% of mCRC have KRAS mutations in codons 12 and 13. Of these mutations, KRAS G12D was mostly commonly found (36%), followed by G12V (21.8%), and G13D (18.8%). KRAS G12C has been reported in around 17% of KRAS-mutated mCRC cases.”\n\r\n(2) 正確，根據 FIRE-3 appendix，RAS-mutant population 接受 cetuximab + FOLFIRI 相較於 bevacizumab + FOLFIRI 的 median PFS 為 7.5個月比上9.6個月。(fig1)\r\n \r\n(3) 正確。CodeBreaK 300 研究帶有 KRASG12C 突變之轉移性大腸癌在接受前線化學藥物治療失敗後(包含fluoropyrimidine, irinotecan, oxaliplatin)，使用 sotorasib + panitumumab 比上 trifluridine/tipiracil 或 regorafenib ，Primary endpoint 為PFS (研究設計如下)。結果顯示 sotorasib + panitumumab 比起 standard care 有較佳的 PFS (fig2-4)。   \r\n \r\n(4) 錯誤，KRYSTAL-1 是一篇 phase 1-2 study，研究 Adagrasib 在 KRASG12C mutant tumor 的效果，其中包含 NSCLC, CRC and other solid tumors 三個 cohort。在大腸癌的研究中，Adagrasib + Cetuximab 比起 Adagrasib monotherapy 有較好的 ORR (46% v s 19%)、duration of response (7.6 months vs 4.3 months)、PFS (6.9 months vs 5.6 months)。(fig5:左為 Adagrasib + cetuximab；右為 adagrasib monotherapy)",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/108/explain_figures/fig1.png",
      "/qabank/108/explain_figures/fig2.jpg",
      "/qabank/108/explain_figures/fig3.png",
      "/qabank/108/explain_figures/fig4.png",
      "/qabank/108/explain_figures/fig5.png"
    ]
  },
  {
    "id": 109,
    "question": "Which of the following statements about thromboembolism in cancer patients are (is) correct? \r\n(1)  Direct oral anticoagulants (DOACs), LMWH, and warfarin have all been used to treat \r\n     thromboembolism. Select regimen based on renal function, hepatic function, inpatient/ \r\n     outpatient status, approval, cost, patient preference, ease of administration, monitoring,  \r\n     bleeding risk assessment, and ability to reverse anticoagulation.  \r\n(2)  For acute DVT of proximal lower extremity, the first recommended treatment is IVC filter \r\n     instead of anticoagulant.  \r\n(3)  For symptomatic catheter-associated DVT, consider anticoagulation treatment for at least \r\n     3 months or as long as the catheter is in place. \r\n(4)  For acute DVT of subclavian vein closed to the port-A, the first priority is remove the \r\n     port-A.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1)正確；Guideline: National Comprehensive Cancer Network 2020 其中的Recommendations \"Choice of anticoagulation regimen should be based on individual risk of thrombosis and bleeding, renal and hepatic function, inpatient/outpatient status, FDA approval status, ease of administration, cost, burden of laboratory monitoring, agent reversibility, and patient preferences.\"，和此選項幾乎相同\r\n(2)錯誤；根據Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline (2023)，起始治療仍是以anticoagulant 為主，再早一點的guideline會建議有anticoagulant contraindication時，才考慮filter 使用\r\n(3)正確；Guideline: International Initiative on Thrombosis and Cancer 2019，針對CVC thrombosis treatment，提及\"For the treatment of symptomatic CVC thrombosis, anticoagulation is recommended for a minimum of 3 months and as long as the CVC is in place\"，和此選項幾乎相同 (補充：NCCN guideline DVT-3 將\"and\" 改成 \"or\")\r\n(4)錯誤；根據NCCN guideline內文，\"For patients with catheter-related DVT, in the absence of contraindication, anticoagulation is recommended. Anticoagulation without catheter removal is the preferred option for initial treatment, even for patients with asymptomatic DVT, provided that the catheter is necessary, functional, and free of infection.\"，使用anticoagulant讓管路不用被移除，是處置的優先目標，若有contraindication才考慮移除\r\n\r\n故答案選B\r\n\r\nRef:\r\n1. Streiff MB, Abutalib SA, Farge D, Murphy M, Connors JM, Piazza G. Update on Guidelines for the Management of Cancer-Associated Thrombosis. Oncologist. 2021 Jan;26(1):e24-e40. doi: 10.1002/onco.13596.\r\n2. Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M, Syrigos K, Young A, Jordan K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023 May;34(5):452-467. doi: 10.1016/j.annonc.2022.12.014.\r\n3. NCCN guideline v1.2025 Cancer associated venous thromboembolism disease DVT-3/MS-17",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 110,
    "question": "一位30歲女性因右側乳癌接受切除手術，術後8個月右手臂逐漸腫起來，下列敘述中， \r\n正確的有? \r\n(1) 有接受液下淋巴結清除術者，比起接受哨兵淋巴結切除者，淋巴水腫機會高10倍。\r\n(2) 越瘦的人，術後越可能有淋巴水腫。 \r\n(3) 舉重物會增加淋巴水腫的程度與機會。 \r\n(4) 衛教她淋巴水腫不會痊癒。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 3,
    "explanation": "Breast cancer-related lymphedema (BCRL)\r\n(1)錯誤；根據文獻內提及，過往研究axillary lymph node dissection (ALND) 比起sentinel lymph node biopsy (SLNB)，發生BCRL的比率是19.9% (95% CI: 13.5–28.2)及 5.6%，比率約為4倍，非10倍\r\n(2)錯誤；根據文獻內提及，過往研究發現與治療無關的BCRL risk factors 為obesity、subclinical edema及cellulitis，所以瘦的病人發生機會比較低\r\n(3)錯誤；文獻內提到，\"there is no limitation on the maximum amount of weight that can be lifted as long as weight-lifting exercises are supervised and progressive\"，舉重物及其最大重量並沒有被限制，間接表示與BCRL無關。\r\n(4)正確；National cancer institute 在lymphedema頁面，有提到\"it is a chronic condition that cannot be cured but can be treated to relieve swelling and improve your ability to function day to day\"；另根據Johns Hopkins Medicine 網站內\"Breast cancer lymphedema after treatment\"文章，提到\"It’s a chronic (ongoing) condition that has no cure\"\r\n\r\n\r\nRef: \r\n1.Gillespie TC, Sayegh HE, Brunelle CL, Daniell KM, Taghian AG. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg. 2018 Aug;7(4):379-403. doi: 10.21037/gs.2017.11.04.\r\n2.https://www.hopkinsmedicine.org/health/conditions-and-diseases/breast-cancer/breast-cancer-lymphedema-after-treatment\r\n3.https://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 111,
    "question": "除了手術治療、化學治療外，有些癌症可經由第一線放射線治療來治癒。下列癌症中， \r\n正確的有？ \r\n(1) 第一期喉癌 \r\n(2) 第一期胃黏膜相關淋巴組織淋巴癌 \r\n(3) 第一期鼻咽癌 \r\n(4) 第一期胰臟癌",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "1. 第一期喉癌，即為Glottic cancer stage I (T1N0M0)，根據NCCN guideline可第一線RT\r\n2. 第一期胃黏膜相關淋巴組織淋巴癌，即為Extranodal marginal zone lymphoma of stomach stage I (T1-3N0M0), 根據NCCN guideline可第一線RT\r\n3. 第一期鼻咽癌，即為Nasopharygeal carcinoma stage I (T1N0M0) ，根據NCCN guideline可第一線RT\r\n4. 第一期胰臟癌，視為Pancreatic adenocarcinoma stage I (T1-2N0M0)， 根據NCCN guideline，Resectable 者去手術、non-resectable者Good PS 可做neoadjuvant management、non-resectable者Poor PS考慮BSC or palliative RT，非\"可治癒放射治療\"\r\n\r\n故答案選(1)(2)(3) ->A\r\n\r\nRef: \r\n1. NCCN guideline v2.2025 Head and Neck cancer GLOT-2\r\n2. NCCN guideline v2.2025 B-cell lymphomas EMZLG-2\r\n3. NCCN guideline v2.2025 Head and Neck cancer NASO-2\r\n4. NCCN guideline v2.2025 Pancreatic adenocarcinoma PANC-6",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 112,
    "question": "合併化學治療和放射線治療是子宮頸癌最常見的治療方式，子宮頸癌其放射線治療 \r\n給予方式是先實施骨盆治療後追加近距治療 (brachytherapy)，近距治療須評估下列 \r\n那些(何者)危急器官(organ at risk)會被放射線治療而影響？ \r\n(1) 膀胱劑量 \r\n(2) 腎臟劑量 \r\n(3) 直腸劑量 \r\n(4) 輸尿管劑量",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "Organ at risk: Healthy tissue or organ received radiation also during brachytherapy. \r\nEMBRACE trial、ABS、CCO recommendation 皆列出等OAR \"rectum、bladder、sigmoid\" 的建議劑量\r\n引用文獻內文中提到傳統OAR是rectum及bladder，故答案選B\r\n\r\nRef: Owrangi AM, Prisciandaro JI, Soliman A, Ravi A, Song WY. Magnetic resonance imaging-guided brachytherapy for cervical cancer: initiating a program. J Contemp Brachytherapy. 2015 Oct;7(5):417-22. doi: 10.5114/jcb.2015.55541",
    "questionFigures": [],
    "explainFigures": [
      "/qabank/112/explain_figures/figure 1.png"
    ]
  },
  {
    "id": 113,
    "question": "關於癌症臨床試驗設計（design），下列敘述中，正確的有？ \r\n(1) Phase II trials如果隨機分派成實驗組治療vs.對照組治療，叫做randomized screening design。 \r\n(2) Phase II trials如果隨機分派成實驗組治療1 vs.實驗組治療2，叫做randomized selection design。 \r\n(3) Phase III trials如果selective biomarker陽性、陰性的病患都隨機分派成實驗組治療vs. 對照組治療，叫做biomarker stratified design。 \r\n(4) Phase III trials如果只有selective biomarker陽性的病患隨機分派成實驗組治療vs.對照組治療，叫做biomarker enrichment design。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 4,
    "explanation": "(1)正確\r\n(2)正確\r\n(3)正確\r\n(4)正確 (補充: Auxiliary-variable-enriched biomarker stratified design，利用較便宜的輔助biomarker來協助篩選病人，可以降低使用true biomarker來篩選病人的費用，與biomarker enrichment design相同之處為只納入biomarker陽性的病人進入trial)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 114,
    "question": "有關Non-small cell lung cancer的 rare mutations及其相對應的治療藥物，下列配對中，正確的有？ \r\n(1) RET fusion–positive NSCLC: Selpercatinib \r\n(2) NTRK fusion: Entrectinib  \r\n(3) EGFR exon 20 insertion mutation: Amivantamab  \r\n(4) BRAF V600E: Dactolisib",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4),(5)"
    ],
    "correctAnswer": 0,
    "explanation": "(1)正確\r\n(2)正確 (Entrectinib在NTRK 1/2/3 fusion NSCLC and ROS1 rearrangement NSCLC中都可以使用)\r\n(3)正確\r\n(4)錯誤，Dactolisib為inhibitor of mTOR complex 1/2 and pan-PI3K; BRAF V600E NSCLC可以使用的藥物為Dabrafenib/trametinib, Encorafenib/binimetinib and Vemurafenib",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 115,
    "question": "有關Antibody-conjugate Drug (ADC) 藥物，下列敘述中，正確的有？ \r\n(1) Trastuzumab deruxtecan (T-DXd) 藉由 selectively cleavable by lysosomal histone proteases linker，帶著 anti-topoisomerase 1 inhibitor 的payload。 \r\n(2) Sacituzumab govitecan是FDA approved於Trop-2過度表現之轉移復發TNBC。 \r\n(3) Trastuzumab deruxtecan (T-DXd) 不只是作用於HER2+ metastatic breast cancer(MBC)，也證實於 low-HER2 expression MBC (HR+/HR-)一樣有不錯效果。 \r\n(4) Enfortumab vedotin已經approved於治療無效復發轉移nectin-4表現colon adenocarcinoma。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1)正確，T-DXd的結構中含有cleavable tetrapeptide-based linker，被lysosomal enzymes (ex. cathepsins)分解後，釋放出payload anti-topoisomerase 1 inhibitor\r\n(2)錯誤，與single agent chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine)相比，SG可增加PFS and OS of relapsed or refractory metastatic triple-negative breast cancer (乳癌細胞的Trop-2表現量>90%)(ASCENT trial)，適用於所有的TNBC，不需要檢驗Trop-II表現量\r\n(3)正確，在HER2-low metastatic breast cancer族群 (HER2-low: IHC 1+ or IHC 2+ with FISH negative)，與physician’s choice of chemotherapy相比，T-DXd可增加PFS and OS (DESTINY-Breast04 trial)\r\n(4)錯誤，目前Enfortumab vedotin (EV)只有被核准使用於urothelial carcinoma (且不需要特別驗nectin-4表現量)，可以使用的情境有一線(EV with pembrolizumab，EV-302 trial)及後線(EV單用，EV-301 trial) ，EV在colon adenocarcinoma的角色目前還在臨床試驗當中",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 116,
    "question": "有關Antibody-conjugate Drug (ADC) 藥物的敘述中，正確的有？ \r\n(1) ADC，例如TDM1，在接近target cell時，linker就會release payload，執行cytotoxicity及明顯bystander effect。 \r\n(2) ADC有精準target 作用，故很少 myelotoxicity, nausea, or vomiting。 \r\n(3) Trastuzmab deruxtecan 需要有 HER2 over-expression 才能執行target cell binding 及internalization。 \r\n(4) Enfortumab vedotin 主要target是nectin-4。",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 3,
    "explanation": "(1)錯誤，ADC與癌細胞表現的marker結合之後被吞噬進入癌細胞，linker part在癌細胞內被lysosomal enzyme分解，釋放出payload，達到毒殺細胞的效果 (並非在細胞附近釋放payload)\r\n(2)錯誤，ADC仍然會有myelotoxicity, nausea and vomiting這些副作用 (比例上也不少)，以EV-301為例，any grade nausea (EV) 22.6% vs (chemothrapy) 21.6%; decreased appetite (EV) 30.7% vs (chemotherapy) 23.4%; leukopenia (EV) 5.4% vs (chemotherapy) 10.7%\r\n(3)錯誤，Trastuzumab Deruxtecan 在HER2-low族群依舊有一定的效果 (DESTINY-Breast04 trial)\r\n(4)正確",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 117,
    "question": "有關Immune checkpoint inhibitor 治療的敘述中，正確的有？ \r\n(1) GI cancers with mismatch-repair deficiency, which has been hypothesized to result in increased numbers of tumor somatic mutations that would produce neoantigen targets, exhibit good response and tumor control to immune checkpoint blockade. \r\n(2) Clinical tumor response after immunotherapy should be assessed by conventional RECIST. \r\n(3) The major limitation to development of combinations has been the inability to identify the critical mechanisms of resistance to anti-CTLA-4 or to PD-1/ PD-L1 antagonists and as a result, accurate biomarkers to select patients for treatment with specific combination regimens are not yet available \r\n(4) The most common side effects observed (irAEs) were renal failure, cardiomyopathy and encephalitis, especially heart failure.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1) 描述正確。MMR deficiency是一種Tumor agnostics。MMR protein是參與DNA修復的蛋白質，MMR deficiency會導致DNA修復異常，因而容易在腫瘤細胞中產生各式突變，進而產生Neoantigens，讓免疫細胞更容易辨識到腫瘤。因此，腫瘤對於Immune checkpoint blockade的效果較好，像是在Colorectal cancer, cholangiocarcinoma等GI cancers中，臨床試驗均證實MMRd對於ICIs有不錯的效果\r\n(2) 此選項錯誤。Conventional RECIST是用於評估傳統化療、target therapy的treatment response。由於ICIs的Response pattern不同於傳統化療、target therapy (舉例來說，ICIs的response包含Pseudoprogression, 產生Response所需時間可能較久、Response可以維持較久等)，因此評估ICIs response不能使用傳統RECIST，而是要用Immune-specific related response criteria，包含irRC, iRECIST, irRECIST, imRECIST \r\n(3) 描述正確。雖然目前驗Tumor PD-L1 expression, MMR deficiency/MSI-H, Tumor mutation burden (TMB)等指標能部分預測腫瘤對於ICIs的效果，但目前確實仍缺乏精確的Biomarkers來預測療效 \r\n(4) 此選項錯誤。最常見的IrAEs是Dermatitis, 其他常見的包含Colitis, Hepatitis, Pneumonitis, Endocrinopathy (Thyroiditis, Hypophysitis)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 118,
    "question": "有關endocrine therapy治療藥物機轉與疾病的敘述中，正確的有？ \r\n(1) Unlike other CDK4/6 inhibitors, abemaciclib has significant single-agent activity in hormone-refractory and chemotherapy-refractory metastatic ER-positive metastatic breast cancer. \r\n(2) Abiraterone, one of anti-androgen agents, is commonly associated with gynecomastia and elevated transaminase levels requiring frequent monitoring. \r\n(3) Raloxifene is a SERM originally developed to treat osteoporosis. Large placebo-controlled  randomized trials demonstrated reduced rates of osteoporosis and a reduction in new breast cancers. \r\n(4) Octreotide and lanreotide are somatostatin analogs used to treat post-menopausal syndrome.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 1,
    "explanation": "(1) 描述正確。Abemaciclib monotherapy在MONARCH1 (phase 2 single-arm trial)和nextMONARCH(phase 2 RCT)均證實其對於HR+, HER2- MBC的療效\r\n(2) 描述錯誤。Abiraterone是一種anti-androgen agents，機制是抑制Androgen synthesis。常見副作用確實包含AST/ALT上升，但不同於傳統Anti-androgen，Abiraterone並不常見gynecomastia。(Ref: Oncology. 2013;84(2):92-9. doi: 10.1159/000343821.)\r\n(3) 描述正確。Raloxifene是SERM，用於治療Osteoporosis。根據MORE trial (multicenter, randomized, double-blind trial)，3年Ramoxifene相較於Placebo可以減少76%產生乳癌的風險 (Ref: JAMA. 1999 Jun 16;281(23):2189-97. doi: 10.1001/jama.281.23.2189.)\r\n(4) 描述錯誤。Octreotide和lanreotide是somatostatin analogs沒錯，不過他們是用來治療Neuroendocrine tumor (NET), carcinoid syndrome, acromegaly等疾病，而非用於治療Post-menopausal syndrome。Post-menopausal syndrome的治療可以分為Hormone therapy (estrogens)和non-hormone therapy (ex. fezolinetant用於控制Vasomotor syndrome；Ospemifene, DHEA用於控制genitourinary syndrome of menopause)",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 119,
    "question": "About cancer genetic alterations, which of the following statements are (is) correct? \r\n(1)  Prof. Vogelstein’s research has shown that tumors from patients with HNPCC requires the accumulation of many genetic events, a process takes decades from polyp to adenoma and finally invasive carcinoma.  \r\n(2)  Circulating tumor DNA fragments contain the identical genetic defects as the tumor themselves; thus, the blood can reveal tumor point mutations, rearrangements, as well as amplifications. \r\n(3)  Major types of somatic mutations for oncogene present in malignant tumors include nucleotide substitutions, small insertions and deletions (indels), chromosomal rearrangements, and copy number alterations. \r\n(4)  The drug-resistant EGFR mutation is structurally analogous to the mutated gatekeeper residue T315I in BCR-ABL, T670I in c-Kit, and L1196M in EML4-ALK, which have been shown previously to confer resistance kinase inhibitors.",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 3,
    "explanation": "(1) 描述錯誤。Prof. Vogelstein’s是研究\"Spontaneous\" CRC發展成Carcinoma的基因變化，而非HNPCC (Ref: N Engl J Med 1988;319:525-532. DOI: 10.1056/NEJM198809013190901)。HNPCC是遺傳性的大腸癌，致病機轉與MMR deficiency相關\r\n(2) 描述錯誤。ctDNA不會包含所有Tumor的DNA fragments，因此ctDNA通常無法完全偵測Tumor genetic mutation。舉例來說，文獻指出使用ctDNA或Tissue檢測NSCLC EGFR variants，concordance rate約70%-90%，而非100% (Journal of Clinical Oncology. Volume 36, Number 16. https://doi.org/10.1200/JCO.2017.76.8671)\r\n(3) 老實說，我不知道這個選項錯在哪\r\n(4) 描述正確。\r\n我覺得(3)(4)都是正確的選項，不過因為選項只有(4)，所以我選D",
    "questionFigures": [],
    "explainFigures": []
  },
  {
    "id": 120,
    "question": "The identification of drivers versus the passenger gene mutation from NGS is of utmost relevance and remains a pressing challenge in cancer genetics. Which of the following scenarios are (is) in favor of a driver mutation?\r\n(1) mutations that frequently occur on different patients\r\n(2) mutations may have characteristics like those causing Mendelian disease when inherited in the germ line\r\n(3) mutations that affect locations that have previously been shown to be cancer causing in protein members of the same gene family\r\n(4) mutations with nonsynonymous single nucleotide polymorphisms with high minor allele frequencies",
    "options": [
      "(1),(2),(3)",
      "(1),(3)",
      "(2),(4)",
      "(4)",
      "(1),(2),(3),(4)"
    ],
    "correctAnswer": 0,
    "explanation": "在腫瘤形成的過程中會累積多種突變，大部分的突變並不會賦予腫瘤細胞產生生長優勢，稱之為Passenger mutation；反之，少部份的突變會賦予腫瘤細胞產生生長優勢，因此稱為Driver mutation。\r\n(1) 高比例病人有這個突變 → 該突變比較有可能是Driver mutation\r\n(2) 該突變具有孟德爾基因遺傳模式 → 代表只要有這個突變就會發病 → 比較有可能是Driver mutation\r\n(3) 突變發生的蛋白質，有已知與該蛋白同一家族的其他蛋白質突變會直接導致癌症 → 有可能是Driver mutation\r\n(4) Non-synonymous single nucleotide polymorphisms (nsSNPs)是指會影響轉譯蛋白質amino acid sequence的SNP. Minor allel freqency (MAF)是指整個族群中第二常見的基因變異發生的比例 (舉例來說:某個SNP在族群中最常見的nucleotide是T(佔50%)，第二常見的是C(佔40%)，則該SNP的MAF就是40%)。因此，此選項描述的High minor allele frequencies的nsSNPs，只能說該nsSNPs第二常見的變異佔整個族群的比例是高的，並未提及與某疾病的關聯，因此不太可能是Driver mutation",
    "questionFigures": [],
    "explainFigures": []
  }
]